var title_f32_36_33344="Pilocarpine: Drug information";
var content_f32_36_33344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pilocarpine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4548?source=see_link\">",
"       Pilocarpine (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33652?source=see_link\">",
"       Pilocarpine (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9772 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33344=[""].join("\n");
var outline_f32_36_33344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4548?source=related_link\">",
"      Pilocarpine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33652?source=related_link\">",
"      Pilocarpine (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_36_33345="Wrist extensor stretch PI";
var content_f32_36_33345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F81293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F81293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wrist extensor stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 517px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hold left arm straight out in front of the body, with the palm facing down. Using the right hand, grasp the left hand and gently bend hand downward until you feel a stretch in the left forearm. Hold for 10 seconds. Relax. Repeat 10 times, then switch hands and repeat 10 times with the right hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33345=[""].join("\n");
var outline_f32_36_33345=null;
var title_f32_36_33346="Patient information: Tricuspid regurgitation (The Basics)";
var content_f32_36_33346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83896\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"         Chambers and valves of the heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"          Transthoracic echocardiogram (echo)",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"           Person having an ECG",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/42/36514\">",
"         Patient information: Heart murmurs (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/41/36499\">",
"         Patient information: Medicines for heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/23/11635\">",
"         Patient information: Prosthetic valves (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/61/39889\">",
"         Patient information: Pulmonary hypertension in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/42/21155\">",
"         Patient information: Swelling (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/53/32594\">",
"         Patient information: Edema (swelling) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tricuspid regurgitation (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tricuspid-regurgitation-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2363568231\">",
"      <span class=\"h1\">",
"       What is tricuspid regurgitation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tricuspid regurgitation is a condition in which 1 of the valves of the heart, called the tricuspid valve, leaks. Doctors call this condition &ldquo;TR&rdquo; for short.",
"     </p>",
"     <p>",
"      When the heart valves work normally, they keep blood flowing in only 1 direction. The valves work like swinging doors that open only 1 way &ndash; letting blood out, but not back in. Normally, little or no blood is able to leak backward. But if the valves are not working properly, more blood can go back in the direction it came from.",
"     </p>",
"     <p>",
"      The tricuspid valve normally keeps blood flowing from the right atrium to the right ventricle (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"UTD.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      ). When it leaks, it lets blood flow back into the right atrium. Many healthy people have a small amount of TR. But some people have larger amounts of TR, which can lead to problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2363568280\">",
"      <span class=\"h1\">",
"       What are the symptoms of tricuspid regurgitation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with TR have no symptoms. They might find out they have it when their doctor or nurse hears a heart murmur on a routine exam. A heart murmur is an extra sound in the heartbeat that doctors or nurses hear when they listen to the heart with a stethoscope.",
"     </p>",
"     <p>",
"      When TR causes symptoms, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling in the belly, legs, or ankles",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        A &ldquo;pulsing&rdquo; feeling in the blood vessels in the neck",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the TR is caused by another condition, people can have other symptoms. For example, TR can happen from a condition called &ldquo;pulmonary hypertension.&rdquo; Pulmonary hypertension causes high blood pressure in the blood vessels that carry blood to the lungs. Symptoms of pulmonary hypertension include feeling very weak or tired, or having trouble breathing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2363568295\">",
"      <span class=\"h1\">",
"       Is there a test for tricuspid regurgitation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms, do an exam, and order 1 or more tests. The test done most often to check for TR is an echocardiogram (also called an &ldquo;echo&rdquo;). This test uses sound waves to create a picture of your heart as it beats. It shows the size of the heart chambers, how well the heart is pumping, and how well the heart valves are working (",
"      <a class=\"graphic graphic_figure graphicRef77971 \" href=\"UTD.htm?33/35/34354\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Your doctor might also order:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An electrocardiogram (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;) &ndash; This test measures the electrical activity in your heart (",
"        <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        A chest X-ray &ndash; This can show the size and shape of your heart, as well as changes in your lungs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2363568350\">",
"      <span class=\"h1\">",
"       How is tricuspid regurgitation treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your symptoms, how severe they are, and what&rsquo;s causing your TR. If your TR is mild or you have no symptoms, you might not need any treatment or follow-up. But even if you have larger amounts of TR, you might not need treatment. It&rsquo;s possible that your doctor will simply want to keep an eye on you to see if a need for treatment develops.",
"     </p>",
"     <p>",
"      If your TR is severe or causes symptoms, you will likely need treatment. This can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines or procedures to treat the cause of your TR, if it can be treated",
"       </li>",
"       <li>",
"        Medicines called &ldquo;diuretics,&rdquo; which help reduce swelling by making people urinate a lot",
"       </li>",
"       <li>",
"        Surgery &ndash; If medicines don&rsquo;t help enough, you might need surgery to fix or replace your tricuspid valve.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2363568365\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=see_link\">",
"       Patient information: Heart murmurs (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=see_link\">",
"       Patient information: Swelling (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=see_link\">",
"       Patient information: Medicines for heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/61/39889?source=see_link\">",
"       Patient information: Pulmonary hypertension in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=see_link\">",
"       Patient information: Prosthetic valves (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=see_link\">",
"       Patient information: Edema (swelling) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?32/36/33346?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83896 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33346=[""].join("\n");
var outline_f32_36_33346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2363568231\">",
"      What is tricuspid regurgitation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2363568280\">",
"      What are the symptoms of tricuspid regurgitation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2363568295\">",
"      Is there a test for tricuspid regurgitation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2363568350\">",
"      How is tricuspid regurgitation treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2363568365\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83896\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"      Chambers and valves of the heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"       Transthoracic echocardiogram (echo)",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"        Person having an ECG",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=related_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=related_link\">",
"      Patient information: Heart murmurs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=related_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=related_link\">",
"      Patient information: Prosthetic valves (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/61/39889?source=related_link\">",
"      Patient information: Pulmonary hypertension in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=related_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_36_33347="Minocycline hydrochloride periodontal microspheres: Patient drug information";
var content_f32_36_33347=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Minocycline hydrochloride periodontal microspheres: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43698?source=see_link\">",
"     see \"Minocycline hydrochloride periodontal microspheres: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arestin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling of the tissue around the teeth (periodontitis). It is used with scaling and root planing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702533",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to minocycline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not chew hard, crusty, or sticky foods.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696736",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not brush or floss near the area for 12 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain where it was placed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad pain, swelling, or bleeding where treated.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11989 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33347=[""].join("\n");
var outline_f32_36_33347=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196969\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015574\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015573\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015578\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015579\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015581\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015576\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015577\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015582\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015583\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43698?source=related_link\">",
"      Minocycline hydrochloride periodontal microspheres: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_36_33348="Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm";
var content_f32_36_33348=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33348/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33348/contributors\">",
"     Alejandro A Rabinstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33348/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33348/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33348/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33348/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33348/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/36/33348/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unruptured intracranial aneurysms are detected in up to 2 to 3 percent of older adults who undergo high-quality noninvasive intracranial arterial imaging (eg, magnetic resonance angiography, computed tomographic angiography). Subarachnoid hemorrhage from a ruptured intracranial aneurysm is associated with a short-term mortality of 40 percent, with one-half of survivors sustaining permanent neurologic injury. Thus, detection of an asymptomatic unruptured aneurysm creates a management dilemma in patients who have indications for antithrombotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link\">",
"     \"Unruptured intracranial aneurysms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss issues related to anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATE OF RUPTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of rupture for previously detected unruptured aneurysms vary according to their size (ie, there is a greater risk of rupture in larger aneurysms), specific location (eg, higher rates of rupture with posterior circulation aneurysms) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/1\">",
"     1",
"    </a>",
"    ], as well as history of prior subarachnoid hemorrhage from a separate aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/2\">",
"     2",
"    </a>",
"    ]. This subject is reviewed in depth separately, and will only be reviewed briefly here (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link&amp;anchor=H13#H13\">",
"     \"Unruptured intracranial aneurysms\", section on 'Natural history of unruptured aneurysms'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with small (&lt;7 mm) aneurysms in the anterior circulation and without a history of subarachnoid hemorrhage, the rupture rate is very low, below 0.1 percent per year.",
"     </li>",
"     <li>",
"      For similar patients who have moderate-sized aneurysms (7 to 12 mm), the rupture rate averages 2.5 percent per year.",
"     </li>",
"     <li>",
"      For those with larger aneurysms (&gt;13 mm) or those with aneurysms involving the posterior communicating artery, rupture rates range from 3 to 20 percent per year or even higher in giant aneurysms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors influencing rupture rates of previously unruptured intracranial aneurysms include patient age (relative risk 2.0 for those &gt;60 years), female sex (relative risk 1.6) and tobacco smoking (relative risk 1.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not known whether antithrombotic therapies influence the rate of rupture of intracranial aneurysms. By reducing thrombus formation in the aneurysmal sac, it is possible that antithrombotic therapy could",
"    <strong>",
"     increase",
"    </strong>",
"    rates of aneurysm rupture. In about 30 percent of cases of subarachnoid hemorrhage from aneurysm rupture there is a history of recent symptoms attributable to the aneurysm and thought to be caused by intramural or minor subarachnoid hemorrhage, also known as \"warning leaks.\" Major aneurysmal subarachnoid hemorrhage typically follows these symptoms within a few weeks in most patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H12#H12\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Clinical manifestations'",
"    </a>",
"    .) Antithrombotic and antiplatelet therapies could exacerbate the severity of the hemorrhage in case of rupture, perhaps even converting intramural or minor subarachnoid hemorrhages into major, life-threatening bleeding.",
"   </p>",
"   <p>",
"    Conversely,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    could",
"    <strong>",
"     reduce",
"    </strong>",
"    the risk of rupture by inhibiting inflammatory mediators (such as matrix metalloproteinases and tumor necrosis factor-alpha) that might play a role in the evolution and eventual rupture of intracranial aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/3\">",
"     3",
"    </a>",
"    ]. Clinical data on these points are sparse, as summarized below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECT OF ANTIPLATELET THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available clinical data are limited and conflicting regarding the influence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    on rates of aneurysm rupture.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Nurses' Health Study, a large prospective longitudinal cohort study, middle-aged women who used &gt;15",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      per week had twice the rate of all-cause subarachnoid hemorrhage compared with nonusers [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/4\">",
"       4",
"      </a>",
"      ]. The excess risk was particularly pronounced among older and hypertensive women, and it was not observed among those taking lower doses of aspirin. In this study, there were an unduly large number of subarachnoid hemorrhages relative to ischemic strokes and intraparenchymal hemorrhages, although the fraction of subarachnoid hemorrhages that were due to ruptured aneurysms was not reported. Despite multivariate statistical adjustments, imbalances in other vascular risk factors between aspirin users versus nonusers in observational trials leave etiologic associations unproven.",
"     </li>",
"     <li>",
"      In contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use at least three times weekly was associated with a lower risk of aneurysm rupture in a nested case-control study of the untreated cohort of patients in the International Study of Unruptured Intracranial Aneurysms (ISUIA) (adjusted OR 0.27; 95% CI 0.11&ndash;0.67) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/3\">",
"       3",
"      </a>",
"      ]. A possible protective effect of chronic aspirin use on the risk of aneurysm rupture deserves further investigation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regarding the severity of subarachnoid hemorrhage, data from two selected surgical case series have shown no apparent increase in the initial severity of bleeding and no adverse effect on long term outcome in patients presenting with aneurysmal subarachnoid hemorrhage who were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    prior to rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. There are no studies assessing the effect of other antiplatelet agents or combination antiplatelet therapy on the risk of intracranial aneurysm rupture or the severity of subarachnoid hemorrhage in case of aneurysm rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFECT OF ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No data supporting higher rupture rates following the use of anticoagulants are available from randomized clinical trials. However, available studies do not convincingly exclude higher rates of aneurysmal subarachnoid hemorrhage in anticoagulated patients due to the infrequency of subarachnoid hemorrhage, which is typically combined with other causes of hemorrhagic strokes in reports of clinical trials.",
"   </p>",
"   <p>",
"    Anticoagulation appears to worsen the clinical outcome of aneurysmal subarachnoid hemorrhage. Death or dependency following aneurysmal subarachnoid hemorrhage occurred in 93 percent (14 of 15) of anticoagulated patients versus 49 percent of those not receiving anticoagulants in the only reported case series [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/7\">",
"     7",
"    </a>",
"    ]. This was due to the worse clinical status at the time of admission of anticoagulated patients, as a consequence of more severe initial bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available clinical guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/8\">",
"     8",
"    </a>",
"    ] and major reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/9\">",
"     9",
"    </a>",
"    ] concerning management of unruptured intracranial aneurysms do not address the use of antiplatelet agents or anticoagulants. Given the available information as summarized above, it is not clear that antithrombotic therapies increase the risk of aneurysm rupture. However, the following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticoagulation with oral vitamin K inhibitors augments the severity of initial bleeding if rupture does occur.",
"     </li>",
"     <li>",
"      There is no evidence that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      worsens the clinical outcome of aneurysmal subarachnoid hemorrhage, but the existing data are meager [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. Consequently, at present, detection of an unruptured intracerebral aneurysm should not be regarded as a contraindication to antiplatelet therapy for patients who have a clear indication for such medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The apparent doubling (from about 50 percent to nearly 100 percent) of the rates of death or disability associated with rupture of an intracranial aneurysm should be considered in weighing the benefits versus risks of anticoagulation in patients known to harbor an unruptured intracranial aneurysm.",
"   </p>",
"   <p>",
"    As an example, for an elderly patient with atrial fibrillation and prior stroke or transient ischemic attack who has a 10 mm unruptured aneurysm involving the anterior communicating artery, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    would be expected to produce an absolute reduction in the rate of stroke of about 6 percent per year (half of which are likely to be fatal or disabling) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/10\">",
"     10",
"    </a>",
"    ], but would augment the risk of fatal or disabling subarachnoid hemorrhage by about 0.25 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. In the absence of other risks, this analysis would lead one to favor anticoagulation in this particular patient.",
"   </p>",
"   <p>",
"    For those patients with larger aneurysms or those whose absolute benefits from anticoagulation are smaller, the estimated harm from anticoagulation may substantially mitigate its benefits. Thus, the decision must be individualized according to the best estimates of benefits versus risks.",
"   </p>",
"   <p>",
"    It is unclear how the need for chronic anticoagulation should influence the complex",
"    <span class=\"nowrap\">",
"     benefit/risk",
"    </span>",
"    equation regarding repair of unruptured intracranial aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33348/abstract/7,8,11,12\">",
"     7,8,11,12",
"    </a>",
"    ]. Anticoagulation appears to double the mortality associated with rupture of intracranial aneurysms, and hence this is a relevant factor in the decision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7908451\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unruptured intracranial aneurysms are detected in 2 to 3 percent of older adults and hemorrhage from a ruptured intracranial aneurysm is associated with a short-term mortality of 40 percent, with one-half of survivors sustaining permanent neurologic injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link\">",
"     \"Unruptured intracranial aneurysms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7908480\">",
"    <span class=\"h2\">",
"     Potential adverse effect of antiplatelet or anticoagulant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet or anticoagulant therapy could potentially increase the risk of an intracranial aneurysm by one or more of the following effects (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Effect of antiplatelet therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Effect of anticoagulation'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By reducing thrombus formation in the aneurysmal sac, anticoagulation and excessive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use could increase rates of rupture. However, based on current evidence, daily use of regular doses of aspirin is safe and there is preliminary evidence that it might even decrease the risk of aneurysm rupture.",
"     </li>",
"     <li>",
"      Anticoagulation can exacerbate the degree of hemorrhage in case of rupture. This adverse effect has not been clearly observed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use. The risks associated with other antiplatelet agents or with combination of antiplatelet agents are not known.",
"     </li>",
"     <li>",
"      Anticoagulation appears to worsen the clinical outcome of aneurysmal subarachnoid hemorrhage",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7908517\">",
"    <span class=\"h2\">",
"     Management issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of a patient with an unruptured intracranial aneurysm who requires treatment with an antiplatelet agent or anticoagulation for another indication is problematical. Two general principles apply to these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection of an unruptured intracerebral aneurysm should not be regarded as a contraindication to antiplatelet therapy for patients who have a clear indication for such medication.",
"     </li>",
"     <li>",
"      For patients with larger aneurysms or those whose absolute benefits from anticoagulation are smaller, the estimated harm from anticoagulation may substantially mitigate its benefits. Thus, the decision must be individualized according to the best estimates of benefits versus risks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues to be considered include the following (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Management'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Risk of spontaneous rupture of the aneurysm (eg, size, location)",
"     </li>",
"     <li>",
"      Risk of",
"      <span class=\"nowrap\">",
"       thrombosis/stroke",
"      </span>",
"      if",
"      <span class=\"nowrap\">",
"       antiplatelet/anticoagulant",
"      </span>",
"      treatment is not given",
"     </li>",
"     <li>",
"      Risk of exacerbated bleeding from an aneurysmal rupture if anticoagulant treatment is given",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/1\">",
"      Wermer MJ, van der Schaaf IC, Algra A, Rinkel GJ. Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics: an updated meta-analysis. Stroke 2007; 38:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/2\">",
"      Wiebers DO, Whisnant JP, Huston J 3rd, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003; 362:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/3\">",
"      Hasan DM, Mahaney KB, Brown RD Jr, et al. Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke 2011; 42:3156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/4\">",
"      Iso H, Hennekens CH, Stampfer MJ, et al. Prospective study of aspirin use and risk of stroke in women. Stroke 1999; 30:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/5\">",
"      Juvela S. Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg 1995; 82:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/6\">",
"      Toussaint LG 3rd, Friedman JA, Wijdicks EF, et al. Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage. J Neurosurg 2004; 101:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/7\">",
"      Rinkel GJ, Prins NE, Algra A. Outcome of aneurysmal subarachnoid hemorrhage in patients on anticoagulant treatment. Stroke 1997; 28:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/8\">",
"      Bederson JB, Awad IA, Wiebers DO, et al. Recommendations for the management of patients with unruptured intracranial aneurysms: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2000; 102:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/9\">",
"      Wiebers DO, Piepgras DG, Meyer FB, et al. Pathogenesis, natural history, and treatment of unruptured intracranial aneurysms. Mayo Clin Proc 2004; 79:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/10\">",
"      Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/11\">",
"      Wardlaw JM, White PM. The detection and management of unruptured intracranial aneurysms. Brain 2000; 123 ( Pt 2):205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33348/abstract/12\">",
"      White PM, Wardlaw J. Unruptured intracranial aneurysms: prospective data have arrived. Lancet 2003; 362:90.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1320 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-125.69.132.100-EF8B9C69FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33348=[""].join("\n");
var outline_f32_36_33348=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7908451\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATE OF RUPTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECT OF ANTIPLATELET THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFECT OF ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7908451\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7908480\">",
"      Potential adverse effect of antiplatelet or anticoagulant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7908517\">",
"      Management issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=related_link\">",
"      Unruptured intracranial aneurysms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_36_33349="Granisetron: Pediatric drug information";
var content_f32_36_33349=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Granisetron: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=see_link\">",
"    see \"Granisetron: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/53/1878?source=see_link\">",
"    see \"Granisetron: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Granisol&trade;;",
"     </li>",
"     <li>",
"      Sancuso&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Granisetron Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Kytril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       5-HT",
"       <sub>",
"        3",
"       </sub>",
"       Receptor Antagonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=see_link\">",
"      see \"Granisetron: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of chemotherapy-induced emesis: Initial dose given just prior to chemotherapy (15-60 minutes before)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;2 years and Adults: I.V.: Manufacturer's recommendation: 10 mcg/kg; or as an alternative based on clinical research: 20-40 mcg/kg/day divided once or twice daily; maximum: 3 mg/dose or 9 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     As intervention therapy for breakthrough nausea and vomiting, during the first 24 hours following chemotherapy, 2 or 3 repeat infusions (same dose) have been administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Oral: 2 mg once daily or 1 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention and treatment of postoperative nausea and vomiting, before induction of surgery, immediately before reversal of anesthesia, or postoperatively: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;4 years: 20-40 mcg/kg given as a single dose; not to exceed 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.1 mg given as a single dose; this dosage is not yet approved by the FDA; trends in randomized, double-blind, multicenter, dose-ranging studies have shown doses of 0.1 mg, 0.2 mg, and 0.3 mg to be more effective than placebo for postoperative nausea and vomiting (Gan, 2005; Shillington, 2005; Taylor, 1997); 1 mg is the FDA approved dosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal patch: Adults: Prophylaxis of chemotherapy-related emesis: Apply 1 patch at least 24 hours prior to chemotherapy; do not apply &ge;48 hours before chemotherapy. Remove patch a minimum of 24 hours after chemotherapy completion. Maximum duration: Patch may be worn up to 7 days, depending on chemotherapy regimen duration.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1 mg/mL (1 mL, 4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 0.1 mg/mL (1 mL); 1 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sancuso&reg;: 3.1 mg/24 hours (1s) [52 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total granisetron 34.3 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Granisol&trade;: 2 mg/10 mL (30 mL) [contains sodium benzoate; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection, tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Given at least 1 hour prior to chemotherapy and then 12 hours later; shake oral suspension well before use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Infuse over 30 seconds undiluted",
"     <b>",
"      or",
"     </b>",
"     dilute in small volume NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W and administer over 5 minutes",
"     <b>",
"      or",
"     </b>",
"     dilute in 20-50 mL of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W and infuse over 30 minutes to 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal (Sancuso&reg;): Apply patch to clean, dry, intact skin on upper outer arm. Do not use on red, irritated, or damaged skin. Remove patch from pouch immediately before application. Do not cut patch.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F177481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, bacteriostatic water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, allopurinol, amifostine, amikacin, aminophylline, amphotericin B cholesteryl sulfate complex, ampicillin, ampicillin/sulbactam, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, cisplatin, cladribine, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, dexamethasone sodium phosphate, dexmedetomidine, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin liposome, doxycycline, droperidol, enalaprilat, etoposide, etoposide phosphate, famotidine, fenoldopam, filgrastim, floxuridine, fluconazole, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, gemcitabine, gentamicin, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, hydroxyzine, idarubicin, ifosfamide, imipenem/cilastatin, leucovorin calcium, levoleucovorin, linezolid, lorazepam, magnesium sulfate, mechlorethamine, melphalan, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, minocycline, mitomycin, mitoxantrone, morphine, nalbuphine, oxaliplatin,  paclitaxel, pemetrexed, piperacillin, piperacillin/tazobactam, potassium chloride, prochlorperazine edisylate, promethazine, propofol, ranitidine, sargramostim, sodium bicarbonate, streptozocin, sulfamethoxazole/trimethoprim, teniposide, thiotepa, ticarcillin/clavulanate, tobramycin, topotecan, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, amsacrine, ceftriaxone, doxorubicin, fosaprepitant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dexamethasone sodium phosphate, methylprednisolone sodium succinate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets and injections: Store at room temperature, protect from light; injection stable when mixed in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W for at least 24 hours; multi-use vial (with preservative) stable for 30 days after opening",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of chemotherapy- and radiation-related nausea and emesis (FDA approved in ages 2-16 and adults); prophylaxis and treatment of postoperative nausea and vomiting  (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Transdermal patch: Prophylaxis of nausea and vomiting associated with moderate-to-high emetogenic chemotherapy regimens &le;5 days consecutive duration (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2138081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Granisetron may be confused with dolasetron, ondansetron, palonosetron",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F177480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fever, headache, insomnia, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agitation, allergic reactions; anaphylaxis (including hypotension, dyspnea, urticaria); angina, application site reactions (transdermal patch), arrhythmias, atrial fibrillation, extrapyramidal syndrome, hot flashes, hypotension, hypersensitivity, syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to granisetron or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with liver disease or in pregnant patients. Use with caution in patients following abdominal surgery; may mask progressive ileus or gastric distension. Application site reactions, generally mild, have occurred with transdermal patch use; if skin reaction is severe or generalized, remove patch. Cover patch application site with clothing to protect from natural or artificial sunlight exposure while patch is applied and for 10 days following removal; granisetron may potentially be affected by natural or artificial sunlight. Do not apply patch to red, irritated, or damaged skin.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists, including granisetron, have been associated with a number of dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QT",
"     <sub>",
"      c",
"     </sub>",
"     , JT), usually occurring 1-2 hours after I.V. administration. In general, these changes are not clinically relevant; however, when used in conjunction with other agents that prolong these intervals, arrhythmia may occur. When used with agents that prolong the QT interval (eg, Class I and III antiarrhythmics), clinically relevant QT interval prolongation may occur resulting in torsade de pointes. A number of trials have shown that 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists produce QT interval prolongation to variable degrees. Reduction in heart rate may also occur with the 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists. I.V. formulations of 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists have more association with ECG interval changes compared to oral formulations.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some injectable products contain benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of products containing benzyl alcohol in neonates.",
"     <i>",
"      In vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F177470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F177402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F177404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F177417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate or well-controlled studies in pregnant women. Teratogenic effects were not observed in animal studies. Injection (1 mg/mL strength) contains benzyl alcohol which may cross the placenta. Use only if benefit exceeds the risk.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonist, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: 1-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.V.: &le;24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2-3 L/kg; widely distributed throughout the body",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via N-demethylation, oxidation, and conjugation; some metabolites may have 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonist activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cancer patients: 10-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Healthy volunteers: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily nonrenal, 8% to 15% of dose excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11376409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral solution is available (0.2 mg/mL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 0.2 mg/mL oral suspension may be made with tablets. Crush twelve 1 mg tablets in a mortar and reduce to a fine powder. Add 30 mL distilled water, mix well, and transfer to a bottle. Rinse the mortar with 10 mL cherry syrup and add to bottle. Add sufficient quantity of cherry syrup to make a final volume of 60 mL. Label &ldquo;shake well&rdquo;. Stable 14 days at room temperature or refrigerated (Quercia, 1997).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 50 mcg/mL oral suspension may be made with tablets and one of three different vehicles (Ora-Sweet&reg;, Ora-Plus&reg;, or a mixture of methylcellulose 1% and Simple Syrup, N.F.). Crush one 1 mg tablet in a mortar and reduce to a fine powder. Add 20 mL of the chosen vehicle and mix to a uniform paste; transfer to a calibrated bottle. Label \"shake well\" and \"refrigerate\". Stable for 91 days refrigerated (Nahata, 1998).",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Morosco RS, and Hipple TF, \"Stability of Granisetron Hydrochloride in Two Oral Suspensions,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1998, 55(23):2511-3.",
"     <span class=\"pubmed-id\">",
"      9853637",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Quercia RA, Zhang J, Fan C, et al, \"Stability of Granisetron Hydrochloride in an Extemporaneously Prepared Oral Liquid,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1997, 54(12):1404-6.",
"     <span class=\"pubmed-id\">",
"      9194985",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1999, 56(8):729-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/36/33349/abstract-text/10326616/pubmed\" id=\"10326616\" target=\"_blank\">",
"        10326616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Coop A, and Philip BK, \"A Randomized, Double-Blind Study of Granisetron Plus Dexamethasone Versus Ondansetron Plus Dexamethasone to Prevent Postoperative Nausea and Vomiting in Patients Undergoing Abdominal Hysterectomy,\"",
"      <i>",
"       Aneth Analg",
"      </i>",
"      , 2005, 101(5):1323-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/36/33349/abstract-text/16243988/pubmed\" id=\"16243988\" target=\"_blank\">",
"        16243988",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hahlen K, Quintana E, Pinkerton CR, et al, &ldquo;A Randomized Comparison of Intravenously Administered Granisetron Versus Chlorpromazine Plus Dexamethasone in the Prevention of Ifosfamide-Induced Emesis in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 126(2):309-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/36/33349/abstract-text/7844684/pubmed\" id=\"7844684\" target=\"_blank\">",
"        7844684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lemerle J, Amaral D, Southall DP, et al, &ldquo;Efficacy and Safety of Granisetron in the Prevention of Chemotherapy-Induced Emesis in Paediatric Patients,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 1991, 27(9):1081-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/36/33349/abstract-text/1659848/pubmed\" id=\"1659848\" target=\"_blank\">",
"        1659848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shillington A, et al, \"Retrospective Cohort Study of Granisetron Administration for Postoperative Nausea and Vomiting Prophylaxis and Treatment,\"",
"      <i>",
"       Hosp Pharm",
"      </i>",
"      , 2005, 40(7): 592-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor AM, Rosen M, Diemunsch PA, et al, \"A Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Multicenter Study  of Intravenous Granisetron in the Treatment of Postoperative Nausea and Vomiting in Patients Undergoing Surgery With General Anesthesia,\"",
"      <i>",
"       J Clin Anesth",
"      </i>",
"      , 1997, 9(8); 658-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/36/33349/abstract-text/9438895 /pubmed\" id=\"9438895 \" target=\"_blank\">",
"        9438895",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13341 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33349=[""].join("\n");
var outline_f32_36_33349=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177430\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177431\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059048\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059043\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177407\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177393\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059051\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177481\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059046\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059050\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138081\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177480\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059056\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059042\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059041\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177470\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177402\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177404\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177417\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059040\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059054\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059055\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11376409\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13341\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13341|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=related_link\">",
"      Granisetron: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/53/1878?source=related_link\">",
"      Granisetron: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_36_33350="Hypoglossal nerve";
var content_f32_36_33350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F86991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F86991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Hypoglossal nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 496px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHwAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKQEHoaWq8bcEdwSKTY0rliiow1ODU7isOopM0uaACijNFABRRRmgAoozRmgAopCwppei4WH5pCyjqRUDyYqvJL1qXKxahcv7h60bh61mwXXz+W5+bsfWrIkpKVwcGizketLkVV30okp8wuUs5FGariSl8yncOVk+aMiq5lpPNpcyDlZZyKMiqvnUCWjmDlZayKMiq3m0vmUcwcrLGRRmq/mU4SU+YOVk2aKiD0u+i4rElGaZuo3UXCw/NFM3UuaLhYdRTd1G6mIdRTd1LmgBaKTNGaAFopKM0ALmjNNzRQA7IozVHUr21thDBcXi2s14/kW53LvaQqThAQQSACeh6c8V45pXi/WND1T4iX+v8AiDV9V0vwpJGsVoLe0U3AeLP7xkhU5DEHKlQMcg8ggHuOaK8Y1L413GlW2qJqHhyL+0bJbGURW+o+bDJHdEBT5piBVhnldvPY96n/AOFw3X9rNoY8OR/2/wD20dHWI35FsSE3+YZvK3AY/h8vNAHsFFeM6L8bjqKabv0BYWvLbUrjAvtwU2gPyg+WM7tvXjHoarD47XFzFpq6R4PvtQvrnS01SW2geaRlRn2BIzHA+48Zy2xe2c8UAe30VDaz/aLWGcRyRiRA+yVdrrkZww7EdxUuaAFopN1NZwPzoAfRRRQAUUUUAFFFFABRRRQAVUf5Lh17MNw/rVuqt+Nsay/88zz9D1/z7UnsVHccGpQ1QhvSlDVNyrE4al3VAGp+6ncViTdRupmaM0XFYfuo3VHupC1FwsSFqaXqMtTCaTZSiSGSmF6iZqjLVLZSiSu9V5GoZ6jJzUNmkUV58kZBww5BHap7O88z5JMCQfr7iqs7HBxVOUgkdR3BHUVnzNamyipKzOjVqC3NYkF+8WBNyv8AfH9RS665ufD2pxwgyO9rKqqoyWJQ4AHerU0zKVNo2t1G+vmnw14d8VRL8IRfQTLbWRuQ6RabJHLYZTAMzMzLknGMog46GnweOvHreHPGNxd6iIJfC1tJZy3CW8JF3eeecSYKYAWMKNoxywJ9Ku3Yz9T6QeSoDMTJgHpya8FHin4gy6fqM+nnVrrSvOsNl9PpapdRxuubkwReWvmhTgAlDwerYzTD4k8exLZ/bX1a20Q6heCTU00xWvGt0jBgaSHyiEDNkFtg4HIXqZZase6tqdouopYNd24vnjMy2xkHmMgOCwXOSueM9KtCSvmjQNV8aaumj+KrO0m1HWm8L3SrcNbhYmm+1fKvygJu2DIXjOK2v+Eg+IBsdSWyu9T+zD7J5F7qOiSLcbypM8axxW5IUY4domUHjJyDRYLrsfQCye9PD8V8+aj4o8fjSdFubaDxDG7wu1xYfYgbyRzKVQ+cLJoFUKM7XWJgOT1BOlc+KPHX/CxbC3sbDX49H/tRLW6ju7RJIjARzKjx24CoP7xmY56qBTSYm0e06dqVpqdqLnTbu3u7YsVEtvKsiEg4IyCRkEEGritXjvw/g13QvgTqotbO8ttdhTUZbWF7YmXzPMlaMiNh82TtIGDnI65pnhnxR4y0a7uLjxLZeINZ04aHZXphg0tPPW7kKrLFGEVASNxJUklQD6Uybnsd1dwWdrNc3k0VvbQqXkllcKiKBkkk8AD1NSW1xFcwRz28iSwyqHjkRgyupGQQRwQR3rzX48nPgS3NwCNM/tSy/tHPT7N56793t0zXH/GTQtR1DxVqd34a0fUngXTIotc+zxMn9qwGaMiCBtvzSCNXyy5wpC9elIlnv+aq6jqdjpkUcupXttZxSSLEj3Eqxhnb7qgkjJPYdTXip0nSD8c9K1CPwrdro6eHxB5jaFMY0nyCik+XjcIsLntjZkHiuf0DS9O0v4G/EuPUtEuNKeWe6lj+0abJaNIhJ+ybS6Luw+MKM7c9Bnlkn0tmjNZPhY3n/CM6R/au7+0PscP2nf183YN+ffOas3+o2mnxhruZY89B1J+gHNJu25Si5OyL2aXNcbqHi1+V0+3AX/nrPx+Sj/GsC71W9uwftV9Oy/3UOxf0xmspV4rY64YGpLWWh6XPcwQAmeaKMDu7gfzrPk8RaTG2DfRMf9jL/wAga8y86GMny4lz3NL9tPZfyFZvEvodEctXVv8AL/M9J/4SfSf+flv+/Mn/AMTQPE+k/wDPy/8A34k/+JrzNrxicY/PFAuj/cH6UvrMi/7Nh5/h/kemnxRpA63f/kJ/8KsQ65pcxAS+twx6B32k/gcV5WLo90/L/wDXT1nhJG5CPwprEsl5bDo2ewRyJIu6NlZfVTkVV1jU7PRtLudR1OdLeztkMksjdFA9upPYAck8DmvMLfaZQ1rLJHKf4kYq351m2WtXniHU7O9mk+3eH9Ol8y0jnJAvJh0mJ7ohH7vOcnL/ANzG0a6au0ctTBOLtF3Z3vhTTb3UtSbxR4hheG9lQx2FjIObC3POG7ea+AXPbhRwCT0UWk6dFJfSRafaJJfc3bLCoNxxj94cfPxxznisyx8V6dcFEuWezlbtMMLn/f6fnit8EEAg5B5BrRSUtjknTlTdpKxiW/hDw1bWEljbeHtHhsZJFle3jsoljZ1OVYqFwSOx7VT8T+BtH1+xmtjBBZfaLgXVxJBY2srTyBSAXE0Uik8/exu464yD1GaUGqIOR0L4c+F9J8OaforaTa6ja2LO8T6jClw+9zl3yy4BJ64A7DtWje+DfDF9a2tte+G9FuLe1TZbxS2MTpCv91AVwo9hW6KWgBkcaQxJFCipGgCqijAUDoAOwoJpxNVLy4jgXdI2ATgDqSfQDvSbsVFXJWkxUKSedcLGnIU7nI6D0H51DHBc3Zy+63g/8fb/AOJ/nWlDEkEYSJQqDsKSuxtpD6KKKszCiiigAooooAKKKKACkZQylWGQRgilooAx4maGR7dz80fQ+qnof8+lT7qbrkZSJbtAcw/fA7p3/Lr+deK/GrSbjUda03UbVbi7extWaKyuNFk1KyuGZuhEeTHJhfvEYwR8wrF6OxutVc9tDU4PXzXo9p4w0jxVfatb6bqVpqVx4ciWzs1g8+1M6I37h5SjFduNwDOrFsKWIOKnj8S/FH/hF9QljnvX1Bvsfko2kSmaBi4Eww1rFGyYJOBvK4+8R81USfR26l3V4J4lvfiZpdzrVrZ6xqV+1hpEdzbXNto8QS7uTMdyBdjZ+Q42q2eAfXL7nxL8Rm8QAJb6hHMb+1SCwTTQbKW0ZMyySTlCUcHPHmAjGNpoCx7ff39rp9nLd39zDa2sK7pJppAiIPUseAPrUkcySxJJE6vG4DKynIYHoQfSvn/xHdeKte8EeMrLXf7f/tl1uIoNJt9JzZtGCPLMcywkuSOf9bknI28U5tb+I1r4lt7KFZbHSrf7EtujWE00U8OweaHMdtIwfPHMke30PUAz3uadIYnkldUjQFmZjgKB1JPYVWstQtdQs4rvT7mG6tZRujmgkDo49Qw4Ir59hvPGcGjWuntY6jpml3V1qYun07RU809fIUxrEdqOTzJsyf7w61T0e/8AHug+DtI06xttZ09LfRFazittL88z3nmnMVxujYxDb67OOd3akNH0kz1E0leG63rnxJGpa3JAuowrbXOmJb21vp6SwussY+07XMZZ1Vs/MG47mmX/AIh8eWtrqFk0PiGadNZuba0v4rKNR9nVFMbShbaTcpJOGSMAkckVNi00j3PJNO/gzXgJ8UfEZtH8PXMsOsfantP9MsLPTGhuHmMzKHMklrLCo2AEqTH655FJo0Pi/wANWXjxdKi1v7fP4ge4G/T1kBtHZN1zCRHtklx/ACRgfcoUQ5z3mVMOfese7vLOK9isZLu3S9kUyR27SKJHQdWVc5IHcivLI7zxrqGraLJc6ddahZW+uTJa3l9pKJO1sIiVeQGNTD83G8KhNUfA8XifV/iL4a1bxLb6w12ljeRXv2jTTbwWkhf5Y0YRqGUrjBLPn17UOndDjUsz2PJFLHuRsxOU9uo/KlxkdMH0PanLjvXLsdZOlzMPvIG9wf8AGs/+zNMFhdWK6NZCzunaS4t/Ij8uZ2+8zrjDE4GSRzVvcKA9VzE8qFQbEjQKiRxgBI0GAoHQVR1nR9K1uOOPWdMsdQjjJZFu7dJQpPcBgcVdJ4pmaVx8qJLZIreCOG3jSKGNQiRooVVA4AAHQVOrVWBp6tQmDRFrmqxaLol9qVwC0dpC8xQdXIGQo9ycAe5q7pT3R061OoiIXpiQziIEIJMDdtyScZzjk1yviljqGraFoikFJrj7fdDr+5tyrAEe8zQfUBq62Nq0vZGLV2y6jVKDVVWqZGq0yGh1zbwXlrLbXcMU9tMpSSKVAyOpGCCDwQfQ1LbQxW0EcFvGkUMShEjRQqooGAABwAB2pqmpAapMzaJKo6xaabeWqjWLa0ubeKRZlFzGrqrr91gGB+YdiOanubiO1geaZgqKMkmvPtW1KbVbpiSVgU/Kvp/9epnU5Dahh3WfkbWq+J5Ji0WmjYnQzN1/Adq5i5nAZpJGaSVurMck02aVY12p2/IVnTzDPzH6Dua5J1G9z2KOHjBWiiw90Sc4BPvULuz8sSf0FQKZHPACA+vJpQmcFizcdzWV2zpUUh+4f/q5pGJPb26+1BO1cjGKUtkEj1BoHYOd2cDtQvQcL0NH8Qz/AJ/zmmnjYc8cikAhJ3N+B4P0pGdgrEZH604ACQZ6EYpn9/6f5/nQNGVqVw2q3EujQMwtk41KdOMgjP2ZT6kHLkdFIXqzbeht7lYo0SMBUXChVGAB9KoRooPCgDPOB3PWnc+WvsapzfQzjRSu3q2bCzRuMHjP5flV7S7+80lg1hMPI7wP80Z+g/h/D9a5hpmRjnNWorl0LEHgVUalmROhdW6Hqmg6/baqPLYeRegZaBjk/VT/ABD/ACcVtCvHopVm2MMrIh3LtOCp9VPY123hPxG95N/Z2plftoXdFKBhZ1HXjsw7j8R7dtKtzaM8fFYJwvKG3Y6ulNIKDXQecNY8VmaovmRcMUdTlHHVT6itNulZWoNhazqPQ2prUv6Rdm9sI5XAWTJVwOzA4P8ALNXKwfCrknUI/wCFZgw/FFz/ACreq4O8UzOpHlk0FFFFUQFFFFABRRRQAUUUUAFFFFACEBgQRkHtXLmM6fdvZNkJy8BPdPT6g8fTFdTVDWbD7fa7UYJPGd8T/wB1v8D0NZ1I8y0NKU+V67GVvppeq1tP58QYgowJV0PVWHUGpCa5rnZyj/NrldZ+IvhrRdSu7HUtReG4tGiW4/0WZ0i83/V7nVCoB9ScV0jVwniL4caRrl3rtxd3OoI+sfZftAikQBfIIKbMocZxznPtimmuonF9DrNB8Tabr63Z0u4aRrSY29xHJC8TxSAZ2srgEdfSsrxX4lvbHxF4c0TSUtjd6rNI0klwpZYoIlDSEAEEscqBzjJ71Qg8EWltq91qFpqer20t1qK6lOkNwESVlXb5bALzGe6k/jUnirQ72+8Q+HNb0qS3F3pcsiyRzkqssEqhZBkAkMMKRxjI5p3Vw5XYvXHjzQYZ9Ria6uHGnCQ3csVnPJDAY1LuGlVCgYAH5c5zgYyQKxPFPxV0TSNCvb3T2fUrq3sodQW1WOWPfDKVCMX2EKDuB56d8VKPAdjH/bMFvqGpQaZq7TSXmno0Xku8qlXYEoXUnOflcDIHGOKy4PhPoq2t9b3N/qt2l3pselsZZIgUhjIKbdsa/MNo5Oc45zQnETUuhrXHjO5i1vwo32dRomuh4AZYJIp4LgKWTIbGVYBh90HockGu4eRIYZJZ3SOJFLs7kBVAGSST0FcQ/hC+vde8Kie++0aRoW+43zsPtFxPtKR7giKgVVJ5HJOMjqT6AkKOCkihkcYIYZBHoadr7Cva9whIdEkQhkYAgg5BB71Megx1HFct4KJ0m5vfCtwzE6eomsGY5MtkxIUfWNsxn2CE/erqDx/KtFGxHNcQOEzk8HmqF9fxQozE/KDz7U7UpfLiyoySeB7+n49K4rWNVVUaMNzIvQ+uP8P1BrOrU5EdWGw7qs3otThu7grH8rkZ2n1HWrBavKlvriCTzI3PnROHVif5+o7H8a9K0u9i1PToLuHIWVd2D1U9wfcHIrkjU59TsxWF9g1bYtbqM0zvS1Ryj80oOajzUDTGK4CN91vumhuxSVy6KcDUStkZFUPEmqNo2gX+oRoJJoI/3MZ/5aSsQsaf8CdlX8apa6Il6K5S8OH+0fEWu6uwPlrINMtie8cBPmEfWZpV9wi11KNWN4a0xdF0Gw05ZDIbeJUaQ9ZHx8zn3Zsk+5rUVsk46iqb1JUbLUuI1Tq1UVepkeqTM3Euo1ShwBkkADrmqitWR4p1A22n+UhxJNxn0HeqcrK4o03OSijH8Saq2o3YihJ8iM4X3Pc1luSi7I/xNMtxgFz1PSm3MvlIMDLMcCuWUr6s9iFNRSjEpXEhJKJ16/So1Ta4I5PcmpWQLg9c9TTVHNZHUthe/wBDQBgjPUEihv8A6xpCSee56/WgQEZUjv8A4UKMcDoRxQD8x9ufzpemPY0DDBbp3GabEPMgmXGHjw49weD+uKIpx5wgkwschwrn+Fu34U60Q/2kkLHYWWRDnt8pPP5VhVqqKk+2vyFsJKuYd+O/FRnHmN7/AOFT3DK5YJkRqNq59P8AJzVMnLBe/T9DWsW2rsqJKMqh9yKGHBApoGQoPOSKfGAWYnpxVANnQk8CmMzR5ZeQRyKnZiWGOgFQOyovzGkxokhmzHuHGOQauR6kYJYblT+8t5UmB9gfmH4jP51jfaYo4mQtyfeptAhk1rWrext1JWRsyvjhUH3j+X6kU4yd0kTUguVylsj3wciionk2jgds0x5gBXr3PklEfM4VTzWDql0kaM7thRVq9ugqMzEBQMkntUOiWLXsqahdoREpzbxt3/2yP5fnWUrzdkbxSprmkX/DtpJa2LPOmyedzK6n+HoAPyA/HNatFFbxXKrI5ZScndhRRRTEFFFFABRRRQAUUUUAFFFFABRRRQBzevWv2S8W9jGIJiEnHYN0V/x6H8Kr9a6e6t47q2lgmXdHIpVh7GuQhEkEktpcHM8B2k/3h/C34j9c1zVY8rudlCfMuV7omIqNhUhNN61ib2IiKbg1ORSYoGRAGnBafjmnAUALATG4YVoZ3dPqKoCpVnCALuAcAlQe471tTdtDGpG+qMXxva3MVvaa7pkTTalpDNOsUY+a5gIxNAPdlAI/20Q9q3rW+tb7T7e9tJ0ltLmNZYpVPDqwyrD6g1nTamsahZGHzLnHpzg15raaodEv9Q0ONyLMFryyx0WNm/eRj/cdgw/2ZcdEqpVUkVTw0pSXZnZeI9VREkRXwV5HPX0rze9uGnnMgJ+bkfWku9Te7nHmE/KcH6VFjBZO4ORXk1a3tJH1GFwyoRt1JZCCElH3Twa3/A2pfZNTk0uZsRT5lhJ6Bv4l/Ec/nWDAQwaI9H5X69xVe7SV7bfAxS6gYPGw7EciphLld0VXpKtBxZ7EyelNrH8Ha9FrelRy5xOo2yJ3Vh1reK56V2LVXR85KLhJxZCarX0PmwnH3hyKuFKaRSBOzKmn3BkTDH5ufzHX+h/GsnXidQ8S6HpSkGKFm1O5H+zH8sSn6yNuH/XE1NMzWmrBVBKzfMgHdx2/Fdw+uKg8Kn7dqGta0QCtzcfZbduv7iAlAQfRpPOcezisMLUfNOnLeP5Pb9V8iqq1Vup04NO6+x9aYDTga6SSvLcPbnLjKnuKhl1ZEXO4VedVkQqwyD1FcZ4hspbOUMCRE54btUzk4q6OihCFR8stzZt/FUUN0I7n/VNxuH8P/wBaqfiO7F5qf7tg0SgKpByD3rj7kSRkFl3A8juCKfBcuiedaOWhH3425MZ/w9/8nm+s30ex3rBwi+eG50pOEUd+tVZ3y/04qlBq8DYErBG9zUkkysxcFSh6EHIrRyvsCpuL1JJCNuO4qJGy3B61HLKu7JdQCMdari7t4zl54h/wIVNzRR0Lufm56HIpCeDz71SbU7In/j4X8ATUb6tZgcSknHZDRzIpQl2NDdxwPagZ2t7isn+14QMKkzfRKadYYgrHbSHPqQKXMh+yl2NGWIyQMOh7H0ParsObkC7xhhbur/7+VU/o1YD6lesBstkGP7xzU2lXl+1lrcLMiSMsUse0dPnw38xXJimuVNd0vk2kxSpytc05A2SR0qOaSOJ90kirg+tZkWlandoJJ7lo4T/HI4jU/TPX8Ka+lWsLESTl2HUk4H4dzWyrxk+WO5ShHa5Zk1W1Q/KxbHtVd9YVsiKKRveoZZdNth99M/7K5P61m3OrwElYVLVTkzWNJPoXpdSumOcBRTLR73Ur+Gys4XubiU8In8z6D3rDlvZ5ZVjjXDN0zXv3wr8N2+i+HobtgJL++jWaWY9dp5VR6AAj8fwrShTdWVr6GGNrxwlPmtq9jF0X4YyNtk1q9CjqYbYf+zn/AA/Gu/0rR7DSITHp1rHAp+8V5ZvqTya0M1FcuFhY+2ABXqQpQp7I+XrYurX+N6diGQ/IzjoRxUEpOKsXjbYC2CQME49KglwyhlOQRkGiRnAzooP7S1VbZxm2hUSTA/xE/dX8xk/SupHFc/ojeVrV1Gf+W8Suv1UkH/0Ja6CqpLS5NZvmsFFFFamIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz3iiExSW98g+UHyZv8AdJ+U/gf/AEI10NQX1sl5ZzW8v3JUKn296mceZWLpz5JJnK5pc1Ws2drdfN/1q5R/94HB/UVYFcKPTHCjFIKdTEJSikNKKBC5qhrjPFpz3EQzJB+8H0H3v/HSavUkirJG6OMqwKkeoNA4uzTZ5drOqyLcBy/A6D69a5fUmN5c2s4fZLbTB0bGeDkMp9mUsp9m9as6/E0N28LE5QtGf+AnFZcTE8HuMV5s6klI+opUISp2tuTyttKkdeh+taTnda21yvR1P6HBrMYeYpHTcM/jV/S45LzQ0hQEzpf/AGdR6B1H9Qa5KtRU7Se1zabsrsmY48ojgsN49jmpj/rFkA+VxyKZqbxteTpb/wCqjbYh9Qoxn8cU+1bzFK/3uR9e9b0Zc8E31M18KZTgvZPDmsfaos/ZZ2CyjsD2b8en4V3et+NrLQ/CdxrVxHJcLGFVIYsbpHZgqqM+pI57CuUntUv4WglGRIpX6HtXIM8b2154d1+NpLOXCkbiCMEFWB7EEAiuqlPldpbHn4zDe1i5Q+I9hude1vT/AA/qOoar4cXzrWHz0gsr9Jg4wSwLOse0rjnAPB+XceK0fCuq/wDCQeGNL1fyPs/262S48rfv2blBxnAz164FclY2qXmg3lldeJdZmW7iWF55GgLpHggqo8rZyCcsVLH14GOu8G6PDoPh+10q1vbq8trVBHC9z5e9UAAC5RVBAA6kZ9Sa67xei3PFcJwfvFXxXbSNZLPAzJNCwZWU4IPYj8ak8NQW1notpZ2SlbW3iSOEE5Pl7Rtz6nHGfUGtq6gWaF42GQwwa53w8Wi3QP1jZoj+e5f5v+VefiHKlXpzWz91/o/v0+ZtG0oPujdBp4NR0oNdpBKDTZ4Y7iF4p0DxsMFT3pAacDTFtscJrGlNpUjbXZrNz/y05UH3PY+jfnjvg3EX2C5jnZSY3HzA/wAa9CPqP8D6V6zKiTRtHKiujDBVhkEV5z4q0g6EjP8AvJfD8rDzFHzPZsejr6r/APq9DXBXoON5w1XVf5HqYXFc3uT3/P8A4Jz+ryxWN08AZ22EqWbox/oKpm8iKjdEOe+BT/EiyLfS/aQHikcyRXCd1Y5B+hHeqcWnmCNZr67W0gfmPA8x5R6qg/mcD3rCNRKCk3uerG3KmyzE0M0yIsYyxC5Pv9KmKQqxUpDkHBwc1Uj1Gxtz/o2mXEso+7PNOEI9wqggfmaga5Z8iLS4I/fe7n9Tj9KFUk38Lt8v8w1fQ1Q0QHAT8/8A69KJY/7sX/fyseNLps5ZYwf9hc/ypRZv3natU2PlRs+dGBn9wB7nNN+3xJ/y0U+yLWULJCfmdz+NItvFu4XI6DJ607sORGjLrCAfIpPvirHh7Vw+pXzTR7o0sJZCufvbWVgKw7kxW6biF9u+al8M77i/1EyfKh06cZPQZ2iufFa0miakI8jK11rF1f3LSyZllbuB09h6CpNlzKB58xVT/d5q3Z6cIV+RlOe45zV1LJT359K2SsrIu8Y6IyY7OJWw4Z89CTSRReVcmPb8rcr/AFrcW1jX+HI9+1FzbCWMAcOvKsKYucyLm0ME0ch5U8cele/fDLVV1PwdYgkGe0UWko9GQYB/Fdp/GvER/pEDRuMSL2rd8CeIj4a1fzJ8/wBn3O2O6/2COFk/DJB9j7V0Yar7OeuzODMcO8RRst1qe95qtMS93EuTtUFiPfoP61KjqyhlIKkZBHeq6ndeTH0Cr/M/1r1JvQ+USJ3wVI7VSthmyh9kAq3Va0/49Ix3A2n6jg1PUpFK4cWt1b3Z6Qv83+63yn8s5/Cunrn7uNZI3VhlWBBFX9BnabTYxIS0kRMTk9yvAP4jB/GrpuzsKsrpSNGiiitjnCiiigAooooAKKKKACiiigAooooAKKKKACiiigDjrxfK1nUIgMDesg/4EoJ/XNAqfXV2eICR/wAtLZT+TMP61wHxg1DVNN8HifSJLiAG6hju7i3XdLDbFsSOuAeQO/YEntXFJe/Y9KEvcTO4FOFeGT/ES30uw1FvBbX97Pb3VpaMdWvfttq/mswDRyrK7ZI6gnjj5Qcip/EnxL8X6Brv9kXun6DHdwQQyu0s6wQXZY/P5Uk00e0KOPuudw5AFPkYe1R7YaWvF9S+KOpv43Og6W1nLDLeTacTLaGKa3lCEqcfaC7jPfy0DYODnp0PwC1W91X4d2Umqasmo3sbOkoYs08JDt8kzM7Et3GQvBHHcpxaVxKabsj0ej2paXFKxR5J8Q7M22uyuB8koEo/EYP6iuQYFG3e/NeqfFCyL2FpeqMrC5jkH+y+MH8wPzrzKSPDFTyPun+hrzMRHlmz6fL6vtKMfLQWNuPoa3fDd1HYabrt1JwYpITD7yMrqPyzn8K5yJ9hIbtwa2NVi+zWdppv/LYD7Xcj/bYfKv4L/M15uLiqqVF/af4LV/5fM3rpStDv+RBEcAHt0qxC5R8DjuKz7WYMCrcHpVsNlQ3p1ruTLaNqEh2BHBPzD69xWJ480w3NnHqduuZI+JMdcdjWlaSErwcMORWZrPiuG2huLe1jSbepV2f7invj1rW6tqYNNS0Of03Wz9maISfMVwDmvVvDniDzNLt7+M7o8CO4X+44/wA/yr5xSdkk3xE7QTtz6ZrtPh54kWx8QRQ3JBsr7FvcI3TJ4VvwJ/Imsa85wj7WG8dbd11RhiMOpxukfSNndw3kAeJgQRXmPxouLnRvCniC5sLia1uHt1eKaGQo6OHUEgjkfKW/OrVtdzaTNNJYyNNbQOUnjJy9ufRh6ejVt3ur297Da3YI/dvhx6qeD+ma0eKp4qh7Snrazt5rW3lseO6Di2ls9Dir/XNQ8F+G7CaYpbXmoypHEbi9n1RJPkJ5e4kgWE5/2sH37UNE+KWqarZ+HHu5NG0GLULWeabUL+N2tzLHK0flIPMTDELu+Z+h717DZktaRhjl0+Rj6lTjP6VIa76daNSCmlvr95zOm07XPG3+IF1pcet7J4En/t17KB5I5LiKQeWrdZblEiBJyMOFx0XvUHgrxLceLfHXgfWr2GKC6uNJvhIkWdgZJtnGSTg7c9TXst9FLPY3EVtcNbTyRssc6qGMbEYDAHIODzg8VR8Mao+raSs1zGkV9C7W15CmcRTpw6jP8J4ZfVWU9605la6RLg7pNnFeI/G/iLS/H6+F7axspZdQkt302cxOVEB3ee0uG5KBTjGOxxXbW+s6X4g0zUDp84uYbeeSznzGy4kTh1wwGcZ6jitUGsjV70ENHnjbnOffFS2mtEa04Pm3POkto49QTQZJcQzOWsGbkLz88J9iOV9CPesXVTJc6pdvs3RtMU29PLwcKB7AAAfSrvi6N5LaS5hJWe0kW4jYdQVP+Gan1MRteGeABRePHdADsXQMf/Hia8Z0+Svps0/k7q/37/efRUfdZVjtSLZEmAaUEZI92AB+uM1oKdynA5diB9OmagL/AMa8/MSB7AbR+pq9aAGG8jHJtkjf8OQf5r+dbSlyq5pJkflRkklRgcUhhjC5KDJ7U/B2qh6nk/1oZhksfup/OrEU7uOOOMIqgu3U1Vunis7c7wN5HPt7CrcziNTNJjd2B7f/AKq59mkv7wKoLYOQD/M1JpFdxIIJLy43yA/0UV0+jwLHHqJCjaLUJyOpaRf6A1Xt4BDGEG73Oepq/boY9NmYggXMwUf7sYOf1f8A8drCurxUe7X53f4JkVZXVjLNmUO6AlPYdPyqSOaVMB1DVpQWk0i7oopXHqqkinNanGH8sH3dQf51tzRva4c66lSO4jYgNlW9DU+OMjkVG1upBHb0PIqMQPGcxSFfY8iqDRjbmHcRJF/rV7evtUCOrnkc9Cp7+oNTvOVOLhDGezjlTVS9Ut+8jI3+o/ioGj0/4W+IAYf7BunPmQKXtGY53xd1+q5x9MehrvLc5muT/tgf+OivnjTLyWK6tby2DfarWUTIFGScfeX6FcivoWzyY2kII8xiwB9Og/QV30KjlFRfQ+czTDqlU5o/a/MtdqrRHZNLEeh+dfx6/r/OrANV7j5JYZPfYfof/rgVu3Z3PMQkw4NL4fJW7vY/4Tsk/E5B/wDQRTZjxSaM3/E0cesRJ/Aj/Gri/eRUl7jN6iiiuk5AooooAKKKKACiiigAooooAKKKKACiiigAooooA5LxhdW1hqEd3fXENtbR2zmSaZwiIAy8ljwBzWHbeJ9AubZLi21zS5rd5lt1lju42VpW+6gIONx7DqavfEzTrvVofsOnanNpV3Pausd5Cu54jvQ5AyPTHUdeCK8sh+D86QXzHxDuvbjULTUkme2kkVZYAw+bzJmdw24nlwR9OK5JpczuzvpuSgrI9Fm8UaBDG0k2uaXHGsrwMzXcYAkQZdCc/eUckdR3qG28XaO9pfXVze2lnZ2lx9ma4nvIPLZsAghlc7c5GA21vauItPhDDvtv7U1G3v4k1q41iaCSwHlzeaqqYirO3AK5yc/TvVpvhYI9Qe/sNVjgu49YbVrVXs98MW5FTy2jDjcAF4YFSO1TaPcq8+x2o8UaA0LzDXNLMSQi4dxdx7ViJ2hyc8KTxnpmsfTvHumS6r4ht9Sms9OstJnghW9uLtVjn82PeCCcAfmc9awfFvwyvvEd3qF3Lr1vBPqWmpp13t08lDtk3h4x5uV6AYJbvz6SN8NL+H+020vxRPYy31xazOYoGXKQxeWY2KSK+GxnKspHTnrTSj3E3O+x2cvivw7Ba29zPr2kx21yGaCV7yMJKF+8VJOGAyM46VtA8Z7V5Ponwas7ObQP7TvbfVLPS7i9na1uLLek/wBoCgA73bGwqDk7iT6da9XPAwKHZbArvcqavax6hp1xaTfcmQofb0P4GvDLqOSGQpMMSIxikHuDj+Yr3iQ15N47tfs/iO4DfLHdxiZD7gAN/IH8a5MXG6Uj2Mpq8s3TfUx9Gjh+1ve3ShrOyQzTA9GI4RfxbH4ZqulxLczS3dwd09wxkY/XtUust9m0rTtLAxLd/wCm3I9v4F/Ln8arQNkFe614tFe0m6z9F6L/ADf4WPbpe+3UfovQhfKTFvfNaEDgjrwRVG9ZI1LOQAKxLu/knRoYm2xDk+prrRci5rWsMxNvaSER9HZf4vb6VwXiPU5Y2gt7cKWmlEQLfdyfX1FaNzceZ+7ibj+Jh39hUFxaW93CY54wybl46EEdwR0NbQSi7yOepzTTjB2Zm3s1xZ2bSzTWibS2XKNgjHAC5659zU2mCa80h7xo/KcRCQrnGDuAH880250ezlgVZombYxcEysWye+c5PQV0BtFsfhy8ylma9vfIG5izbEXceTz1bFTVqxjFJbtk8lWMry2tZat6/d/XU2db1jULSbRfE2mXLRXWoWa+f3WR4/kYMOhBAU/jXTaTq1v4jsZTouLbVFXM2mluH77oif5VyE8LT+APC0SjMhnu0Qe25KxvLWTWA9i5ia0UIsiHBZ88n8K5MJhva2jSdpq6T8k2kn3X5dDmrJRhzH0V4d1xTYWclzlPPTDBhgrIvysD+Sn8a6hSsihkIIPQivJtF1O68VeFr22kA/t/TiJwQMG4XGPzwMflU/hPxvGgSKd/Yq3UGunL5Spxlh6qtKDtby3Xytt6HnSo+0XPA9RxXMal/wASLxPBqg40/Uylne+kc3SCU+gJPln/AHo+y1vWWoW14gaGQHNJqtjbanp1zY3qCS2uI2ikU91Ix/k16Sdjkknt1JrhtkTGuNvpmled1yQXCL7hTz+uan03WZ10i5tNScyappj/AGa4dusxx+6l/wC2i4Ps28fw1n3biKJIUJ3EdfQV34ShDkqVam0V/X9eZnKrLmhCmtZP8jNvow+n327B/cvnH+6axlY/YtIlbnZYox/DP/2Na+tyi18OajL0xCyj6kYH6ms7UIvJSxtTwVt7eNvbEau36n9K+ertOtHl83/X3n0lG90mLbpiSNDyFA59hyf1xU1jObeSO6BP70szjbuDoexGR2xVQ7mjlOcNLiIfieT/AJ9KtM2Z9qdBhR7U5JSVmbtXNK6jhaP7ZZOJLaQ7QO8bf3T+vPcVXuYxE4iY/cG6TPY+lP0SQR6xHHtDW042SIehwMg/mBWbe3BSM7vmJ+d/f0H4nFZU3JScG72/X/hiIp3sZut3JYhB7fL9eg/qfwqTT9P2RBmldXb7xBxVPT42vr0yE5SPOG9WPU/0rfit2eRY43dmY4CqBkn8q1btqzduysLZ6c1zOkMMshkc4GW4HqT7Ac1q6hJbRPHFYbJBAojSaQblAHUqp4JJySTnrx61XkSK1t5LWFjJLJ8s8gYkAA/cU/XqR16VSNpF3VfxrljD28lUfwrZd/P/AC8vU5/jd3sWbqZLwZvmZ5h/F5p2kf7ucD8MVV8q0XowH0kP+NOFtCP4F/KgpAnXFdMYqKtFaFpJaIaTbjpcMPpJSeZGPu3LH68/0pxlhj5Ix9eKifUrZTgMhPoDn+VMoUy5GPMRweuRioxAWYeQo9SrH5T+vFL9vJGY7dyPdCP54q3p+pyRMWMCKxHdd354NNWYndLRHR/DnQI7vWmvpYnWG3GfKkH8fbnoR3r1sHNc34P3LoUUsixiSb94fLHGD0/TFbYmr0aUVGJ8xjKkq1Vt9NC1uxUF237jjruX/wBCFJvzVaaYSFQv+rXnP94/4Vo30ORRJJXzUugfPqFy39yNR/30T/8AE1QkkCqWY4ArZ8O27Q2JlkGJJ28wg9QOij8sH6k1dPWQ6vuwNSiiiuo4gooooAKKKKACiiigAooooAKKKKACiiigAooooA5nxJzrVr7W7/8AoS1TFWfEJzr0Q/u2382/+tVauKp8bPSo/AiDUJmt7C5nQAvHGzgHpkAnmvJfCXxT1KabRrjxONNi0u/0ifU5JLaCVWt/Kchv4n3jAzwAee+OfYQaeKSatqU029GZz6p52jwajpVtNqMdwiSwpEVjZ0YAhv3hUDg555qguvaop/eeEtZZf+mM9mx/8enUfrXQU6hNLoS031OfPiK/xx4P8R/992H/AMlUxvEWof8AQn+Iv+/lh/8AJVdLUcnequuwuV9zmG8R3HSXwz4hib0KWz/qs5H61y/ji8OraWrHQtbgnt23xyvFDgA8MDiXOCP1xXosprN1WLz7CaPGcr0qJ2kmrGtPmhJSTPHdela68TXtwYJYdmESKUAMgAxtOCRnA7E1XMiQfvifkxW34rs3g1Wa+Jxa3yLJvPRJQvI/Ha3/AHya4e5uXu3CRhymcKijJYnsB3NeFhlelCytoj6qhUTpK3YTULx7xyxO2MdBVXXNKvNOs4mvFMPnAERH72O270+n/wCqvWPAXgH7IY9S19Fe64aG16rD6FvVv0Fcn8Y3zqCCvQjR5VzSOJ4xVKnJDbuebqcVYtzmAH1Ymqj9K0rWHFrFuHv+tZ1HZHbQV2V7lSI2PbOK7Xwno0finwbJphuRby6ddtdMfLLlonXBwo5Jytcvcw4sgSOSR/Ornhb+0oNYhuNHuTa3ERYtIRldmeQw7g+lcGKi5Um4uzWqZ0V4PkbTs0amr3trZeH4JrKORbW1RrTT0mGHdixMkrDsSe3YACuU8NkC6RD1Ocn17/0rtfGiR+IPD9n4itFVEmDxTQIcrFOrHdj2brXnumTGC9jf0P6V1ZLJQlGfW+v36/18zzatPnoS7tM9DsNRm0PV7TVLbP7s4kUfxIeorU8a+Dxf6kuq+FLiNpb1PtBsSQrMO7J2PPUdRWfbQfaMRkZBHNWZtOGs6VceHJHKanag3WmS5w2f4kB9/wCeK9nifAum45jSdre7L0ezfo/wPnssxLjP2Rhwa/rXh6TZf2tzbleokQj+ddHpvxRITFwd6kdjyK8zsfHHi6yRoDrNy8acGO6AmH0w4NbOm6/qGqWH2m40Pw/ey7yvNoImbp3QivIU8RHRxT9H+jX6nv8As+fVxO7h1RtY1y11awQzwYW3vFU8mMtlGx6xt83+6XA5Iq092ZbiSXdgMcL6be3+P41R1C4j8NeFmeO0iguLg7jBCSArN1AJyeB9aq+G/Fnh28hFrqVjNaXh4SSe4PkOfRmUZT8se9etmteWAwtPD8rbesrW08t/6seVgIxr4ipi1H3Vorfi/wCu5c1eO41lbTSYg0aTTK9xL/DHCnzM2fwA+pxTdRu1vdXnnQYj6IPQHt+AFO1bxMbW5k0u48KNFCqrJmHUGAlz0O7b844yOcc1DDq+lhvm0DUIsc5W7Vh+q185CtOpL2rg7W0s4v8AX+rHtU2783L+X+YK3+lRj+GFTIfc9B/WpbdsRvKevQfU01tV8PxI5ltdVj83A/10ZOB6fLSQa74ZHlhoNakRTnaqoQ3sSDWrxDX2Jfd/wTTn8mbGmKLaykv5B0DRw5/idhgn8AT+JFclrVy2zahw0mCf6fkOfxrd1HxDo85Akt9XWFBsjjjiVVQeg5+vNZNvq2l3er+VbaJO8iZLTX02VTj+4oGew5NZ0qk9ZODu/wAF0WrCEmndpmn4d0tmswVwkQwXllYIifUmtmSawtI2jtNRgXcMPOiOzsO4XjCj3zk+3SsHVtUPlobuUuF/1cYACr/uqOBWbClzqDb5mMUHZFOPzNVKjOr/ABHZdl+t9/yB05T1k7G5JqmiQHy2vbtmH8KWuf03ZpYri2vARY3Wx+y3cLQ5+hG4fniqKLaWKYRVB9hVSPVRd3LWflbLgtiAH5xcD+6uBw/X5DyRyueQN1SnLaT/AA/yFO0LOT0NeXTdWMZkbyBEOrxv5oH/AHzwPxqoLBn/ANZdzMPSNdoq3YeH/EE7B7axnhB7yERD8ic/pWxB4E1mYZur+3iHopaT/CtIU6nXX8CXXpw+KaOeXTbVOWiLH1lepRLbQDC+Uvsp/wAK6y3+HUPW71KeT2jRU/nmtW28C6JEP3kMs59ZJW/kMCtFRkzGWPorq2eaT6oifdCj3NT2Wl63rWPslnOYj/y0ceWn5nGfwzXrun6LpmnnNlY20Lf3ljG78+taNWsP3ZhPM/8An3H7zO8JWt3pGhxWd7LFPIpJBTICj+7k9fyFawuGH/LMH/gf/wBaocetG5VGWYAe9dK0VkeRP35OT3ZM8jS8NgJ/dHQ/X1oLYHJqvHMZ22Wcclw//TMZA+p6D8TWrZaFLMQ+pPtX/nhGf/Qm/oPzNaRg5bGcpRp7lXTLRtUnyy/6Eh+Zj/y0I/hHt6/l9OspsaLGipGoVFGAqjAAp1dcIKCOGpUdR3CiiirMwooooAKKKKACiiigAooooAKKKKACiiigAooooA5PWW3+IZ/9iCNf1Y/1qGnXp3a1qL9vMVB+CL/Umm1wzfvM9OmrQQCnrTBTx0qSwFLR0oFMkd2qOTpUlRydKYkVJahxmpZetR0jRHO61o8Vzay2dwpa1mPy4IBUkjjn3AI9x6E1W8I+CdO0KX7WJHu7r+CSRQPL+g7H1PX6V1bosiMjqGU8EGqTpPasGQs8ffjJx7jv9Rz7GvPlTeGqOpGN4vV23T7pdU+q3vr1NlVk48idi+3Q14D8W5d+tBfSvc0vUeJiysCByVBYD8un4gV4D8ShLca85jjdl7EKTWv1mlVjeEkzbBRaqanIQR+bKqAZ3HFdJdRrEwjUfcXH6f8A16reGdHvrjUUZbK5ZV5yIm6/lXUSeE9Xld5biCOziOfnupViAGfc5rz8RiacXaUl959Dh504K8mkcveKWtkVQSSQAB9a2NVs5tI0mPTIFLanffPOqclE7L/n3rXS10jQYotTvdRN6sLAItpbtIhfoBvOFyD9elVLrxhOyzXGiabHZTyAk3lywmnP0GAq1wyrTrSSpRvFd9Ff59FvoFSs60rU1dfcbHhbR47LwvfeGtRmQaxeq99Da9TGF5G70J9K8dnj8q5ZGH3WxW/4X1W4sfEUOs3E0k88N2GmkkOWdScNk/Q0eP8ATP7L8UX1uPuB9yH1U8j9K6MLGVCtKMnfm9759bfgYxg4Nxl11/z/AEOt8IXAngjY8sUAP1FS+PvPs5NO1eyytxauCCO46YrD+HU+6Tyj/DJj8xXd+KbM3OiXEWPm2nH1r9KdJYzB2ltKJ8NUqLC4z/Czzr4k6bb3UMPijSUH2LUeJlX/AJYz/wAQ9s9fzrX+E+lOukfbL2PZCsjSRbv4uBz+GKi8C211e2mpaRLEsmk3Wx2L/wDLN1YHK+5AI/GtbxfqabU8P6UQmIx5m3+FPT8f89a+ZybCPB0XicX8MPh7vt/l+J72NqVK1b+zsK7uWjfZf1uc94n1lNd1KUwSA2dsCN5Pyj1JqLRPCmoa/wDJYQeWrdJ5nK4/4CBV7w14dOs6va6XCFSIfvZuPvHOBn8Aa9w07SH0iIRQIvy4HTHtXNN1MbN15dTurVKeVwWFpbpHBeHvBesabpUun65LHc2ok3W0qv8A8e7e2edjHqOxwfWs/UvDniBnzb6TchGOSwKn8ua7zXvFdnZzpp1+GV542YMBkDGP8a2dA1eC/wBOt5EmRi4IHzYJIOD178frXC6UaVfl6S6ef/BX5eZzRxmIjD2nLdM4T4ZafrmleJLs3mkSpaXUeBOyruiK9Fz12kZ49QPeut8VeAbbXIzd6eqWWpLnE0SgCQ+jr/EP1HrXR7mHOxgPWp7e5kjbch+ortUrR5HscFTE1JVPbR0fkeBX2ka7YyC3vNOvBICV/dRNIjZPUED+eDV3Q/APim9eaf7J9m85iS0zhSfw619BwXYf/WAD3FW1mQ9CKzVGL6nTLOK1rKKueAn4YeJoroSPBb3IHQicDH51LceDvEiKVTTjuHHDr+nNe+iQHoQTUVwQV561Tw8OjIWcV+qR454X+HqMqXfiBzLIeRaqflX/AHiOp9hx9a7i70TTrzSpNMuLOB7B12mDbhcdRjHQg4II5B5rSRAGkx03t/M1FO8nmxW9sge5mO1Aeg9SfYVrTgorQyrYmdd3m/8AI5OHUbnwtcw2HiO4a50uVhHaarIfmQnAWK49D2EvRujYPLdVEtxcDNvY3Lg9CU2D/wAexW5aeHrFLeRL6GK+kmUpM06Bg6ngrtOQFxxjv3rC0+z1Pwbf29nZRXOp+Fp5FiijUmSfTCTgD1e3HHqye6/d61RvrI894jl0iT/2fqjfdsFX/fmUfyzSjStWYf6i1X/enP8ARaj1vxjdR+NY/Cvh7SotR1UWf2+5e5uzbQW8RbauWCOxYn+EL05zTtT+IGj6BDCnip30vUGha5ktER7swwh9vmuYlYLHnHzNgc461XsIk/WZko0XVT1ayX/gTN/QVInh++f/AFt/Cg9I4Sf1JqlL8UPB8WotZPq/71biK0ZxazGJZZV3RqZQmwbhyCWx19KjtviToiJe/wBpXMKSw6tPpMUFklxdSyyRAFh5YhDlgDkhA6jj5zT9jATxEzaj8NQ9Z7y7lPoGCD9Bn9auW+h6bAwZbVGcdGky5/Ns15xffGLTLbxnZItzBL4Rn0STVGvobWeWVXWcxnIQEqowc5TII5Irp2+J3hBftA/thS0BtQyi3lLN9pAMGwBcuGBByuQO+KpU4rZGbqze7OyAAGAAAPSiuRX4i+GJdWfS4NTDXomktULQSrA88a7miE2zyy4HVQSfbtXM678X9MtPh+dWsp7WbW7jTJtQs7S3iubmMqhK73Ployx7hgs4QdeeM1ZB6pRXJxeNLDT/AALofiDxLOtouoQWxYxQyOPOmQEKqqGbGTgdfrUOm/EzwpqOo21jbalMLq4unsUSWyuIsXCDLQsXQBHH91iD7UAdlRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVW1O4Fpp1zcH/llGzfkKHoNK+hyMMnnNPN/z0mkYfTcQP0AqWoLOPybSGM9VQA/XFT15+56traAKeKYKeKBDqBRSimSLUMnSpjUMlMEVH60ynv1popFi0UUnegCvepH5DuyLkDg45FeC+JfGevWurTw2eqXCRKcAEhsfmDXuusvs06Y/7Jr5e1x/M1S4b/bNcmJoUqlnOKfqj0MDFSvc6fSfEGv6lBcvd61fMijAUSbRn8KgsNLl1rU47dnlmZ2+Z5HLbVHUmmaIvkaKWPG9s/gK6OUNougC3ibZqWpJ8zDrFFjr9T/X2rx6/LS92kkm9Fp+PyPoIpUqaUF7z/r8DnvF+t6dfXkWmWFzbi0sDsjgWQZ46sR1pmheTrAS20y4guZnxGFikDYJOBnHSuasLC60zSrfT7nTFkeFpW87zE8uXhsEc7snOOQP6V2Xwt02+s9b1rxHcWjRwW+nCOH7Q0ZcTFjtVRGcbMZ685ArepThhaEuR7barVt/qzl+sVKVONo6vfR6er9fvMWXTYrPV9X06OQSrGzJuznJABz+da/xAia/0Dw5rZBLXNoIZW9XjO3P6ViaMjLq98ZnLOZGZ2Pc9Sa9B1iyFx8M7KwyPPs0hnK/3fOaQj9Ctc+Im6U6Tbu72+9W/OxtW93kvvt/XzPP/Akxi1ORc9lb8if/AK1e0ugnjGRlWArwnw+xtvEESNxuDJj36/0Ne56VJ5tjE3tiv0/KKntMBD+62vxv+p8DndP2eOm+6T/C36HLeMdVtvCGgMmnRIs7cIg/U1g39lbWniu3urIu1pqdjFcxs7ZJyMNz9TVP4mbptdiV8lPJ/Dkmm2FyZ/BPhm4c5k066n06Q+inDp+gxXyXEeJqPExpJ2jHS3qr3+9W+Z9LkGGjRhSxG7ne/wCRo+HPEA8NePYJblc2ki+XIQOVx0YfTPIr6LgmjniWRHV42XcHB4I6g5/OvlXxmDDe210gyNyk/Q8f0FXFu76W0tNN1G8uotJZyXjQ7hChPPyZ+Y/njnHvzYXE+zgos780yt4ms6kXbv10/wAzvfit5UviixMLRsvksMoQRkMuap2iq/h14yMm3u/l9hIuf/ZKg8UabpelP4Zt9EkElm1tM6ybt2/LxncT+NXtHhMmn6tjoht3P5uP61yZj8fM+6/Gy/UWCssPC3R/rYNP1m/08N9lupUXZjbuyKveF/iFerrP2PUv39uYxsZgNykcHJ79B+dc+T0H+z/SsLSTu8USj+4gP5lv8KqFSUdmdNbDUqq96O59D2uu6dcIGEhQH3qe51bTrWNXlv403MEXJ6knH9a8ospAmM9MH9D/APWrN1p/tOt6dApO1I3mP0PA/wA+1brEXWqPNnlNPm0bPcY7uEjKXkX4PQmprMj/AGeQyYYqDjgkV4wztGysrsCFyee2P/113/gZ2k0fT2brIWk/AsW/liujD2rX0tY87HYOOFjFp3uzr0URx4JzjqfWp/C0fnXV7eOM7SII/bHLfqR+VV5/9U30rU8JJt0KBu8jPIfxYn/CumiveOCs7Q9TYooPAriovib4bnvL6zt21eS+sovOuLc6PdxtEu0sC5eJQmQDgsQD611nCHjX4caP4s1JdRupruzvTbGymktxE63EBbcI5I5UdGAb5gduQQCDwKwJfgb4Ua20iONrlZdMs/sMc0sNrcmSLeX+dZ4XTduZvmCg846cV3vhHX7XxT4a07XNPjnjtL6ITRpOAHAP94AkZ+hNa9AHnEvwf0CSG/iN1qSre3lpeyCNoUCvbKFQKqxhVUgcgD6YHFSt8KNGS8a+s9Q1az1Matc6xFewyRGSCW4ULKihoypjIUcMpPvXoVc/4L8V2Pi6wvbvTYrmKO0vZrFxcKqkvGcMRgn5fTv7UAcnafBfwzZwNDazalEj6PcaM2JUJaKd2eSQkp/rMscHoP7tVf8AhUluvxG8KaxGYjpGgaXHaoruTPcTxArC0ihQp2KSd2c54wAK9WqrqN/Dp6QtOly4llWFfItpJyGboWCKdq+rHCjuRQBw0Hwl0GHVYrkXOpNZw30upwac0kf2eG5kGGkX5N/uFLlQe1UD8EtATTbaytdT1q1WLSpNFlkikhL3Fq8hkKvuiIyGYkFQp+tdl4h8V2Oha94f0m7iuXudbmkgt2iVSiMi7jvJIIGPQGugoA5LW/Aemax4S0nw7cz3qWWmPbPC8bqJGMGNm4lSDnHOAPbFZkPwq0OLUlvVutSMq6/J4iAMibftDgAp9z/V8cDr/tV6BRQBleGdG/sHSxZf2lqWpfvHk8/UZ/Ol+Zidu7A+UZwB2FatFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWL4tkxpSw97iVI/wzuP6A1tVzfiht+oWMYPEavKR78KP5tWdV2izWirzRn0tApa4z0RRTxTB1p9AmApwpBThTJA1BLU571BLTBFV+tJSt1pKRYUUUUAZfiM7dKnP+ya+X7/L38vu5r6b8WPs0ac/7Jr5mbL6g20FmL8Adz2Fc9Z21PUy9XTO38OWMd00S3DbbGyj8+5J7jqF/HFR3l4+p6pJeSLtMmNq/wB1R0H5Vf1aP+y9Mt9IQjzpV8+8I7n+FPoP6e9ZkI/fP7DFeDR/eydZ7bL07/P8rH0FH35Op02Xp/wSjq/LQj2Y/wBK9J8A2iXmgavbu6x7hCFZugbLY/XFed3MTT6hFFGjO5VQFUZJJIrtNegfSPC0Wll9l3c4uLjaeVA+4ufXgmljVzxjRi7SbX4O9zLFe8lCL1bX4HLWXhK/i8QX9xrcT6fpUc2Xkk4M/wDsR/3s+o4retrp9Qm8T+YArT2scqqOi7ZAAB7AEVlaffr4tzZXUjf8JHp65jLNxdxDtj++P1q/oI/4n13Ef+W2nyjHrjB/pWVRylCcqvxRtp2V07r1tv8ALoYtuUW57r/P9TzvVR9l16C4HCtIj/g3B/ma9i8LzeZabPTmvKPGEB8hXUfMu5f6j+dd54Mvd8Vu+eJEB/MV+kcM1OehVpdrP+vwPleKKXLVp1O90YvxKtwl3aS9CwdD+GCP5msTQIy3gnxZEAT9lubW+T2JLK38q674owZsYJh/yzlBJ9iCP5kVkeA7OTULHxXY2+wSXFhHtLsFUEP1JPQD1r5/iuPsq/tO/K/ukl+h6mST58tXeEv8n+pXuo0vdItLhxuEfJ98cj9QK4y2lN1dTTsxF0XJRyemDwK9N0nw1ef8I3LbxT2N+6DrZXCzdPYc9q8x+zSW95cxlGDRyHKngjPNeTh6kJ3UXc+jr1Y1IxlB/wBdP1NbSb52120i81jbCN5I4yeELbSwH4rXp+kXK2dtdNJny7mSOFv90B8n8Cyn8K8e0628rWdOeOR3kklMYB7Aqwx+tenqCtupYEErk59cmrr01NJPb/I5klO6empDcG4VS0N7cQKF5WPbgnHXkGsbSZ9Qm1q4jOpXIVVUBlWMNznqdtbV8MWRI/uA/oKyfDa7tYvW9HUf+OirjUmlZMmeHpSfM46nTC3vPJdv7W1Dhcj5k7/8BrMsDf3N/dltVvtkREanKZ6Z67feuhfC2XuSo/IZrK8Ox5snmYZ8yZz+GSB+mKarT7ieFo/yodcR3iy7Rq2ocqOrJ/tf7PtXaeDtHmvtJ0yV9c1lDJCGIjnVQDt7ALxXJXiN9qLAfLx/Jv8AGvRPh5/yAdK9oAPyGK78FUlLnu+h4mb0IQjTcVbUuTeGnWJj/wAJBr/43Q/+JrU0LwkZtHs5W8Q+IlZ4lYhL3AGfQbauXH+patrwyc+H7D/rktdVFty1PFrxSgrGbaeE/s11DP8A2/4gl8p1fy5bzcj4OcMMcg9xWDH4J1JfGnj/AFcz2f2bX7CC1tV3tvRkiZCXG3AGWGME8V6HRXSch89W/wAELmy0kx35sPsh8Kvpl8tgHaSe7WTzI5QmweZt2rgn5sgDHSq/h/4T634s8CaDd+Jwq6ze63banrCXjSQSm0hjaFYRtG4PsOQPlwWPIr6NooA8K1b4MaidenOjTabBY/aLF7DUJZpDe6VBbqFMMIKkMCAOd6553bjzTtD+DmpWGtaRqMr6T50GuXt9dSIz75rOcYEOdg3d8qfl5PJya9zooA+avB3wp1zUtJ8Z2T3l5pyWiT6H4dmuoWiZLYzmV3wRna+VTeB93djI4rej+EGuebJLAdE0q3fVtNvl0qylkNtCtsCJGU+Up8x+uNoHqT1r3eigDwvQvhFren+ONI1e4bRZ/sWsXWoT6kZZDeXcUqkIjgx8FPTeRycY77HxU+F17408UXuox/2W9tJ4dm0yBLssWjumk3pJgIQAP7wOQegr1yigDx7w34A8W+E9S1LUPDs3h/7Td6bYWzR3LzeVJcRACeVwqgksN2Gzkk8969hoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuQ1OXz9dvGBysQSEfgNx/8AQq6yaRYYnkkOERSzH0Arh7MtJCZpBiSdmlb6sc4/pWFd6JHVho6tlgUtIKUda5jsHLT6aop1MliinCkFKKBA3Sq0tWGqtLTBFdutJSmkpFhRRRQBgeNP+QHP/umvFfA+nhL251u7XNrZE7Af+Wkp4UD6Zz+Ve3eLozLpEqKMsw2gepNeZvAklz/Y9nKsWm6Uu66uGHymZupPqeuB1JNePmtW0VSXXfyXX79kengLNWZiSPLdXcskpLyyMCT6knNaUWkS26eZqUsdijnKiXJkI9kHzfngUJqq2m9dGhaDJObqUAzOAP4R0QfTn3qlao8qtJIzO7ZLOxySfc1xx9pKyXur8f8AJfj6H0ceeS091fj/AMA1dJuLebXrbTtIjeHz3AnvZf8AWmMDcwQDhBgHpk89adrFydQuZ7kjAlfKj+6uCFH4DFZXhaYR+N9ODEBJHePJ6fMCgrSkiaLEUi7XRgrD0IGDRTpRhXb62X4t3/JGEIKNV+h53JHKvinzLaRorhUEkTqcFWBr1fRGGs6pp2t26BGkjntb2ID/AFcxiY5+jYzXmV4PK8UWb9iWQ16L4CnFn4iihZttvfjYw9JF+ZT+PI/GlmVNyoucd0n93X/MzxUHyOUd1+RzfiexzZXJxyMOPpnB/mKb4ClP9n2gJ5QlD+BI/pXRa7b74ihHJDRH8f8A6+K5LwUxQTwnrHOf1AP9a+z4Vq2xLj/NF/ozwuJ4c+FjPs0dp8RIvO8OXBH8KiT/AL5Ib+lcT4YXzvDni9R1NnDGcehl5r0XxLF9o0KVP78RX8xXnPw/fzNK8UITy9nHJ9cSL/jU8XU/3dOp52/8mRz8M1L06tN7Xi/xHfDeyM1k5VmikUth0OCDuNWdQ1ez1LUxpvigR2+o8rb6uq4yQeEmA6jn73UVsfC2zDWE7N0Mrflkn+tcH46jDa8i9974/SvmJU1Und6PWz6r+vuPrq1OMqWm8Ui/qemT6P4s0WO6iCSiUy5U5V1VchlI4IOetewaxo6ajYJc2RX/AFecDjcT/k15N4Z12Fza6T4giaWyjBa2ugMyWbHg7fVD3X24r1LRLiTR7uG1uJFls5Y8xSryrA9CD71tRq6+xrLV9ej9P1X6HmVOe/PH4l+KOV1eN7ewdJVw21Qf0rK8KLm8vW9ZD+gx/Su58c2IbTHnQ5y2cAe3/wBj+tcR4K+dZ5ByHlc/+PGqqQ5G0dVCsqsUzqb9glpk8ABm/Liqmkj7PpdkjHBCAt9cDNVvEdrE1rcThpxO0YwVndeTwOAcelVr2yt432Ibjgcn7TJ/8VSioW1b+7/ghN1r2UV97/yL8t0rO2ThV/wr0r4exmLQNLWQFWMRIB7g5Irxi3sGvZUgge5Es0ixR4uZOCzAD+L3r3DU/BGgWunp5dq/m7kRWNxLljkD+93r0cFFWlJM8LOKk04U5Jd9Hf8ARHQ3TBLaVj0VSTW/4fjMWh2CNwRCmfyrzu98FaI0Sxw2brLK6RqRcS8ZYDP3vTJrqR8PvDH/AEDP/JiX/wCKrqopXbR4lduyTOqrmbvx14etdYudLlvZWurVkS5MVpNJFbs/3VklVDGhPozDrU2l+DtC0q/ivLCx8q5izsfzpGxkEHgsR0Jrz3xV8M9a1Hxg+saBJZ6FdzXaSz6pY6jcxySRAjKyWu0xyNtXGd6g5OQcV0HMexUV4Vpnwn8R2PiLSZnuNJfTdO1+81dZFmkE0kc4GE8vy8BgR/fIOfbnlfhd8J/El94Q0i5YR+FLlNJv7GSRVkjvbl5ZHCGdCi7VTgr8zHGCMcYAPp+qsV/DJqU1iqXImiRZGZraRYiD02yFdjH1AJI7ivnuH4Fa3/wj8unmWxheeaye4Kaj+5lEDfMwjitIijkE/MWdjnls/NW74h+C968+vweGbqz07SrrTrSztLd5pWLCGUu8cpwW2MDjIYnnpjigD3Guf8ZeK7HwnbabNqMVzKl/fw6dEIFViJJSQpbJHy8ckZPsa8in+CWo6jPAt8dKtdHk11dRl0ayuJVgtrcRFGSF1RDubOTgIOOtdz8T/Atxr3hPw9o/h2KwWLSNQtLlbe+ldY3hhBHl7grnkYGSD3zmgD0SuH8afEvR/COp6hY6lbahLLZaUNXkNvGjKYTMIdoy4+fcc4OBjv2rzS6+CfiCbRbW3+3aYsK6re38mjROFs4451UJHG0kEi/u9pIJh6ucbTzU2s/BrX7zTpra2vLNQ3hcaHH9rvXndZReCYFpBCm5AgwDtBzgY70Ae9QSCaGOVQQrqGGeuCKfXgyfDy8k+Ou1IrhfCgFvrt4rQssEmoRq0aKjkYY5IkYe3OOK6n4s+ANS8W6xY3toul6haQ2VxaHTtVkdIY5JBhbhNqPl1+g9mBoA62Txba/8Jwvha3s725vltReXE0YQQ20ZJClyzgkkjGFDe+BXR15J8NfhXdeFvGv9t6rPYajIuk29kl0UJuDOg2vJyvAK4XO4kgYNet0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAY3iqXbpf2cHD3LiL/gPVv/HQfzrEAxwOlTaxP9s1p9pzFar5S/755Y/yH51EK46suaR6NGPLAWlFJXmPxkvL60udGez1mzsraISvcWd1qEunrdcALi4QjBU5O3cM+/SoiruxcpcqueprS18/t8V9Y0+xt44FtbFf7COqRRa1vnuZ5vtDxiAOHTduUZU7ScckHto3/wAQ9Z07UvEU0NlDBcLcaPF5N3JPKIvtMJLjYZAqlTx8gTOPmBPNXyMz9oj3AU4V4xP8UdVtNP1KK+fT4tStNcl0mKVLImGcIoIJ8y4jWInPVpD04Bqr8OPE9z4x+InhfW76CKC6ufDt0sscOdgZLvZ8uSTg7c9T1o5HuL2i2Pb2qrLVlulVpKg0RAetJQaKCwooqOeRYYnkc4VQSaG7AZ+ryAK7M4SOBd5Y9Ax6cd8dcfSvG4NQbUGuFihNrp0EreTb9Szd5JD/ABOf06CvYZLc3Fq5mGSuWPu5/wABgfnXkOwR+fjvIx/X/wCtXgxputJ4qf2vh8ktn89/K57WWxXM12GiJfKJ/wBn+ZqxGojs+PTFRtxGR9BWT45uL218JXMmm7xcALlkGWVcjcQPUDNaRjzSSR7lSp7Om5vpqQyITd/ISGVFZSOoOSa7S31Gy1p4V1AXNvqZIVnhh8xZz0BwCMN69q8qWbMdwvhue41BnMSNJ9oEpiGOXBdgC3+zkYOOB36P4OaxcW1hBe3YuJ3gnkXfOwkZhuI65J4zj+VRisPL2bqx+JbdzinXU5KMU+azaa206X6/11Oi+K2i6Z4dh0Rbd3a+mug8hfqVx1wOg5qnHI0UHnREiSBxKuOvymue8e6lPrOoT6nc7lbzE8tD/AgOMV0ljhpGQ9GBH+fzqMNSnGjGNV3b3+ZtRpyjDlqO7On8Qos0s0kWNkyrOhH+0M/1rz3QSI/EOpxKMKWSQD65/wABXfW58zQtLY9VR7Zv+ANx+hFcKqGDxjMuMeZET+RH+Ne1wtNwxVJPpeP3XR42cQ58umu36M9Fvzu0hT7V5r4AhaDWdTsm6XOnXIT328j/ANBI/CvSbjnRV+lcB4cmSHxn4edjjzrq6tH+hY4H/kWvc4ujfBJru/yb/Q8Dh+q4VZx7x/I7TwDaJBpYSPJVmLc15L40l2+I4cjjc5P6V7J4QXytOZCcNGzKfbBrxvxYwj8RqZBlGDDB9c18jSd2n6n31T4alvL8xNMKS6sqcFREAR9d1ekWeoHTYPs95G1zpWEPlg/PCSPvIe38q820FE/tqfZ0DqB/3yD/AFr0O4/1D/RP5U60FP3ZHPGKnGzNHxBdXUGkwNHIL3Tmk+W5Tp9GH8JHNc74IULY7h03Mf1JomvbvRkNxpsgXJbzIXG6ORcnhlPBFbvhSfTtX0hrm2sm0+6QAzW8PzxkHHzICcgc8jJxWLq1IK1TVd/81/l+BnBeylZr5jNaGfs8R5D3Ea/guGP8jVK5JO9+5q1qbb9QtAP4RLN+m0f+h1DOOUHvmtuh0LVm58M7AXHi2y3ruSBXuD/wEbR+rg/hXrLlrvUndv8AUWx2Rj1cj5m/DOPzrg/hQoik1y+cfLBEkYP/AH0zD/0Gu+tIjBaRxscuBlz6seSfzJr1qC5KC8z5XMp+0xcv7tkT6epn121QfdhVpm+uNq/zJ/CuqrB8KxbheXZ/5ayeWn+6nH/oRat6uuirRPIryvO3YKKKK1MTh/Hfjqbw7r2l6LpulxX+oX9vcXQ+0Xf2aJI4U3N84RyWPYAe5IFcNN8ey+mz6hp/hoy2ltpEOrzefe+U4R5fKZFURsCQ3IJIDDnivX9b0LSNehjh1zSrDUoY23Il5bpMqn1AYHBqK48M6DciUXGiaZKJoFtZN9pG2+FTlYzkcoCAQp4FAHnFx8ZXtZdXs7jQFXUrS/sLCCNb3MMpvELxM8hjHlgKDu+VsHgE9a53WPiNrWteOvCMGl2slpfWWranpt7p66g62t3JFArDMoT5l5yMpkHtXtU3hvQpkvkm0XTJEvxGt2r2sZFwEGEEnHz7RwM5x2otfDWhWgsha6LpkAsWZrUR2ka/ZywwxjwPlJHBxjNAHk8nx7ig8O6FrV14dmjs9ZsLia123W4tdxSFPs33P4sAh+vP3eK0dU+MU+mXuoJdeHQtrpVzZWWpML7M0c1woOIovL/eKpONxZN3UCuw1j4faBqbeHE+yrZ2WhXZvbSxs444oDJyQWUL0BJbCkcnnNbFz4c0S71iHVrrRtNm1SHHl3klqjTJjptcjcMexoA8ssfineuU0q0sZ77Vb/VtTsYHvbxIY4o7VdzMXjgGOCNq7Wb1Y9as/Dbxfe6V+zfZ+KdTa41e8tbKe5kNxcMZJysr4BkYMegAzzXotz4T8OXdv9nutA0iaDz2uvLkso2Xzm+9Jgrjee7dTVmPQ9Ji0U6PFpdimklDGbJbdBBtJJK+XjbgknjHegDyTUfjheaba6pcXfheHy9Ngsbufy9TLEwXW0KVzCMupcZU4HXDevsNlqVjfy3UdjeW1zJayeTcJDKrmGT+44B+VvY81Rn8LeH7iOeOfQtKljuI44plezjYSJHjy1YEchcDaD0wMVestNsbCW6ksbO2tpLqTzrh4YlQzSf33IHzN7nmgC3RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVTVbxbCwmuWG4oPlX+8x4A/E4q3XL+Irj7VqcdqpzFbASSe8h+6PwHP4ioqS5Y3NKUOeVjPtojFCFY7n5Zm/vMeSfzqak7UCuI9Iyz4j0NdX/ALKbWdNGqbgn2M3SCbcRkDZndnHPSlXxNoJvLizGt6Wbu2Vmng+1x74gv3iy5yoHfPSuL174bX+t+LLbV7rxNcPbWupQahb2skTsIRH1iXEojwf73l7h6nnKR/C6ZfB2oeE/7bjOhXEjTRf6GftMbmUSDfJ5m2QAjBBQEjuMVaUe5k5S7HQpqPgo6m/i5dY0fz/J/sxtQGoL5ezcJPK+/s3ZIP8Ae59K2LrxPoFpLax3euaXBJdKr26y3camZScAoCfmB7YrkvE3w+1DxL/ZFxqet266jpjSiF7W1mt4XikQKysiXAfPB5WRRg4II60Lb4US2V3ps2laxBpBtFjjeTToLmOWWNHLeWS9y6lST0dWwOM4p+73JvLojv4vEuhS6hPYxa1pj30AZpbdbuMyRhfvFlzkY756VHD4s8Oz2T3kGv6RLaJIsTTpeRlFdvuqWDYBPYda4U/CR5hrFvLrz2ul6jDMj2GnRSxQmSRg3mlZJpF3AgfdCZqDUPg82qi6l1XW4Zbq4azVvK0/ZCYrfopjMhyWHVi2B2GOKLR7ivLsd+virw9Lb3E8WvaU8NuqNNIt5GViD8IWOcANkYz17VfkrzDxN8N1vfib4fu9MsI7Pw9b26m+SHYkMjRPuhjEYOeG5JxjAxmvTpaUkuhpBt7kJoooqTQKzdYlIMMIGckyMPUL2/E4H41pVkFvtGtMuMhNq/gMsf12Vx49v2LhHeVo/e7fkXTWt+xeWPyLEoxyQpLN6nqT+ea8ZukIRR3bn8//ANdeyas/l6ZduOoib+VeWahCPkwOgFTiIqEYwjsj1sq3k31Mt+R/wI0+6/1aih1wVFJdnkCuE+gRhQv/AKZKeuZSPywP6VvoPn/H/CudtTm4z6ysf1NdNCMvQN7HK+L4v3FyMfwk/kc1r6XLuFtJ/eRW/T/61N8Q2Ul5ObeBC0koKgD6VU8PyF9LsWPXYF/I4rW62Mup2en5Ol3qf8+90sg+jqc/+g1yOs5j8Y2rfwyIw/TP9K7LR/nj1VO720cn4q+P/Zq43xaNms6XOO74z9Rit8nqezxq8pr8bf8ABPKx0OfDVoeT/I72TnRB9K811P8A0CKx1EAg2uvA59mjVv8A2UV6Sp3aH+FcF4vhD+CNZfHMF/byj2yAp/nX1/E8b4OP+NL77r9T43JJWxNvL9Ud9YgwaxrFsD8ondlHsTkfoa8n8dwKuqKWXjeQfx//AFV6zBDJ9qtNTHMGo2kMoI7N5agg/lmvNviLHt1BiDtO4EZFfn+DlzQh9x+j05KVFv8Aur71uYXhpB/bEgRiR5i8n/dFeg3XFs/1QfoK4Dwdl9YbIAO/nHTpXeXks0cZW3js3cugP2qOR1Ax2CSIc9O+PbuO2a96zOanL3OZK5k662LJvpIf1NbHw6byDp7DO15FhceqsuCKwtavryO0kM1noEihHJX7NdLnr/09Vt+F59TSG3lt4/D9uIw0y5srp9pUZHW69cCpq04um1zLr3/yMp1ptP8Advb+7/8AJF29i8vWrlNwYQRRxqw6HJLE/kgqvNhW9gMVHby6oZLyRY/D4PmhCfsV0d2FAz/x9cdSKZcXOqKT+58PueuBZXXP/k1VezVkuZfj/kVCtNaum/8AyX/5I9S+H9r5PhGHIw+o3TSn/dB/ltT9a6y6lEUMkh6IpY/gK5fStL8WW1jaINQ8NweRF5aR/wBk3D7F44z9r5PHWn3tv4saIRvqvhxxK6xY/se4GdzAf8/nvXrNKyinsfJSm5zlNrd3PSNGtvsmlWsB+8kY3f73U/rmrtcr9h8cf9DD4b/8EM//AMmVoaJbeI4bt21zVdIvLbYQsdnpkls4fIwSzXEgIxnjaOo54wexKysec3d3JL/xLoWnalHp+oa1plrfyDKW091Gkrj2UnJ/KrlhqVjqJuRp97bXRtpmt5xBKr+VKv3o2wflYZGQeRmvF/HfgvxRJ4w1fU/B1rqFveanNALg3E9pcaZcxxhVDTRyfvVIXdwqvzgjFZP/AAgfjnSLDxpb+G4dQtbu+8QNfxXK6nuS6sWYExoPPVlm4yXbYxAx5nSmI+iKK8Dg8F+P9QXw5YXet+K7TTxqF69/cJex29xBbvEnlICLicyKHDBSzM4yc44Yzx+FPiFBryXsN7rTiPxcHUS6tvibSCvzFojJtIyB8uNwycAUAe5TzRW8Ek1xIkUMal3kdgqqoGSST0AFYyeLNCk1bStNh1KGe61WF7iyEOZEnjQZZlkUFcc+vPavHNN8HfEW+KWWr3GpoJbHUINYuLjVd9tfSSbvsxt41kJhC5XOEj4yCD3zdD+GvicQ+D0fS9X0+TS9IvrW4l/tdd6XLRqIzE6TEqhYDCrgDByoB5APpGivmm/s/iBBr/grw9ca9qUN/wCItNSDVYxfFpLI28itJPGyttVmjGzcD8xzySa6O68F/EGSDx1f2Wva5b6nLfTJo1pJqYa3a0ZozuUZJR9odVJI256DOaAPadR1Kx01IX1G9trRZpVgiaeVYxJI33UXJ5Y9gOTVTUvEOl6brmkaRe3XlajqxlFlF5bN5piXc/IGFwpzyRntmvIk8P8AxDxcmxbWbTTG17T57SyvNWE11DaIP9J8yXzW3IxwQm9uB0qn4Y8G+Nm+InhDVvEtpqFzPpt9qb39/NqKS25jljKweRF5hKL2ICKemc44APfqK8d+KXh3xvq3irWbjw7Pqsenjw6I7EWuqG2T+0RcZHyCRefLJ5YbSOCe1T+Grbx74b1vXZ202+1uwuU077NBdasp2SFMXTqXZioDHO3AB/h4oA9booooAKKKKACiiigAooooAKKKKACiiigCvqF3HY2U1zL92Nc49T2A+prj4BJsLznM0jGSQ/7R5/Tp+Fafiefz7y3s1PyRfv5R79EH8z+AqhXJWleVux3YeHLG/cKUUCnKKyOgcorhfiB4p1fRvFPhzR9GFgv9pwXsjy3cLy7DBEHUAK68HkGu9UU4CqWhnLU4j4eePbXxJpGgrftHBrmpWTXn2WJHKlFcozBiCAMjoTn69azD9nvfi74ifWpjFBpWjRfZWMhj8mOXeZpVYEFW+UDeMEAda9LrPm0XT5tdttZe3/4mVvC1uk6uykxsclGAOGGRkBgcHkYNO6JadkeK/DvW7i6121tvFmvanFpI0y5m0maa7eD7fb+ZIGnncOD5ixhSvPC/PkGqOi3VvrH7O+sane6xcXmr2Msl0tzPevcS280cpMBG5jsJAUcYyDnnNfRFZuvaJp+vWsVtq1v9ot45knERdlUuhyu4AjcAcHacjjpVc5HJoNgurptBt7prUy3rwJI1uGEZLlQSuT05J61kSavrHfwxN/4Hxf4V08nSqklTfyNVG/U5/wDtbVv+hZn/APA+L/Cj+1tW/wChZn/8D4v8K26KObyHyPuYZ1fVgCT4ZnwP+n+L/Cjw5K12JLiS1ktZG3PskkVz8zY6rx/AK0tSl8iwuJP7qE1Fo8XlW2D1GE/75UA/qDXDiHz16VO215fcrfqawjyxbuR+I226NcD+8Av5kV55e/e+gFd/4oONOUf3pB/WuAvPvH61OK3PZyte6/Uy5eZgKr3f36sNzOfrVW6P701ws96JyA1VLfU4LSKCe6umBl8qELkJ6ksQOvvWx/wl1nBq6ad9muWunjSQKzRRfe6D946kn2AzWGulytrcGoWFylvcmMQuJIvMRlxkcBlOQfet3VPD13rVqtleamjWDmJpF+zDzSVwTtcMAMkZ+6etdEFSur/qcVV4iz5e+m1rff8Afp6I9L8OR2tpaanrV0QBaRFFyOhIzn9RXlfhiUSaSpAxskdcenOa63X7118Jz2EJObi5DycdEAX+ZH6Vxvhn5BfQ9knyPxFcOGpyU6lSfV6eiKpQkpynLq/wPQ/DrZvJV/v2co/Ig/0rlvG0e21gmHWCUH9cV0fhhs6rZA/xxyx/nGayfGUW/SLgegz+XNbUJOGIk1/df5/5EuKlKcH1X+Z01gd+hH6VyXiGPzfBHixAOVW3l/JmP/stdN4bkE+ghv7yA1i30fmaB4rh/v2GQP8Ad3/419/xLrl05LpKD/8AJkfneV3jior1LnhHWDbaT4eF0S2n3Vl5Unfy3jkdQ4/DAPt+Fc98XLWS0m3OvBCsrDkMM9Qau+EmWXwX4eZgCI5riEj23K3/ALNU3jjUhYWDWOp2g1LSWXcIy+yWE56o+Dj6EEV+bUYyhPmgvtO6+b28/wAz9HhBxpuUFupJr79TgfA7j+0TJ2yT+td5dHM2P9pT/KsHwRp/h2+uP+JZrcttKWbEGowiM5z0DqSp/IV1l/DZWt0ySTy3EysMxxxlFHA6s39Aa7KleLqONnf0ZjhqkeRR6nH+JnxZuv8AeTaPxNdVpSBNNjH+zt/NhXKeIT5ksC4Ch5I+B0HINdNNP9k0OSQ9UXd+QP8AhV9EdHcfpTeZp0Tn/lrJJL+BckfpitPw/a/a/EOnwtja0yk57hfmP8jWdawyR6daxQTvbvFEql1RHPA54dWH6VreFNPvr3WraP8Atm7jwC++O2tVYfQ+TxxmtqcIzmtTkxVWdKjJqOlt7nsx6VUlG67sF9bqP9Dn+lY7+HLzH/I0a7/5Lf8AxmoE8P6gNSsEh8V64jPLjdstHI+UnI3wEA8dcV6aSutT5O7s9D1OiuV/4RfV/wDoe/En/fjTv/kWtbTLG603TriO61bUtXkO51luEgWQDH3VEUca9sjIzk9cV2nnmpRXzB4b8J69Z3l1pOnafcX0Nxp995urXGjSaffwSNG2xJJZMx3JZm2dXwOQVqbS774iaJ4E8I6ZoK61aWyWckV1PcaU/m2tyqjZEY1tJXMI4IYRncSR5gxwAfTNFeFnUPijf6nqDx6lPZWtjoUV4qRaIWS9u/KbdHGZUV1JfadpUsOBtHOadtr3xYtrG5MUWoajdTeFYdQjW701IhBfmVVkiUrGoLhNziNsnIHGOKAPdtR1Kx01IX1G9trRZpVgiaeVYxJI33UXJ5Y9gOTVqvm3xOPGviSO1tZYde1DSLXxDpU9nfXelfZrpRtYzs0QiUbEbHzMmB6sOau634z+IPhTwpca7qctzcxaR4judPkgurKOF9RsmCrBIMIucOeDHtDZ74oA+haK8E8Qar8UdKtre3mudWlvF0VJ4ZtP0mO4W71FpMtDMREwiRVO0fcyBktnim3eoePdPvfEU9tpM2nvc6vpiXdzp+krLJHbtB/pMkWIybgq/wAuSJMA/kAe56dqVjqSTPp17bXawytBK0EqyCORfvI2Dww7g8irVeS/A6x1TS/Bfiw3NtqMN3LrV9c27XtqYpplYKUk2FV+914UDOeO1cfZ6z8V5NGtpJrnXlu5vDlzfyD+x4QYr6N28uEDyeC6hfkOSc8YyKAPoqiuU8DeIr7Vra1s9X0jVbTUo9Otbm6uLi1MUDyyRguiEn7ytkMuBjpXV0AFFFFABRRRQAUUUUAFFFFABRRRQAVHcTJbwSTSttjjUsx9AKkrnvFdyHEOnryZSJJfZAePzIH5GpnLlVy4R55JGNC7ztJdTAiWdt5H90dh+AwKloFKK4Lnp2sKKlQUxRUyCmhNigcUoFFFMi4UUUUCCg0UGgCOSqklW5KqS0y0RUUUUiihrQD2qQnpLKiH6ZGf0qxY5+yRMerjefqeT/Oqero8k1sif7X5lSB+prSAAAA6CuSMG8TKb2UUvxbf6Ft+4kY3ic/6NEvuT+lcJeD5x9a7nxKciJf9lj/KuI1AYf8AOoxO57WW/AjGBxMfrVWb/WGrX/LY+xqBYZJ5NsMbyOeiouT+QrhPcTsYNmMXUQ91/wDQRXVW5+VfoK5xoRZX6LfTW1m2QQlzOkTnjsjEMfwFbEOpWflr5AvrwgAYt7R1/Wby1I9wTWqpT3t+hhLFUVopXflq/wAC7eQ/aNNlHcLkVxek/utavYjwHRZPyOK7KK5v5IZBbaXDHHt5e7u8sf8Atmikf+RK4/z73+2oE32dsZo23Na2iknHOMzGQgfTFaqmktWjL28pfBBv8Pz1/A7jwsHbVtM8tGci4UEKM8Hg1X8UzWcVtPbXV/YwTnK+VLcosn/fGdx/AVmQ2cdzCrajNdX0YdS0V1cPJERnkeWTsAx2AxXRarplpYNf21jbQW8SyMVSGMIMZyOB7YrnXs41urbXps/n3MX7d1eiuvN/5dzN8G6pDHoqQW0N7qTKmzdaW5VMjj70xjGPpn2zUtvumk1CF0MbT2EuUYgkEY4OOO9Q/DJiNNuIWPMcrr+fP9ass8kOvDyohK7wzIIy+wNwD1wcdPSvuMyTrZNUlfeMX91mfCxXscw5e0n+pi+B2P8Awgdl/sai4H4xoaf8URmxJ/6ZGqnha4nj8K20dtprPbjUHw73YVi/lrkY2HjGOc1N4+ubiSyAvtMMS7CMx3gc/qgr4WlSak3db90fodHERUWrPr0f+RxvgONZpDvUHEjfzr0W4BIUFiQrKoz2G3Nee+BZ4k3NZ2c8vzt/rJ1T+Smu4mu7rALaXj5v+fwf3f8AcrrrU25vVfecuHrxVNaP7n/kYOqDdq9jH1+YEj6J/jW14hbGnxW4PMrrH9ckf0JrGSZ5/EKEafIZYgfl+1Lt6+uz2rQvp57jU7GN9NIdGaYKLsYOBjk7Pep9m7rVfejT28bPR/c/8joxwpH0Fdj8PLdVvHuCMkkRLnt8hY/5964D7Xe7f+QUP/A0f/EV2Xga81vZI1podvKqfMBJqOz73f8A1Rz93FbYan793+ZxZniF7BxSerXRnpr1Fa865po/6asf/IbVgvqXibv4dsv/AAa//aabZ6j4l/tezK+HLIyBmKg6rgH5DnnyfQ13xj7yPnJS91nqFFcr/avi/wD6FfTf/Bwf/jFV9Zt/EviLwxremz2q6FdTWrC0u7HU2eRZuq8hEKjIGeeRkV2nnnZUV82+BfiBrerWGu+NNYu7+x07w3pUGmNA0ck8ct9kedM8Cum8gkDkjAbORjNTad8ctfuo7iGWHRYFTVrSybV5I/8ARbeCZGbzZVS4dc/LjibHPJBGKAPoyivANL+NOtNHoE2ppokVlfXOq2s12I3ji328YNuFJkIBdjjBJz0GKrSfG3Xk0PwzqNwNCgj1GxE9ysCLc3Imado1WO0N1FIUwM7lLnOeOKAPoiqmo6bY6pFFHqVlbXkcUizRrcRLIEkX7rgEHDDseorjviN4q1bRNb8Iabov2FG1y8e1klvIHl8oCPcGCq6d+oJ/KqXws+JkHifQfDw157e08QasboRW1vHIY5fs7sHZSchRgA4ZvpmgD0miiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAbI6xRs8jBUUFmJ7AVxCSvdzzXkwIknOQp/hUfdH5fqTWv4qut/l6dGf9b882O0Y7fif0BrMArlryu+VHdhoWXM+oopJGKRsyozsASEXGW9hkgZ+ppwodXMbeUyrIQdpYbgD2yMjP5isDoOU8M+P9J1nT7q+uUm0a0t7s2Pm6nLBEsk4JDIpWRskY74znjPOH6r8SvC2m3mjQNqtpcR6rI8cVzb3MTwx7ByXbfwM8ZGeeK5yy+FV2mjx6fd69byxx66muBo9PKEuGLPGcytwcjB7YOd2eJYPhVLZ38V9Ya1HHdwa7dazF5llvjAnUKYiokBOAvDAj6VraJztzO8PiPRBqUunnWNNF/ErNJbfak81AoySUzkADk8VW/4THwx5Il/4SPRvKJwH+3Rbc7d2M7v7vP05rhIfg7DBqt1cJqaS28t1cXcSXMdw8kDzKQxUrcLGevUxkkcEnjF7R/hTZaVa+EI7S5t4ptDnNxPNFZKjXzbSuXw3B56ktRaPcLy7HXXHi/w1bQ2s1x4h0eKK6UvA8l7EqzKDglCW+YZ44qvo/ildT8Z63oKWwCabBbzi5Eu4TCUE8LjjGOuTnPauAk+DN/8A8IxBoMPi6aPTUhniktxbOsbtJIziTaky5K7gMMWU46V2XgzwT/wjWtXmoHUPtRuLCzstnk7Nv2ePZvzuOd2c47epoajbQacm9UaFn4w0a5vb63N9aQi1uUtPNe9tyskrZwihZCwbKkbXCkkHAODVi48U+H7e2e4uNd0qKBJ2tmke8jVVlX70ZJOAwyMr1rzQfD3VvEeseJ9SvQ+hNdavZahYCdY7hs26FcukcmMEseA4PH5wX3wz1TQJrbVNJmn1fVo9SvtQVYrSJYV+0xqjKySXCYxt4cMSM8qcUcse4uaXY9Q/4SbQZIRJHreltGYGug63cZBhU4aTOfuAggt0BFc1/wAJ5pv/AAk2o6ddS2dtp1pZwXi6lJdqIpFlOFAJwAOmDuOc1x+kfB/UR4W0mG41aGwv10WfSbuI232hdksjSZUh1wylsZ5BxWm/wwvbdXbTfE89lcHTbPTvNhtypKwAAkkSBgHHZSpH9407R7jTn2Ow/wCEp8PiyivDrulfZJWZY5/tcexyoywDZwSByfSrs2p2ELWgmvrWM3hC2weZR55IyAnPzHHpXm2n/CCCH7Kl/qUV9bRavNqslvNaF0l8xFUxnfIxOCudzFie/rXXeOfCcfibw9Fp9tdHTLi1miuLO6ij3G2kjPylVyO2RjI61LUb7lpytqjdsruz1GPz7G5guo0doy8MgcBgcEZHcHqKr6nr2kaU5j1LVbC0mzgRTXCJIT6BCck+wFZPhrwxc+HYNFsdP1UrpNhatDNaG2Um5lJz5pfOVOSTgdc1t6fpen6cG/s+xtbTd97yIVTP1wKWg/eaOU1rxNZXUyGwtdWvhsKjybF4weeoaby0I9w2K5nULu/kb5NIjhHZrq8GfxjRGH5SV6DrY3XiD/Z/qDXI6yMSj2FcdeSWyPZwNNySTk/lp/wfxOXc6k2Wa7tbY45FrZqc/wDf4yfpj8Ko3FkLmJ0vrq+vI26xz3LtH/37zsH4Cta44VvrVRhlT9K43Wnsnb00/I9qOFo2vKN/XX87mFZW0FrqQS2gihQY+WNAo6H0rrbZMxA56AVzSD/iZ59h/Jq6mzUtHtUEkgYAqN3qb6RVkXLUfuH9+K4HUMRarp7+kpQ/iK7+4X+z4AdQkhsUIzuvJVgX83IFcDrMmmmYP/asBMcqviCKWbPPZkQp+bCt40ptbHNLE0o3Tkr/AI/cdFaKXs519j+ldJqLfaFE/a4t45B9dgB/UGuY0683GRbPTLybP/P3NHbAdP7nmk/kPwre0SW6vtNnt7lLWJrEARxRb2fYSSSzkgMMkYwq4569uatD2TjUk1pp99u3nYxlXTnFpO3e1vzsYfw6zFq+rQN0LiQfQjH/ALLWrcfJ4o08noZSn/fSkVj+EW8rxlLH2mtmP4rIf/iq0/Ecn2bULS4PSK4jc/TcAf5191hk8Rk86fXkkvzPi8yXss0v5r8TI8LqV8H2rdP+JrJx/wBs1p3xLfbZbjyFjY/pUmiAw+D7UEddXnH5ACqnxHuLWaBrZr/TopjE2Yp72KJ+Rx8rMDX5/hk5ydlfVn6DRqRhScptJe9ucf8ADvizDY+8zH/x6vQrs4gz/tH/ANBNcF4L+yWOnolzqmjxOCeG1O39f9+uxuNV0kwOBreiE7sgf2nb+n+/Xo1ac3N2TOGhiKKpRTmvvRQ8NIZtavpj0T5fyBP9a0LT994gu2BytvEsY+pP+AFUPCt7plnpsj3Ot6ItzKxcqdTt85zx/H9Kk0G/0uEXss+t6IrzTEgHU7fO0cL/AB+mKn2U7v3WX9Zo2S5196OjJwpNerW+n/2Xa6NOuUZYooZgOjBh3+jEfrXkNvquhyXESS+INCSNnAZjqcGACRk/f9K9T8SeOfCNzbFLbxX4dYh4iManB2dT/f8AaunDU5xu2jys1xFOfJCMk93udI9O00Z1yy9hKf8Ax0D+tc23jnwgenizw7/4NIP/AIupNM8deD49Yhlk8WeHVjSGQbjqkHUlMD7/AKA12wi+ZaHhzlHkep6XRXK/8LH8D/8AQ5eG/wDwaQf/ABVZ3iP4k6VaWWmN4aks/Ed5qd8NPtI7O9QxGXbubfKu4IFUgngnkcc12HAd3VDWdKt9YtBbXcl7HGHD5tLya1fIz/HEytjnpnFc/d+N7bQbe2TxjENM1O4aURWll5uoGVIxuaRPLj3lAvUsi4wc8YJq3nxX8F2i75dZ3x/ZY70yQ2s0qLBI21ZGZEIUbuDkjB4OKAOm8N6DpnhrSIdM0O0S0sYiSsaksSScklmJLEnqSSa064x/id4Sjt72aTVJEWyuYrSdWs5w6SSjMQ2FNxDDkMAVI70WHxO8JX1/b2cGpyrcT3Mlkqz2U8IWdBlomZ0ARwOdrEGgDs6K4q0+KPg+7juZIdXPlQWs16ZHtZkSWGLPmPExQCULg58vd0rR8MeOPD/ie9ltNGvnluY7eO7MUttLAxhkGUkUSKu5TxyMjmgDpKK5tfG2hya1eaVbTXl3eWbFLgWmn3FxHC4XdsaSNCgbA+6TnPGM8VnXHxR8I2tpqlze6lPZrpYia8jurC5gliWRgqExvGHIJIGQCOaAO1org/8AhbnglrOG7j1ppbeWF7gPDZzyBIlkMRkfah8tN4K7mwDjg1lL8X7F7/xpbiyMcXh1Y3W7m8/7PcKy5LM6QN5Y/u4Dbx8y5HNAHqNFeUeOPi3a6ZFp1v4dkt73U5NQsra8Q208kECT8keaAqh8HIUkH1Xrj0DxJ4hsPDlqLnVBfCDDMz21jPchAoyS/lI20Y7tgUAa9FU9G1Oy1rSrXUtLuEubG6jEsMqZw6noeeauUAFFFFABRRRQAUUUUAFQ3dxHaW0s87bY41LMamrlvEV2Ly9WyjOYYCHmx0Z+y/h1P4VE5cquaU4c8rFBHknllup12zTtuYf3R0UfgMVKKQU6uLc9LbRABUqCmotTKMUIlsKKKhvrj7JZXFz5Us3kxtJ5cSF3fAzhVHJJ6ACmQTUtfOPgnTvG/h3xE3ia90u6L+J4Lo3McKSSyWs3LwmSMxjy8HCgZI5OcdK6DSNZ+IiRQG9m1DN14eNy0l1pBZbW+83aF2wxBs7edhDHvjHFW4eZCn5HttFeFjxN46GhRxtaeKTfPdNCL0W0flYEYO8p9h81YyxOAYs5H38V2mj6t4wuPg2mpNYs3jD7K5FvcQeUxkDkAlDjB2jOOMn60nBoammegUvavFtY1zxlFoejPoVz4hvTNKBqk97pPkTWx8sELGgtGJQtuywjlxgDIzmp9EuviLquveHbO41V7K0OnG4v7tNHbyppUuCNn76ONo3aMDggdyByDT5Bc569JVOSvGWu/iJqGmeJtP1i2nmj0nT7qISPp0bpq07M3ksiFMMoQDhRgnAIrT8Oal4jXWFt9e/tmwtYYbQWVrYaWrQXA8oFxJJ5TCM7vlI3Rhf1ocS4z8j0i6uYLO2luLuaOC3iUvJLK4VUUdSSeAPenwyxzwpLC6yROoZHQ5VgeQQR1FeC3GreN9asdfsbvT9ck0y60W6CQ3lnmVJwcKu5LeIbmHRRvHo2eBetW8VaXDrg023fTZfK0mOG4Oju7ygWx84bo4XZmBGNzq4Q/LxkUcge08j2+iud+H97qOoeFbS51m3v7e9cuXjv9nm43HGdiRgDGMZRT6juZptN1q4ncyeIWtoCx2x2VlEp254BaUSc46kY9sVNtbMvm0ukTahG0t8gRSx2ngDJrifEk9tZ3LrfXtlZsPl23NykTE+gDEEn2Fbl74XspZtt/calqKlcst5fSyIf+2e7YPwWudu9LsNNMi6dY2tonTbBCsY4+grlrci31PVwLqtpRsvx/wAjnZ9R08rmOe4uiOStrZynP0ZwiH8Gpkdy7o32fSpmGPv3d0kJH/AEWTP/AH0Ks3XUCpbZcW7H2NcSnG+kT23RqcvvVH8rL/g/iYKz3zX+2NNOtHwvzw25lfndjPms6k/8AH0rdjs5plIutS1KUAfcW5aCM/WOLYh/KsuFN2rn/tn/AFrpIlxu+lUqs+jt6aEvDUn8Sv6tv87lWw0fTrMb7WwtYZCCS6RKGJ9ScZNcj4vXC3J9MH/x4V30Y+UD6fzrh/Fy/Jef9c8/rSu3qzaMVFNRVjd0VsuT6gH9BV9JZbHU4r62GWQEOnZl7g1k+HW3RwN/eiQ/pXSabD9o1GCHoHO0n0GeT+VZVFFwant1FUScXzbFaTw/PZ+KNN1izRpNKnjc7+8YcBgGHbkdai8W2NzqMUsFhE807r8ioMkms/xDrV7Hq8WpWF5Naq10sO2M4XyyQoGPTkGtjWb3VHtAjanP5cinIjwmfqRzX0fDssylhfY04wktrybTV11STv8AernxWdU4U68alZu9k9F2K0FpCnhxNFiuEl1fS5mvruOM5AEjNuAPcqCuayfHiBrFG7FSP0rjfCOpzaTrNvqFsMvG7b0PR0JO5T9Qa774ixRR6RFc2zF7GZd8T+2OQfcdK+RhTeHqOnJ3u7/Pqv1X/APvMKvZRjFvSSuvmtV+v/DHF+BkC6RDjuGP866HWfNuki020Ba4uplQAdsgCsHwYypoUMjHA2En9a9D+FGlvqevXGvXS/6LbExwA/xPjBP4Dj6n2r1FBzqWOCdVUaCl5Efj+2Ogad9niVVklAhhC8bmwBx9M/pVbT7UWdlBbL/yzG38e9P+IF+ut/EGytYjmDT3VP8AtpjzG/RQPqTUo5wfbNTVSi7IeGlKcVKW5t+C13+LNKH/AE23fkCf6V6l4hQmGVz915IlH4uorzTwCmfF2nn+75h/8cI/rXousvvkiiH8c8Yx/und/JTXThlePzPHzVt11bt+pM1W/Dw3avct/ct0X82Y/wBBVR6v+F1/0jUH/wBqNPyXP/s1dtL4kePW0gzfrn/GXhOw8V2tml7Jc21zZXC3VpeWjhJreUfxKSCOnBBBB9K6Ciuw884TU/hraalNZXlxr2vf2xarPGNSEsPnPHMNrxlTEYguAMBUGDyOSSctvgl4WGn3tjby6lbWt3pcekukUyfLEknmbgWQ/OWySTkcngV6fRQB51qHwj0G+utUuJbvVA+o3FjcyhZYwFa0TbGF+TgEfeznPbFOb4SeH3u2nkuNRk3a7Lr7RtIm1p5F2shGz/V47df9qvQ6KAPMrb4MeH4rQ2st9q9zbRafc6ZZxzSxn7DDOCJPKIjBJwxAMhfAre8MeANL8Oa3DqljcXslxFpMGjqszoVMMONrEBQd5xyc49hXX0UAcOfhzZR3Wuvp+sazp9nrkkk19ZWskQiklkTa8is0ZkRjwflccgduK5mD4BeF4tK1SwF9q3lajbQWszr9njbbDIsit8kIBclQGZgS3fnmvXqKAOG8X/DTSfE+q3l/Ne6nYy31mLC+WzkjC3cAbcFcOjEem5SrY4zVS6+EuhyL4hhtrzU7Kx121itLuzgeIxhYkCRsheNmVgox97BzyDxXolFAHmdz8G9CmunkTUdYgt5Lu2v5LWOSLy3ngUKjkmMtyByAwHJ4HGNr4hfD3SvHUmmvq9xeRixMmyOLynjfeu0745UdCQOhxkHkEHFdlRQByXhDwLaeFX01dO1bWZLSw0/+zo7Oe5BgYeYX81kCgGXnbuGPl4xXW0UUAFFFFABRRRQAUUUhIUEk4A5JoAztev2sbI+SR9plOyIH17n6Ac1zNvEIkxksScsx6sT1J96sXkrXt69y+duNsSn+FP8AE9fypAtcVSXNI9GjDkj5jaeopQtSKtQaNiqKqWGq6dqM11Dp9/aXU1q/l3CQTK7Qvz8rgH5TweD6U3Xpr630S+l0m1N3qKQubaDcq75MfKCWIAGcZyeleEeHPhz428H291JpmLq51rRbiK8a3lEElte7WeJi7SfO29ygdMAdcDqbUU+plKTT2Pfr+9tdOs5bvULmC1tYhmSaeQIiDpkseBUyOsiK6MGRhkMDkEeteD6v4G8aal4f1fTZ31GeK70C0xHdaoZFOoIVMqjMhxnDf7BOPbEuueGvH01xZrpcuvWGlpYxpBFBdpNcWsyvl/M3XcaybsHBZpQFOML2fKu5PO+x7ZqF9aabZy3eo3UFpaRAF5p5BGiZOBljwOSBVhWDKGUgqRkEd68UvPCPjqbTPG16ura8urTXMqaRaJqapCYWZCHUbvkIwwALDAzxzzZ1LQ/H8nieSWCbUNx1G3ltrtNQC2cNmF/eRSQb/nfPfY2eu4Ucq7hzPsexUV5/8KfD2v6ZHf33inUtXmvp55US0ur0TwxxeYSjIBnBIPc9OMCuYbRPiD/b2tvp8l/5VzHdNb3epXez7O7LiJI4orl4mX3aJSM56jFLl13HzO17Hs9Z0+uadBr1rostxt1O6heeGHYx3Ipwx3Y2jGe5zXl93pXik+GrC00/RfEKX5kjF/cXmvPI4IQhpIgl4m4ZJypaMcqdpxxk6Z4T+IclvoN3db01600W/tGvbi5jkZJnkPk7iGJYldvzc4701FdxOb7HuslU5RXiVv4a+Iy6O0Ru9e+0STWbSRyXaIFCN++ZJftcjkEZyuEB4wo6CbU/DvxBisr62srq/exTXZZYo3vjJPLYkDYFk85HwDn5TKje/qcq7lKb7HsNFefwaX4mj+El5pwutRn8RfZ5UgmndIbgsSdmXWVwDjGG356Z5rkdU8MePUs9WOm3OsG4W2sJLIHVic3A2i4B3SdMbsq3ynsOlJRXcpza6Ht1IehrM0271O6l1JLzTVsFhmMdpK0yzC4THEhVcFRn+EnPvVUw+Ksf8hPw5/4KLj/5LpWKv2Rdux/ph9o/61xmtDhj68/nWzcJ4mWeQtqHh0lU5P8AZNwP/buub1Y65HuEsnh6TGBxp1yP/buuatFNb/n/AJHp4KpJNWi393+Zz91/rMVPGdtk7HspP86pT3OpeYd0Ph8nPX7Hdf8AyVUs1xqiWUhMXh8rtOV+xXXPHr9qrhVON/iX4/5Huzrzsv3b/wDJf/kitpvz6w59JMfgEH+NdB/Cfeue0a41GWZ5Irfw/G24/MbS6bPJ/wCnr2rYM2rgDjw/z/043P8A8lVfJH+Zfj/kZ+2nf+G//Jf/AJIvx9B9RXHeN0CWl646+WB/X+tdPHLrO0Y/4R4f9uFz/wDJVcx4wu76KzuGurTQLhdpLKLW6TOB7XXtVKEf5l+P+Q/bT/59v/yX/wCSLHhY5tLQ+sa/yNdhYYhiu7nvDbtt/wB5vlH/AKEa4rw1eX01va+Va6FDGV6La3JIHsTc9fqK7NyF0CQd5riJPwAJ/wAK5MTFcnKne7S+96/gEpynGzi1tvb9GzjvFsBTRJyg+eN1dfqNp/pWzPcCWyhIORUPiJA2n3II4BB/n/hWJpN0W0mBGOWRQh+o4P8AKvsuFqtpVIej/Q+a4opc0adT1Rydr+41KZOm2Zx/48a71b60XR20zWZNmjXg2mXGTayEcSD2z1HpXn+qsINVuj6Pu/Pn+tW7yabXrSHTLEFi3MjdlHqa+ZzDDp4ipB938tdz6rD1FVwNO+9l+R0Xhzwpfz6lH4dUgJb/APHxcRnKbOcMp75HT/6xr13Wb2x8G+D5XsoxHBbR7IIl6u56fUknrXLeFBcaJoEVlEVijVArMB88nGMkn2H4D0wK4jxXqlz4h13yjKxs7Qhm9C+MD9M/pTp1FCPd9WcE8NUqOKm9F0I/BIefVLy5uJGkmCNIzn+J3xz/AOhf99V2gRijPj5QQtc94PhEdreTYx5kpA+gY/0WuquFMdvaIeP3fmEZ6lvm6fQqPwrmqT95LudsbRskb/w9TPiWFv7sErfqortbydZ9XsgoAAlkfj2Qj+tcZ4EPl60xxkrakfm4/wAK6/SYhPcPfAfuNpjgz1Zc/M/4kDHsK9DDp8i+Z4WZNe1d+yNB+ta/hlf3N4396f8Akij+lZL1s+GR/wAS12/vTyfoxH9K7KPxHjYj4DWooorrOEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKoasxMBiB4b7309Pxq/VDUBmpnsXT+IwtmWNPEdWliqRYq5eU7XMqrHTtlW/Lppjp8pPOVCtNIq20ftUbJSaGpFfFJUjLTCKmxSYlFIaQnFIY7NFNzRmgLDuKUUzNOB5oAVhxVSUVcPNVphTBFM9aSnOOabSNApD1FLSd6AM28/wBbce42/mBXK68OZD711dyMzt7sP0P/ANauW14funPuT+tctbZnqYJ+8jiZOZvqas32BZMO3H86rn/j4/Gnay23TpcH+HivPifQz6EXhxStpGT1Y5P5VtkZ2+wJrN0tPLghX8/yrUP8lqzNbkkfEYP+zXHeOvmtZV/vRt+qmuxb5YT9K4zxo2ZJF7AH+WKZcdRfBzZs7E+qf1rtZs/2JZjt9tb9FFcL4IP/ABK7E+gx+tdzMxGiQAfwXjE/iv8A9asKy1j6mVTaPyMzWU32F4PVR/WuEtJ/IW5jY4CSk/nhv/Zq9A1FkW2ujKwVNqkk1yejeH31G5e5vUeO3cKRCeC2BjLdwPbqfpXtZVjY4Kq6strHn5pg3jaSpR3vcw7PQ7nxFqMsygw2ZIzKe+ABx+XXoP0r0rRvDtvpVmpSIRxjkAjlj6sf8/0re0jSoreBC0aqij5I8AAY9f8APFZ3iLUQytEh+Tp9f/rVx4ms61SVWWnM7nXh6apQjSjqoq1zmvE2tNBA4TnsAOpzwB+JqjcaTJpFuIZyGmlxI0g6PuBOR7c1XskGp6jPPKu63iysRPR36M34dB+NdF4h1O8tvD+kKkylBBJlZYlkHyyMAcMDjj+VcdSUouKj1/yv+hcpNSVh3gzTnuNIiYxyNCE82UoMnnnA9znH69q0bhJftLNPG0byHOCMfl7Vzq6+0ywWcrT3LqoVIoVAGfRUXAH1q7PDfhlE8i2qn5hHEQzj6sePyH40lGfNzz/r+vQcYyvdne+BrVbrUL8SE+WsUaED+IHJxXoGAqgKAAOABXnnwjkZ01VZpC80cqqSepXGV/Qgfga9EPQ161D+Gj5zMW/rDT8vyIW61teFznR0PrLMf/IjViv1rZ8Lf8gWL/rpL/6Mauuh8R5eI+BGtRRRXUcQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVWulzVmo5RkUpbFRdmUAlSBKk20oWs7GjkR7KQoKmxRinYVyu0dRtH7Vb200rUuJSkUHjqF460WSoXSocTRTM9lqMirzx1nare2WlWcl3qd5b2dqmN81xKsaLk4GWYgCocTRSFIopYnjnhjmgdJYZFDo6HcrKeQQR1FLtqbF3GilFKRTJZEhieSV1SNFLM7HAUDkknsKAJailHFMsLy2v7SK6sbiG5tZRujmhcOjj1DDgimajfWdhHG99dQWySyLCjTSBA7twqjPUnsOpphchkFR021vbTUIWm0+6guoldoy8EgdQwOCuQeoPUU41Ja1Ck7mlpB3+tAzOPzTj8T+rf41zWur/on/AAEV0gPzbv8Aplu/PmsHxCu22b2Fc1X4T0sI7VEcFj/SR9aZrPzwrGOruq/rmpiP9KFF1GDLESfukv8Apj+teej6KT1RPaj5kHuf5Vebq/0xVO1HzoKt9Sx9xVERJmxhQfUfzrhfFmJGkbP+c129wdqE+grhfETcY7nNDNIdRfBTgadAp/hkK/ka76MCXStQjHLxlLgDuQvDfoc/hXl/h28S1sCTlmE7BUXkseeAK7vw6l9PqsF4wxKDiODOUXPBB9SQSCegzgetZ14txflr92pjNc0dCGGCbULoXF0Cka4McPUL6M3q3oO316dXo9mqjzGA45GT+pNQpDYCSRrdbr7OGPlgquMfXd0/CqOt64sMPkwxiM45JcsfqenPtipjWcmmov8AKwlLmVorcteINaSJWiib5R95h3rgL65k1S9ayicqSMzOp/1adcD3P6D8Kqa9q/2VdzENcMMoh/hH95v8P/rk4mg6sLG2mmlbdPcOcd2OOPzzmuhJv3mU2oJJbHf2tugkjt7cIgSPABOFRRgkn0AFZHjnWbW4h020s5MRLE0OSOeZGBbHuPmx71V0u11zUVm2/wChW82FaWYfMRnOAv4Dr6VtWPhrTrO0lSRTcSuMPNJ1weOPTn+VYyh76k3sJQc2pPZGl4fsoLGNJLNeHA3SHlm9yau6im9SwBBU1i+E7prWd9IvM+YuTE5/iX0/CummTch3DoNp9xVJ3RvKPKyPwdqY0jxRbSSHbbXo+yyk9AxOYz+DZX/gdex9q8DvbfzYZoGOCQcEdj2NeyeEtWGt+HbK/OBJImJQO0g4YfmDXbhJ3Ti+h8/nFDlkqq6mlIa2PCzZ0kD+7NKP/H2P9axpK0fCco230HeOYOPoyj+oNehRfvnhYhXgb9FFNlkSGJ5JXVI0BZnY4CgdST2FdZwDqKwYPGXhi4sZ7238R6LLZwMElnS+iaONiQAGYNgEkgAH1reoAKKKKACiisvT9e03UNc1XSLO58zUdK8r7ZF5bDyvNUsnJGGyoJ4Jx3xQBqUVVuNSsba/tLG4vLaK9u95t7eSVVkm2DLbFJy2BycdKqJ4h0t/E8vh5LnOsR2ovXt/LbiEttDbsbfvcYzn2oA1aKKKACiiqt5qVjYz2sN7e21vNdv5VvHLKqNM+M7UBPzHHYUAWqKbI6xozyMFRQSzMcAAdzWXc+ItIg8Nz6+dQt5dGhha4a7t286Py1zuYFM7sYPTNAGtRVfTb231LTrW+spPNtbqJZ4X2kbkYAqcHkZBHWrFABRRRQAU1+lOpG6UAQY5pQKd3oqS7iYopaKAEppFPpKQEbCo2WpyK5K48f8AhmDXG0mTUj9sW5WzbbbytEJ2GRCZQvl+YR/Buz7UWGmeIwwav4fs/ibqHgzw/qVjrM2oQvpkiaHIrPbmSMOIw8WCOWJXHq2OM1Y8aWHjTWNTXTLt9burGw8WWP2W6XT4wxt2VmaUkRbGWNgPmxt+Y7s8Y9N+FPjW78bQ65qF0sNvYW17Jb20X2OaJlRSRueVztckDlVUFO/WrVt8S/CF3HcSQ6sfKgtZbzzHtZkWWGLPmPExQCULg52bulJjR5w2sfEdfGt3bziWCxhvpIoojYyyxT223COrx2zKHPXLTKM8FFFVdJh8eXOleCdT8QtJqV5c6rC01tPoscb6fGFlDMx2Epk7PnwpHbrXo0nxU8GpBLNJqk6RRRRTuz6fcqFilx5chzHwjZHzfd5HPNXJfHfhpNc/sk6l/pf2lbMkQSGETsMrEZgvlhyP4d2faoa8jRPzPJodf+JRt5G8jVHvv7P1CS9gk0tVis50DfZhbP5f74sQvG6TOa7nw7a+I5PhpdP4mv5dS1a+sWmEf2Jbd4C8A/cFF6sG3ckA5OMDGKpeCPipY6lp7DxNLHZai094IY4bSfy5YrckttbDBnCjJUHPTA5FbrfEbwl9lNz/AGxGYBZpfl/KkwIXfYhPy/eLcBPve1TJPsXFrueQ+EL74g6R4WSx8PWGpyraaECbfUdO8gQXfmY2xFkRpDs3NglxnvzirNy3jHXtHtE1lLy/EOu6bPCh0+eOaFAW80uWtoVZQQDlVO3OCehPp1x4+0hksmsLiJzNqkWlSxXaT20sUrgkL5ZiLbsDgOEU/wB4Vkp8SLfU/iB4e0bw+8V3pd+t2Li5a3lUFoV48qQ4RxkEEjcPcUXfYLLa55odT8WeA/CNpe2dvOkdzq9/aPp88AVpJZSxt5F3LuxuHY4IxXuOjQXlto9lFql19rv0hUXE+1V8yTHzEBQABnOBisjxd4r8I6fqX2XxFJE13pwS9/eWMk/2YM21ZdwQhOTjdkYz71f0XxJpWvT30Gl3LSzWTqlxG8LxMhYZU4dQSCOQRwR0NRK7V7GtOydrmpTTxGx9Mmop720t3CXF1bwuRkLJKqnHrgmq82p6ebdwuoWRYqQB9oT0+tTZmnMr2uRsMLKPSFR+lYviMfuG98VrS39gWnxf2ZBCAf6QnP61j65c20yYiu7Vu/E6H+tY1IS5djtw1WCmm2jhyP8ASjTZjmRvYAVaMJ84nfFj/rqv+NQmBizHdF1/56r/AI15/s59mfQPEUv5l96JbX76n0FW4xyPc1BbxFckvCP+2q/41ajVQwzLAOv/AC1X/Gn7OfZijiKVviX3oivj+5IHU5rzzxE7yXZtoQWnZMKo9TzXeavI0cBMISaTGFVJFOT788VjaPohSd7i6khNxKdzuZF4HoOf0p+zle9mUsTStbnX3oqeD/DaWMZeU75j8zOei59PQfz+ld7YQ+XbySJldwEa9sA5yfyBA+tVrO3VwCdggU8BXDFj7471Bq+qCMGKE8+x/l/j/kY1YuWki0ozjaD0G63qiwKYoCN/QAdv8+lcHrmqfZFYjEtxgscnhfcn/Pp6mpdX1LyiUiYNcOOvZR0/L+fQeoy9B0ePUL2ee9cyQxvt2Z/1jYzz7D0q0kvekEm/ggZVvpWoa5dtLCD5T4D3D8DPsO/4V3+geHrHSIN8UPmTpz5snLfX2/CrdrGqlggAUAbVA6Adq0hjoOhH+f1oqVXUk7KyKpUVTilJ3YyVc78HbkAjH16/qKRXyqlgOpVx/n3p0bYRc/wkofpVdvkmKt9x/l/Ef/WxWZqUNbt3AS6gJF1btkEdSR/iK6DSb+LUbCO4QjJGHX0PcVnS/vAA38Q2N9e1c3bXraFrTJISLW5OGHYMO/8AX86S0Y27x1Oi1K8WG5ZPs17Ky4+aKIFfUckgHr2zWz8NfEdxZ3V/pdnourXJlP2uOJzbR7BwGwfOOf4eKgija9RRArSSdNqDJYe2OtZdhrFlonijT71rlbia3dopLW0PmyMHBXaxHyIQWHEjJXZQdpJqP5nk4+CnSlGc9ei0/wArnqrar4hfHl+GkXv+/wBRRf8A0FW5/wA5qO31jxPpt2bybS9Asrdk2TTXGsSGNAOQXP2dQvcZyRzSk+KtUHAstAtz64vLr+kSH/v4KjbwdpzET3xuNV1BPmjudRkM5jbqCin5I/8AgCrXpJqLufLuLmrDP+E38Z6p8nhTT9J1Zj/y8QwzfZB/23kaNXHvHvP+z6b95o/ibW/Autaf4yj0q/nvofJWz0gyWwVTw376Rm3Ng5B2qPl6HPHZaZdpf2MNynAkXJH909CPwOatV1p31OBqzsz5n174beOdY8K63pqw389hBHarpUGqz2sd8dkoZo/Ngcq0YTOA7Y3YIAIBrd8XeG/iLd+I/O0W58Q2OifZbf7DHBdpPcWjrgyLOHvY0lZiDlmMwIOBgjNe90UxHgOq+CviJJ4c8dX1rrHiP+3rrVJY9Isl1dVhWzNzDIsifN8jbFdQCwwpI2jPOhf+GviBb3GvW9hcavNon9uWtxBD/aubmew2Hz44Znk3xndt4Zk6HBGefbq57xz4ssvBukQ6jqMF1PFLcxWipbKpcvIcL95lGM9eaAPKNP8AD3xFjOltrf8Abl9oKXt67aZZ6wsV/HA237Mstx5yeZt+bOJe45boItf8HeOxrvizUPDEN1Y2+o3GkMFe8U3Nxbw27JNHvWZWDhioJMilsHD9z22mfF3R77V7XT30vWbSWbVJdFZ50hKQ3cYyY2KSseRjDKCvPWu91W9TTdLvL6RSyW0LzMo6kKpJH6UAeKWvh34lxW/h5LTUdXaS3XVhNJfzxx7GktwLQSKtxN5qrLnaSzkdwOp5+w8DfERLjUtR0621Sw1ibw1BYteahqkdxNLdrOjzCNxK5QMofaeFGeimvQ/C3j+5svB3hS68Q/bNY8QeKS9xZ2FhDEpCFfM2LuKKERCuWds8nk9rniD4t6R4fXWxq2l6xBPo9nb3l1Bshdgs0gRVBWUqWBYZ5xjoTQBxs/hr4iTR3CWL65Z6TJr1jNb2dzrAe8gs1Vhc75hKxKMSpCb2PHSl0bwz8RtN1DTbhZdWuFt9bvleO61kyRvpzJ+4D5kbPzE4bBkX8BXR+G/GPiHxnqXjzRLO3fSpNNlMGnalEkTBG2gp5iu77ixOeExtzkq2K6v4W+JJfF3w+0PXLlAlxd24MwHTzFJRyPYspIoA8g0Tw/8AFEXGstdjXdNtLzRzFHFb6it29vd+euDF9ovHyfL3ZffHkZwAwGWXHgbxnqNl4butZ0nUrh9J1p5Xhh1uUXctqYwvmZkunWN8r0SbjJxjJz9F0UAeH2Ph/wCI6+LY5pZ9TVl1W4muLx9SDWMtgUxHDHb+Z8rj18sYPO81z2q+DviVqHhGw03WIdZ1FW8O3FrJbxauiFdRaVtr3DGZfNTyyoAy49RX0jRQBjeCrK403wboNjex+XdWthbwSpuDbXWNQwyODgg9K2aKKACiiigAoPSiigCM9aSnMKbSHcKKKKACiiikxoQ15/cfCvQ59alvmudRFrLqa6zJpoeP7M14BjzT8m/nqV37T6V6BSd6BnNeE/B+neGNEu9Ks2uLi0uria4lFyysSZTll4A+X/Oa5S3+DegRWptZb7V7i3jsLjTbNJpYz9ihnBD+WRGCThiAXL4FenkUhFIZ5le/B7QLvT72zkvNVEV3pdrpMhWWPcIrcqUYfJ947Rk9PQCpH+FOhnVDc/adR+yNqKas+nb0+zvdqMeafk35OMkbtpPavRiKaRSdxqx51pnws0TTbnRpobnUJG0q7uryFZHQh3uBhw4CDKjsBj3JrmvB3was7DwlrWla6U87Ur37Sr2Mrf6KiNugWNmUcrknlcfMetezMtRMtQ2zRJHnP/Cr9HMqXNzeajc3/wDa0OsTXcjxiSeaIEIrBUChAGPCqD71D4e+F+leH9V0e8s7/VJI9IFwtlayvEYoVmyXXiMMRkkjLE+5r0d1qFlqHctJHBeKPh1pPiK/1i7vbi+jk1SxSwmEToAsaOHBXKnDZHfIx2qA/D6yh1LUL601TWLSe+ltJZjb3Cx5+zpsVOFztYH5gc59q751qF0zU3ZokjFvdMsbuUSXdlbTyAbQ0sSsQPTJHuartoWkFCP7LsOn/Pun+FbMiVCRipNdDHl0HSdzn+y7Hkr/AMu6ev0rC1vRdMCSldNshjCjEC/4e9di/T8RWLq0ZMR46sT/AF/pWdS9jqw1lJXPM7jS7BZpD9htcD/pkv8AhVZNMsfLH+hW2Sf+eS/4V0Oo2rIG45NZ0iFcD0rzXdM+ijyNbEcGl2GxSbG15P8AzyX/AAqO9g02zjUDT7WSdl+RPKX8zxwKuyyeTAMDLkfKPeqMMBmnd2fkY8yU9vYe9HM+5pGnG2xn2WhWstxJNLa2xc8u5iUKnsBj9P61uwaJp5CE6fbLGPuJ5S5b3PFX7S1SONS67VHKRk9P9pqzdV1EndFAflxhnPcensKlyfctU4vRIbd3lvZRPDp8MKE/eMaBVH5f5NcnqOqFZDHFmW4ft7epx0Ht/wDrqLxBq6wFLaAgzuec87O25v8AD+lS+G7JGLyy5aUn53bq1NLrIUnb3YhHokgsJppWLSt8zMe/+cVW8MsYtTu7fPDqJF+oOD/Ou0vyqwFeACMY/wA/WuK0hCniiMEdUdf0z/Sm/eTElyNM62FiGyP8/wCeKsLITFwfumo/li8tz91uD/KhYXiuJUc/KpAP09axsb8xIXJD/wC0M496YT5yED7/AG+o6VDPNLbvtiszdSZI5nESrjux2sffAHbqKjjS+nnEdxffZkkGPK04GAZ95MmU+hAcA+laRimrydvzMZ1ZJ8sI3/Bff/kmWbye3siqX9zFayuAywvlpj6ERKC5HuFIrB16QXkYe30p3BAZJL+Ty1JH/TOMliD6l0PtWnaWEFoJEsYY4dx3ttXBYnqSepOe59aVx5ls6MCXTLAew6j/AD6U+eK+Fff/AF/mT7KpP+JKy7LT8d/usY3h68/tiL7Nq08syqP+PMHyrdkHYxrgPj1fcfeu50fw/HdXAtY4VFm8TFAq7RjB6Y7jn8q4S30gjULlraQxXSBZ4cdCD3/Ehq9l8C3cWt6PDNaxrBcQth4x/wAspB/Q/wAvpW9OMqr95nJXlDDwbprfd/59TrdHna4sUWYk3EQCSE9WOPvfj1qywoe0aBEuogQSNzpjqvcfUdR+PrUrqCNy8g85FejKDifLqabdh/h25+yag9o/+puSZI/ZwPmH4gZ/A11FcVcRF0+RikikMjjqrDoa6TQ9RGoWpLgJcxfLMnofUex6itaM9OVnPiKevOjRoooroOUKyvEnh7S/EtjFZ61a/abeKdLlE8xkxIhyrZUg8Ht0rVooA5WP4feGI7wXSaZicao+tBvtEv8Ax+MMNLjdjkD7v3fatHw/4Y0fw94cTQdIsxBpKCRRbmR3GHYsw3MSTks3fvWzRQBwei/DXTbfwvpeh61NJqcekTM+mXSNJa3FtHk7F82Nw2QDtLAqCAMjip9Z+F/hLWjKdU0+5uWmtktJ2fULndPEjBkEpEmZCCAQzZPHWu1ooA5K88EWUP8Abl34akbR9Z1W3MEl2HlljB2hRIYPMVC4A4bg+5yQdbwjoNr4X8MaZomn5+zWMCwqx6tgcsfcnJP1rXooAKKKKACiiigAooooAKKKKACiiigBGqOpT0qM9aQwxRiiigBKKWkoASgilopFDaQinUlADSKaRTzSEUhkRFRstTkU0ipaKTKrLUTLVplqNlqGjRMqMtQutXGWomWoaNEyi6VA8dX3WoWWpLTM946rzWwk+8M1oTGOIZkdV+pxVY3KE4iSSQ/7K4/nUuxop8ph6lpQkGQOa4/WLI27nIxXpvl3UwwtuFHqxqpceGlvX3XRH0XisKlLm2OzD5gqfxbHkkgeWTauQO7Dt7CrtuvkqG8sfJ9xey+5969Ug8JafEc+WpP0zV2PQrKPpCv/AHyKx+qSe7Ox55TXwwZ4jqN9M+UVJHz2VTz9f8K5zxC17Z2aMYpEeU4X5TxX00mm2qfdjAp5sbcjBjGKpYNbtmUs+k9FD8T4ybTbpwJTBLtJOWKkk+ua6SwneGAA5V8At9ehr6kk062cENGCD2xWbceFdIuCTJZQEnv5YzTeGb2YU86ivih+J8/m78513Pn6/SmeHbKbVfFkUdlGZXRJHIA7bCP617pJ4B0KTObVRn04/lWl4U8J6T4fuJ5rCAJNKoUuSSQPQZop4V81pPQutnUHB8kXc81m8PXZeKOW1dUZNnTo3XP6GtW58Ny3UUc8WOEeJwepw2Af8+levGCCQAtgGmfZYFQqAv5V0LBQ7nHLO6js+Wx4TN4Z1CPVArwkqwPzDoSBz/Kq2p6DfWEMdyYsqDk7Tkqc9/yr3h7aAnkDPaq8ul286tHhSjDBHtjFQ8vj0ZrDPpJrmieET2zJqKuqnyZVOfxqMW8ouYpIly4kCnPQkd/xHP517bd+HLOdSssaDP8AEOD9ahi8K2McSKOWCjJx1IJIJ/AsPoaz+oTvudKz2lbVHj3ibTX0e407UUTEEUpt5/8AZRzlCfYHK1c8N3n/AAjXjS2uckWF23k3AHTB+634H9K9gv8Aw7pt9p8tpdoJIZozE6k9VP8AUHkGub0T4eWdukY1SeTUJI8hWc4BGeDj1xitfq0oTUkcrzSlUpShNM9BSENGUzweVI9azXga3JRlxGT8uOgPp/n6elXraEQW8cKE+XGAFBOcYGBzUoYFGWRVdW4IPeu7RqzPBUmpXRiyJ1qsRNBcJc2jhLhBjn7rj+63t/Krt0UtnCyuBG33HY/oarGSFzhJY2PswNczXKzsjJSRvaVqsN/mPHlXSjLwseR7j1HuK0a4qeBZCpJZJEOUkQ4ZT6g1saVrLtMlpqIVZW4jmXhZD6H0b279q3p1b6SOerQ5dY7G7RRRW5zBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFMan0xqAEooFLSGJSGnYpKAEoxRRSHcTFFLRRYY00EUtJQAhppFOxxSGkMjIqNhUppjVLKRAwqGUqgJchR6k4p1xMQxjhXfLjOOyj1NQfZ/m3ynzJP7x7fQdqzZomVZbgniGMt/tNwP8ariOeVvnlIHoowP8a0jGPSkCDNZtFXZTisYFOfL3MerNyTVxIlUcAD6U/AFNZwKVrE2Y7ApSQKrPMBVaW7wcDk+gp3DlNAuBTGmAHUVlu9y/3UIHucVE9vduCS6D8TU3HyM1Tcj1FJ9pHqK5yRZ1YhpOntTMzf89P0pcwuU6cXC+opwmU1zAaYf8tB+VTRvPn76/jmjmCx0e9T3pQwzwcVzF7qb6e8az/MZAWUpznGM/jyKih8S2pfDyFT0wykU+Yr2cnqkdgHYdDTi7EVhW2t2UqgpcxH/gVXUv4WGVkUj2NVzEOLW6Lh3Ggbh04qsLyP++Kd9rT+8KLhYn+bPJNKAfU1X+1x/wB4Un2yMdxRzCsXAoqRWxWeb+ED71RtqUI/ip8wcpqGU9BSeY2OtYsutW8fJaqVx4kjKEQoxb6UnU8w5TVvW8+5jjHJBz9KuC1iMeHXNZWjHcrPIczNyf8AAVtociktdQehmXNq1v8APCSyd0P9PSq8iR3EO1gGjattgDwehrJnjNvc/wCw5wfr2P8AT8qUlY1pVOjNDQdSkEv2G9k3uRmCVurjup/2h+o/Gt+uMuYfOj25KsDuRh1Vh0IrotCvzf2QaXAuYzsmUdmHf6EYP410Ual/dZnXpW95GjRRRW5zBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU16dTXoAZS0lGakpodmkoopiENFFFABRRRQAUlLRSKGkUlPpMUgI2FQTlljOwAueFzVkio2XkGk0UmVIoRCmByScsx6sfU0jVYYVCwrNotELUw1I1MqWaIY1QODVk800ipsUikYix+YnHpSqoXhQBVhxUTCpsWhpoBpDSUFEdxbrNz0b1rNmt2Q4IrWBoYBhhhkUmrkONzE2kVIgrRa2Q1GbUjpyKmxm9NylPZi8e2yMtHIGX8QVP86Zd+FI5ZyzEDPOQO9aUcRU1dhLDua1g0lZoXtJR2ZzKeD44ndllcrnIX/wCvWrpthDYX5EcY8i6QDaRkB1yf1B/8drdUsR1pkluGXBAODkY4Iqvd6IftpPSTInsrVusEY+gx/Kon0y1PRGX6OanIYcAsPxzQTJ2YfiKnQVyk2kQn7ssw/Ef4VE2iKTxcyge4FaW6bsqH8SKN1x2iT/vs/wCFK0R6GX/YCHrdS/gBT08PWg+/JO/1YD+laWZ+8SAf7/8A9ajfJ0+RfxJrSNK+qRLmkQRaPp0XItkY/wC3lv51b2RLGY1jRUxjaBgUwlyOZQv+6P8AHNRlAfvSyN+OP5YrRUmifaIxrQm0uniJyI3wPp2/SuiiP61S8mJQQqD6nk09ZGjYbiSh7+lR7FxV0yXK+5dbpVe8hE8DKeuO1Thty5pAcGs2NaGXCxeP5vvqdrfX/PNJb3H9m6il1nEEmI5x6DPDfgT+RNSzp5N10+V+D/T+v6UyaNXRkcAqwwQe4qFdO51JqcbM66isjw3eNPaNbztuuLY7GJ6sv8LfiP1BrXrui+ZXRwSi4uzCiiimSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNfpTqR+lAERPNGaaetGak0JBRTAadmgmwtGKBRQKwlFLRTASilxSUmNCUtFAoGBFRsKlpCKLCuV2FQOKtstQutQ0aRZUcVEasulQsprNo1TI6KUikqShjVC4qdqiYVLLRCetN71IRTSKRY2igiikAZo/Q+1FIDQA9XIPzAMPUcGpopo84zz6Hiq1BAIwRkU7mbppmojL64pLm4jt4TJK2F6DHesxdyf6tyo9Oop7PvKedCsm07lI6g+uDT5jN0miKwvEkv9haVN6kKjvkk9ecng4zwB/Sr0Fz51w8YgkAT70h27QfTr1qgI1XzPs8ixTueGdcFR3xnv7//AFqqJBJZJtmgkuRwzc7kyT029/rj3wKm7RbSZuxzwyyBInDn1QbgPqRxU4Brm7XUma9824uNkSjiNehHsP8AJ45xWsNYswF3SMpIyQVJx7HHfiqjNMiVNrY0KrSrhuOlOS9t3cosq7xjg8den48HiluiAoJrelLUxkmQ96SmeavqPzoMyeoroYkx+KCMgg9DURuFHTmo2ucnAFSmkNq5bt2Kgr1wcVOagtgdu5+pOanxxXJLfQpFe9UPGp/Cq6ncoJ69DV2RQykVSA2ufQ8H61DNqbsRxzCw1CG8JxGP3c3+4e/4HB+ma7CuSlQOjK4yrDBB7itXw1dNLaPazMWmtSEJP8Sfwt+XH1BrajL7JOIhdcxsUUUV0HIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNfpTqa9AER60nSnEUYqCxlOFLiloABThSAUtUSLRRRQITFJS0UDEoxRS0h3EpTRilC0xMaRmmMmalxQRRYLlVo6iaOrpWkKVLiWpmcY6aY/atEx00xe1S4FqZmNGfSoWjPpWs0NRtB7VDgWqhkslRsprVa39qia29qlwZaqIzCKTFaBtT6UxrU+lRyMvnRRxSYq79mPpSG2b0o5WPnRTFOqc27DtTTA3pSsx8yIhSin+Sw7UeWw7UWYXQYBGCAR70qRoPu5X2UkD8qAjelOCn0pkuw1odwwZGI9GAI/lTTbfKVxCVIwf3fb86nANOANOxNkV4IRAS0UNurHuq7ar3EV9M2WMAHYBj/hWhg0oBqoNx2JcVLcylsrr+Ixfmf8ACpUtJB951/AE1oYNIVPpVOpJiUIlVbUfxOx+nFDWqbflLBuoOc1Z2n0pdp9KhtsuyK8EjAkNww+8KuBgRmq8kJJDqPmH6j0qSJW/A1NmQ0h5NV5l+b61Z8tj2oa3LU+VjTSKXUUkEzWWowXI4ib91N/unofwP8zV9bU55FSfY1dGVlyCMGnGLTuU5pqzNmiq9juFuqOcsny5Pf0qxXWjiasFFFFAgooooAKKKKACiiigAooooAKKKKACmtTqKAIqKlopWHcipcVJRRYLjBS06iiwhKKWimAmKTFOooAZiin0UgGinUUUwCiiigAooooAMCkxS0UAJtpCtOooAYUHpSeWPSpKKVh3ZF5Q9KQwj0qaiiyC7IPIX0o8lfSp6KLIOZlcwL6U37OPSrVFHKh8zKht19KT7KvpVyilyoOdlE2i+lJ9kX0q/RRyIfOzP+yD0o+zD0rQopciD2jKH2YUv2YVeop8iDnZS+zCj7KDV2ijkQc7KYtFpwtV9KtUUcqFzsrfZlpBaoO1WqKfKg5mQCBR2pwiHpUtFFkLmZF5Y9KXYKkoosguxijByKfRRTEFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33350=[""].join("\n");
var outline_f32_36_33350=null;
var title_f32_36_33351="Structure of the spleen";
var content_f32_36_33351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Structure of the spleen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The splenic arteries progressively branch to form peripheral arterioles which open freely into the splenic pulp. Blood flows through the reticular tissue and is collected in the terminal venules which coalesce to form the larger veins. The veins do not accompany the arteries within the spleen. The splenic pulp is important for opsonization of encapsulated organisms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary, 27th ed. Baltimore: Lippincott Williams &amp; Wilkins 2000. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33351=[""].join("\n");
var outline_f32_36_33351=null;
var title_f32_36_33352="Chapter 5B: Collecting tubules";
var content_f32_36_33352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 5B: Collecting tubules",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33352/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33352/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33352/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33352/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33352/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33352/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/36/33352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 14, 2003.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CORTICAL COLLECTING TUBULE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cortical collecting tubule has two cell types with very different functions: principal cells (about 65 percent) and intercalated cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The types of transport that occurs in these cells is depicted in figures 1 and 2 (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"     figure 2",
"    </a>",
"    ). The principal cells have Na+ and K+ channels in the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/4-6\">",
"     4-6",
"    </a>",
"    ] and, as in all Na+-reabsorbing cells, Na+-K+-ATPase pumps in the basolateral membrane. The intercalated cells, in comparison, do not transport NaCl, since they have a lower level of Na+-K+-ATPase activity and they have few if any apical membrane Na+ channels that are required for the entry of luminal Na+ into the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/1,5,7\">",
"     1,5,7",
"    </a>",
"    ]. They appear to play an important role in H+ and HCO3- handling and in K+ reabsorption in states of K+ depletion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Principal cells",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Sodium and potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal cells contribute to net Na+ reabsorption and are the primary site of K+ secretion. The entry of luminal Na+ into these cells primarily occurs down a concentration gradient through ion specific Na+ channels [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] in the apical membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison to the electroneutral Na+-K+-2Cl- and Na+-Cl- entry mechanisms in the thick ascending limb and distal tubule, movement through the Na+ channel is electrogenic in that it creates a lumen-negative potential difference. It is important to consider why a Na+ channel rather than a cotransporter must be present in the later part of the collecting tubules. These segments can lower the urine Na+ concentration to below 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in states of volume depletion. This value is less than that in the cells; thus, an electroneutral cotransporter that depends upon a favorable concentration gradient for Na+ entry would not work in this setting. Rather, it is the cell electronegativity (generated largely by the Na+-K+-ATPase pump and subsequent leakage of K+ back out of the cell) that provides the energy for passive Na+ entry into the cell; this negative potential can only affect electrogenic Na+ transport.",
"   </p>",
"   <p>",
"    The relative lumen-negative potential created by Na+ reabsorption then promotes either passive Cl- reabsorption via the paracellular pathway (the major route of Cl- transport in this segment) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/2,10\">",
"     2,10",
"    </a>",
"    ] or K+ secretion from the cell into the lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] through aldosterone-sensitive K+ channels in the apical membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Na+ reabsorption in this segment also enhances K+ secretion by a second mechanism: the transport of reabsorbed Na+ out of the cell by the Na+-K+-ATPase pump increases K+ entry across the basolateral membrane. The ensuing rise in cell K+ concentration and therefore in the K+ transport pool permits continued K+ secretion, which is the primary determinant of urinary K+ excretion (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=see_link\">",
"     \"Chapter 12B: Renal potassium excretion\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Aldosterone plays a central role in these transport processes, primarily by increasing the number of open Na+ channels in the apical membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. As an example, going from a high to a low sodium diet (which is associated with enhanced aldosterone release and increased Na+ reabsorption in the cortical collecting tubule) can increase the number of open Na+ channels per cell from less than 100 to approximately 3000 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also a later increase in Na+-K+-ATPase activity and in the number of open luminal K+ channels. These changes can at least initially be prevented by blocking the Na+ channel with the diuretic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    , suggesting that they are in part secondary to enhanced Na+ flux through the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/12\">",
"     12",
"    </a>",
"    ]. As an example, increasing cell Na+ concentration directly and rapidly stimulates Na+-K+-ATPase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/16\">",
"     16",
"    </a>",
"    ]. This initial response may be then be sustained by a later increase in Na+-K+-ATPase synthesis mediated by aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two different types of mutations in the luminal Na+ channel have been described. First, an activating mutation in Liddle's syndrome, a disorder with clinical characteristics similar to that of a high aldosterone state: excessive sodium reabsorption and potassium secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/18\">",
"     18",
"    </a>",
"    ]. Second, an inactivating mutation in the autosomal recessive form of pseudohypoaldosteronism, producing signs of a low aldosterone state: hyperkalemia and a tendency to hypovolemia due to Na+ wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cortical and medullary collecting tubules usually reabsorb 5 to 7 percent of the filtered Na+, and variations in Na+ reabsorption in these segments are probably the major determinant of diet-induced fluctuations in daily Na+ excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. For example, a reduction in Na+ intake enhances aldosterone release via activation of the renin-angiotensin system (see Chap. 6). This results in increased Na+ reabsorption both in the cortical collecting tubule and, to a lesser degree, in the papillary (or innermost) segment of the medullary collecting tubule (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/2,22\">",
"     2,22",
"    </a>",
"    ], leading to an appropriate fall in Na+ excretion. The opposite sequence occurs with a Na+ load as aldosterone secretion is diminished. Enhanced release of atrial natriuretic peptide also may contribute to the natriuresis in this setting, in part by diminishing Na+ reabsorption (via a reduction in the number of open Na+ channels) in the papillary and perhaps the cortical segment of the collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42422?source=see_link\">",
"     \"Chapter 6D: Natriuretic peptides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to these effects of Na+ regulating hormones, Na+ reabsorption in the cortical collecting tubule may also influenced by alterations in Na+ delivery, locally produced prostaglandin E2, and perhaps antidiuretic hormone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreasing Na+ delivery, as might occur with volume depletion, leads to an increase in the number of open Na+ channels in the apical membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/24\">",
"       24",
"      </a>",
"      ]. This response appears to be mediated by an initial fall in cell Na+ concentration (due to the decline in delivery) and a subsequent reduction in the cell levels of protein kinase C (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19988?source=see_link\">",
"       \"Chapter 6A: Mechanisms of hormone action\"",
"      </a>",
"      ). This enzyme normally diminishes Na+ reabsorption; thus, a decrease in its activity is associated with an increased number of open Na+ channels in an appropriate effort to conserve volume by preventing further Na+ loss. The physiologic role of this effect remains to be determined.",
"     </li>",
"     <li>",
"      By activating the EP1 receptor, prostaglandin E2 inhibits Na+ transport in the cortical collecting tubule [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. ADH, on the other hand, may increase Na+ reabsorption, perhaps by inserting new Na+ channels in the apical membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/13\">",
"       13",
"      </a>",
"      ]. The importance of these hormonal effects in the regulation of Na+ balance is uncertain, particularly since they appear to be present in only some species [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/13,26\">",
"       13,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Water",
"    </span>",
"    &nbsp;&mdash;&nbsp;The water permeability of the apical membrane of the principal cells is relatively low in the basal state (in contrast to the highly permeable proximal tubule which has water channels in both the apical and basolateral membranes) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/28\">",
"     28",
"    </a>",
"    ]. However, collecting tubule water permeability can be increased substantially by ADH, which inserts cytosolic vesicles containing preformed water channels into the apical membrane (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    ). [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. These water channels, termed aquaporin-2, are different from those in the proximal tubule, which are called aquaporin -1 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/28,32\">",
"     28,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in luminal membrane water permeability induced by the insertion of these water channels allows the dilute fluid entering the cortical collecting tubule (about 100",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    to equilibrate osmotically with the isosmotic cortical interstitium. As described in the preceding chapter, this ADH-mediated water reabsorption plays an important role in urinary concentration by markedly diminishing the volume of fluid delivered to the hyperosmotic medulla (",
"    <a class=\"graphic graphic_figure graphicRef80467 \" href=\"UTD.htm?33/5/33885\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The increase in water reabsorption induced by ADH might also be expected to diminish K+ secretion, since the latter process varies directly with urinary flow [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/33\">",
"     33",
"    </a>",
"    ]. This does not occur, however, because the inhibitory effect of the decline in flow is counterbalanced by direct stimulation of K+ secretion by ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/34\">",
"     34",
"    </a>",
"    ]. This response may be mediated by insertion of new K+ channels into the apical membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/35,36\">",
"     35,36",
"    </a>",
"    ] or by stimulation of local Na+ reabsorption, which will enhance the electrical gradient favoring K+ secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    therapy can lead to polyuria and polydipsia in 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/38\">",
"     38",
"    </a>",
"    ]. This toxic effect results from interference with the ability of ADH to increase the water permeability of the collecting tubules, thereby reducing water reabsorption (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=see_link\">",
"     \"Renal toxicity of lithium\"",
"    </a>",
"    ). For this problem to occur, filtered lithium must first gain access to the collecting tubular cells, apparently by entering the cell through the apical membrane Na+ channels. This observation is important clinically, since blocking the Na+ channel with the potassium-sparing diuretic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    can minimize the severity and possibly prevent the development of this defect in urinary concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intercalated Cells",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hydrogen and bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intercalated cells are primarily involved in the Na+-independent regulation of acid-base balance [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/1,40-42\">",
"     1,40-42",
"    </a>",
"    ]. As depicted in Fig. 5-3, intracellular water and carbon dioxide can, in the presence of carbonic anhydrase, lead to the formation of H+ and HCO3- ions. The former is then secreted into the lumen by a H+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/43\">",
"     43",
"    </a>",
"    ] or a H+-K+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/44\">",
"     44",
"    </a>",
"    ], whereas the latter returns to the systemic circulation across the basolateral membrane via a Cl--HCO3- exchanger [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/41,45\">",
"     41,45",
"    </a>",
"    ]. The Cl--HCO3- exchanger is structurally similar to, but not identical with, the band 3 exchanger found on red cells. The bicarbonate exchanger is the product of transcription initiation on a kidney specific site of the AE1 gene. Mutations in this gene can impair urinary acidification and produce a picture of distal renal tubular acidosis (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect of these processes is H+ loss in the urine and an elevation in the plasma bicarbonate concentration. This process is appropriately stimulated by acidemia, since the ensuing urinary changes will result in an increase in the extracellular pH toward normal [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=see_link\">",
"     \"Chapter 11B: Regulation of renal hydrogen excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aldosterone appears to contribute to this process by enhancing the activity of the H+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/48\">",
"     48",
"    </a>",
"    ]. This effect in normal subjects is probably permissive, since there is little evidence that changes in acid-base balance alter the release of aldosterone. However, changes in aldosterone secretion can affect acid-base balance. Disease states associated with hyperaldosteronism usually lead to increased urinary H+ loss and metabolic alkalosis, while hypoaldosteronism is often associated with H+ retention and metabolic acidosis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The homeostatic needs are reversed in the presence of an alkaline load. In this setting, loss of HCO3- in the urine is required. Although this can be achieved by reabsorbing less of the filtered HCO3- in the proximal and distal nephron, the cortical collecting tubule contributes to this process by secreting HCO3- from the cell into the lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. This is achieved by reversing the polarity of the transporters in Figure 2 (",
"    <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"     figure 2",
"    </a>",
"    ) in what is a second population of intercalated cells, called the type B intercalated cells as opposed to the hydrogen-secreting type A intercalated cells (",
"    <a class=\"graphic graphic_figure graphicRef62465 \" href=\"UTD.htm?17/31/17917\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the type B intercalated cells, H+ and HCO3- ions are again formed within the cell; however, the H+ ions are now secreted into the peritubular capillary by the H+-ATPase pump that is located in the basolateral, rather than the apical, membrane. The HCO3- ions, on the other hand, are secreted into the lumen by an anion exchanger in the apical membrane. The identity of this transporter is uncertain, however, as it does not appear to represent the same Cl--HCO3- exchanger that is present in the basolateral membrane of the H+-secreting intercalated cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of these proteins in the maintenance of acid-balance is illustrated by the observation that mutations in the H+-ATPase proton pump result in distal renal tubular acidosis, a disorder characterized by diminished acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/52\">",
"     52",
"    </a>",
"    ]. These individuals also have sensorineural deafness, suggesting that the proton pump also maintains the proper concentration of H+ in the inner ear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the cortical collecting tubule normally secretes K+, there can be net reabsorption in this segment in the presence of K+ depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/53\">",
"     53",
"    </a>",
"    ]. This process occurs in the types A and B intercalated cells and appears to be mediated by an active H+-K+-ATPase pump in the apical membrane that reabsorbs K+ and secretes H+ (",
"    <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The activity of this transporter is increased with hypokalemia, an effect that may be mediated by the associated reduction in the cell K+ concentration. In addition to maintenance of K+ balance, this transporter also contributes the increase in acid secretion in metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/54,56\">",
"     54,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within the type B intercalated cell, potassium reabsorption is also linked with Cl- reabsorption via the luminal",
"    <span class=\"nowrap\">",
"     Cl-/HCO3-",
"    </span>",
"    exchanger [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/55\">",
"     55",
"    </a>",
"    ]. Concurrent activity of this exchanger and the H+-K+-ATPase pump may result in active KCl reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Water",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intercalated cells are relatively impermeable to water in the basal state and appear to be minimally responsive to ADH, which primarily affects the adjacent principal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEDULLARY COLLECTING TUBULE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction between the outer and inner medullary collecting tubules is arbitrarily based upon location, with the dividing point being the level at which the thick ascending limbs of the loop of Henle begin. Nevertheless, this differentiation is physiologically appropriate because the cells in these segments have some important differences in function and hormone responsiveness (",
"    <a class=\"graphic graphic_figure graphicRef78299 \" href=\"UTD.htm?36/11/37054\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Outer Medulla",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hydrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transition between the cortical and outer medullary collecting tubules is not abrupt; as a result, the early portion of the medullary segment has cells that contribute to Na+ reabsorption and K+ secretion, similar to that seen in the cortical principal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/2,60\">",
"     2,60",
"    </a>",
"    ]. However, the majority of cells in the outer medullary collecting tubule, are comparable to the cortical intercalated cells (although there are variations between species), being involved in active H+ secretion by H+-ATPase and H+-K+-ATPase pumps in the apical membrane (",
"    <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/56,60,61\">",
"     56,60,61",
"    </a>",
"    ]. The activity of these pumps, which is much greater than in the cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/40\">",
"     40",
"    </a>",
"    ], is stimulated in part by acidemia and by aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/48,62\">",
"     48,62",
"    </a>",
"    ]. The net effect is that this segment plays an important role in acidifying the urine (i.e., in lowering the urine pH to its minimum level) and in the excretion of ammonium, the major mechanism by which the kidney excretes the dietary acid load [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=see_link\">",
"     \"Chapter 11A: Renal hydrogen excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outer medullary cells are also capable of reabsorbing K+ [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/65\">",
"     65",
"    </a>",
"    ], perhaps via an apical membrane H+-K+-ATPase, similar to that in the cortical intercalated cells. This response can contribute to K+ conservation in states of K+ depletion and also is essential for the recycling of K+ within the medulla (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=see_link&amp;anchor=H3#H3\">",
"     \"Chapter 12B: Renal potassium excretion\", section on 'Medullary recycling'",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Water",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other major function of the outer medullary collecting tubule is its role in urinary concentration. This segment is impermeable to water in the basal state [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/66\">",
"     66",
"    </a>",
"    ]. In the presence of ADH, however, water permeability rises markedly due to insertion of aquaporin-2 water channels into the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/28\">",
"     28",
"    </a>",
"    ], allowing equilibration with the hyperosmotic medullary interstitium (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=see_link\">",
"     \"Chapter 4B: Countercurrent mechanism\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Inner Medulla",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inner medulla is composed of several cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/67\">",
"     67",
"    </a>",
"    ]: the initial one-third has cells similar in function to those of the principal and intercalated cells in the cortex and outer medulla, while the inner two-thirds contains a decreasing number of principal cells and is composed primarily of a distinct cell type that contributes to Na+ reabsorption and the production of a concentrated urine [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/1,68,69\">",
"     1,68,69",
"    </a>",
"    ], but plays a lesser role in urinary acidification [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Na+ entry into the inner medullary cells primarily occurs through an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    -sensitive cation-selective channel, the epithelial sodium channel [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. The lumen-negative potential created by this movement of Na+ may then promote passive Cl- reabsorption via the paracellular route similar to that in the cortical collecting tubule (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The factors that stimulate this reabsorptive process are incompletely understood, but aldosterone plays a contributory role [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/2,22,69,71\">",
"     2,22,69,71",
"    </a>",
"    ]. The net effect is that the urine Na+ concentration can be reduced to 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less in the presence of volume depletion, a setting in which aldosterone release is enhanced. As mentioned at the beginning of this chapter, passive Na+ entry into the cell cannot be driven by a concentration gradient in this setting, since the lumen now has a lower Na+ concentration than the cell. Rather, the cell interior negative potential provides the electrical gradient that promotes Na+ movement into the cell.",
"   </p>",
"   <p>",
"    In contrast, Na+ reabsorption in the inner medulla falls with volume expansion, a response that may be mediated both by the reduction in aldosterone secretion and by increased release of atrial natriuretic peptide. The latter hormone activates guanylate cyclase, leading to the production of cyclic guanosine monophosphate (GMP); this compound then appears to diminish Na+ reabsorption by decreasing the number of open Na+ channels in the apical membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42422?source=see_link\">",
"     \"Chapter 6D: Natriuretic peptides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Water",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inner medullary collecting tubule plays an important role in water reabsorption and the excretion of a concentrated urine. As in the other aspects of the collecting tubule, the water permeability of the inner medullary segment is increased by ADH, allowing osmotic equilibration with the hyperosmotic medullary interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is, however, one important difference from the response seen in the cortex and outer medulla. The latter segments are impermeable to urea, both in the basal state and in the presence of ADH. The inner medulla, on the other hand, has a relatively high basal urea permeability that is mediated by specific urea transporters in the basolateral and, to a lesser degree, the apical membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Furthermore, the net urea permeability is increased approximately four-fold by ADH, primarily by increasing the number of luminal transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/78,80\">",
"     78,80",
"    </a>",
"    ]. These characteristics allow urea to accumulate in the medullary interstitium, where it accounts for about one-half of the interstitial solute and therefore limits urinary water loss by contributing to the excretion of a maximally concentrated urine (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=see_link&amp;anchor=H5#H5\">",
"     \"Chapter 4B: Countercurrent mechanism\", section on 'Role of urea'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inner medullary collecting tubule can contribute to the maintenance of K+ balance. This segment usually reabsorbs K+, an effect that is more pronounced with K+ depletion. On the other hand, it can secrete K+ after a K+ load [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/69\">",
"     69",
"    </a>",
"    ]. Tubular secretion presumably occurs through the cation-selective channels in the apical membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/72\">",
"     72",
"    </a>",
"    ]. These channels also may have a role in limiting the degree of maximum K+ conservation. K+-depleted subjects can only lower the urine K+ concentration to a minimum of 5 to 15",
"    <span class=\"nowrap\">",
"     meq/L;",
"    </span>",
"    it may be that a lower luminal K+ level is prevented by passive leakage of K+ out of the cells through these channels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hydrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inner medullary cells secrete hydrogen ions [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/70,81\">",
"     70,81",
"    </a>",
"    ], a response that is enhanced by stimuli similar to that in the other acid secreting cells in the collecting tubule: acidemia and aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Cell volume regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their transport functions, the inner medullary collecting tubule cells (as well as those in the thick ascending limb) must maintain their cell volume in the face of constantly changing osmotic pressures in the interstitium. Fluid restriction, for example, will sequentially raise ADH levels, increase interstitial osmolality, and cause cell shrinkage by osmotic water movement out of the cells across the water-permeable basolateral membrane which contains both aquaporin-3 and aquaporin-4 water channels [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/82\">",
"     82",
"    </a>",
"    ]. Fluid loading, on the other hand, will produce the opposite changes, leading the cell swelling.",
"   </p>",
"   <p>",
"    Despite this changing environment, the tubular cells are able to maintain their volume by altering the concentrations both of ions (sodium and potassium) and of organic solutes (called osmolytes) that have the advantage of not interfering the protein function [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13203?source=see_link\">",
"     \"Chapter 4C: Maintenance of cell volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RENAL PELVIS, URETERS, AND BLADDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor modifications in the composition of the urine can occur after the urine has left the tubules. The renal pelvis is modestly permeable to urea and water. As a result, urea may diffuse out of and water into the pelvis from the inner medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Similar compositional changes of as much as 7 to 15 percent can occur in the ureters and bladder, particularly in low-flow states when contact time is prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33352/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This text is continued separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19988?source=see_link\">",
"     \"Chapter 6A: Mechanisms of hormone action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/1\">",
"      Madsen KM, Tisher CC. Structural-functional relationship along the distal nephron. Am J Physiol 1986; 250:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/2\">",
"      Stokes JB. Sodium and potassium transport by the collecting duct. Kidney Int 1990; 38:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/3\">",
"      Grantham JJ, Wallace DP. Return of the secretory kidney. Am J Physiol Renal Physiol 2002; 282:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/4\">",
"      Frindt, G, Sackin, H, Palmer, LG. Whole-cell currents in rat cortical collecting tubule: Low-Na diet increases amiloride-sensitive conductance. Am J Physiol 1990; 258:F502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/5\">",
"      Sauer M, Flemmer A, Thurau K, Beck FX. Sodium entry routes in principal and intercalated cells of the isolated perfused cortical collecting duct. Pflugers Arch 1990; 416:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/6\">",
"      Wang WH, Schwab A, Giebisch G. Regulation of small-conductance K+ channel in apical membrane of rat cortical collecting tubule. Am J Physiol 1990; 259:F494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/7\">",
"      Katz AI. Distribution and function of classes of ATPases along the nephron. Kidney Int 1986; 29:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/8\">",
"      Canessa CM, Schild L, Buell G, et al. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 1994; 367:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/9\">",
"      Horisberger JD. Amiloride-sensitive Na channels. Curr Opin Cell Biol 1998; 10:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/10\">",
"      Dietl P, Schwiebert E, Stanton BA. Cellular mechanisms of chloride transport in the cortical collecting duct. Kidney Int Suppl 1991; 33:S125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/11\">",
"      Sansom SC, O'Neil RG. Mineralocorticoid regulation of apical cell membrane Na+ and K+ transport of the cortical collecting duct. Am J Physiol 1985; 248:F858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/12\">",
"      Sansom S, Muto S, Giebisch G. Na-dependent effects of DOCA on cellular transport properties of CCDs from ADX rabbits. Am J Physiol 1987; 253:F753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/13\">",
"      Schafer JA, Hawk CT. Regulation of Na+ channels in the cortical collecting duct by AVP and mineralocorticoids. Kidney Int 1992; 41:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/14\">",
"      Chen SY, Bhargava A, Mastroberardino L, et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci U S A 1999; 96:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/15\">",
"      Masilamani S, Kim GH, Mitchell C, et al. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J Clin Invest 1999; 104:R19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/16\">",
"      Coutry N, Blot-Chabaud M, Mateo P, et al. Time course of sodium-induced Na(+)-K(+)-ATPase recruitment in rabbit cortical collecting tubule. Am J Physiol 1992; 263:C61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/17\">",
"      Horisberger JD, Rossier BC. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension 1992; 19:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/18\">",
"      Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/19\">",
"      Chang SS, Grunder S, Hanukoglu A, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996; 12:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/20\">",
"      Stein JH, Osgood RW, Boonjarern S, et al. Segmental sodium reabsorption in rats with mild and severe volume depletion. Am J Physiol 1974; 227:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/21\">",
"      Stein JH, Osgood RW, Boonjarern S, Ferris TF. A comparison of the segmental analysis of sodium reabsorption during Ringer's and hyperoncotic albumin infusion in the rat. J Clin Invest 1973; 52:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/22\">",
"      Husted RF, Laplace JR, Stokes JB. Enhancement of electrogenic Na+ transport across rat inner medullary collecting duct by glucocorticoid and by mineralocorticoid hormones. J Clin Invest 1990; 86:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/23\">",
"      de Zeeuw D, Janssen WM, de Jong PE. Atrial natriuretic factor: its (patho)physiological significance in humans. Kidney Int 1992; 41:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/24\">",
"      Ling BN, Eaton DC. Effects of luminal Na+ on single Na+ channels in A6 cells, a regulatory role for protein kinase C. Am J Physiol 1989; 256:F1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/25\">",
"      H&eacute;bert RL, Jacobson HR, Breyer MD. Prostaglandin E2 inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium. J Clin Invest 1991; 87:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/26\">",
"      Chen, L, Reif, MC, Schafer, J. Clonidine and PGE2 have different effects on Na+ and water transport in rat and rabbit CCD. Am J Physiol 1991; 261:F123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/27\">",
"      Guan Y, Zhang Y, Breyer RM, et al. Prostaglandin E2 inhibits renal collecting duct Na+ absorption by activating the EP1 receptor. J Clin Invest 1998; 102:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/28\">",
"      Nielsen S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/29\">",
"      Fushimi K, Uchida S, Hara Y, et al. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993; 361:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/30\">",
"      Sasaki S, Fushimi K, Saito H, et al. Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct. J Clin Invest 1994; 93:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/31\">",
"      Deen PM, Verdijk MA, Knoers NV, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994; 264:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/32\">",
"      Schnermann J, Chou CL, Ma T, et al. Defective proximal tubular fluid reabsorption in transgenic aquaporin-1 null mice. Proc Natl Acad Sci U S A 1998; 95:9660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/33\">",
"      Wright FS. Renal potassium handling. Semin Nephrol 1987; 7:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/34\">",
"      Field MJ, Stanton BA, Giebisch GH. Influence of ADH on renal potassium handling: a micropuncture and microperfusion study. Kidney Int 1984; 25:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/35\">",
"      Guggino SE, Suarez-Isla BA, Guggino WB, Sacktor B. Forskolin and antidiuretic hormone stimulate a Ca2+-activated K+ channel in cultured kidney cells. Am J Physiol 1985; 249:F448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/36\">",
"      Wang WH. View of K+ secretion through the apical K channel of cortical collecting duct. Kidney Int 1995; 48:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/37\">",
"      Schlatter E, Schafer JA. Electrophysiological studies in principal cells of rat cortical collecting tubules. ADH increases the apical membrane Na+-conductance. Pflugers Arch 1987; 409:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/38\">",
"      Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987; 10:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/39\">",
"      Batlle DC, von Riotte AB, Gaviria M, Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 1985; 312:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/40\">",
"      Levine DZ, Jacobson HR. The regulation of renal acid secretion: new observations from studies of distal nephron segments. Kidney Int 1986; 29:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/41\">",
"      Steinmetz PR. Cellular organization of urinary acidification. Am J Physiol 1986; 251:F173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/42\">",
"      Kim J, Kim YH, Cha JH, et al. Intercalated cell subtypes in connecting tubule and cortical collecting duct of rat and mouse. J Am Soc Nephrol 1999; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/43\">",
"      Nelson RD, Guo XL, Masood K, et al. Selectively amplified expression of an isoform of the vacuolar H(+)-ATPase 56-kilodalton subunit in renal intercalated cells. Proc Natl Acad Sci U S A 1992; 89:3541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/44\">",
"      Tsuchiya, K, Giebisch, G, Welling, PA. Molecular characterization and distribution of H/K ATPase catalytic subunit gene products in the kidney. J Am Soc Nephrol 1993; 4:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/45\">",
"      Kudrycki KE, Shull GE. Primary structure of the rat kidney band 3 anion exchange protein deduced from a cDNA. J Biol Chem 1989; 264:8185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/46\">",
"      Karet, FE, Gainza, FJ, Gyory, AZ, et al. Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc Natl Acad Sci 1998; 94:6337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/47\">",
"      Verlander JW, Madsen KM, Tisher CC. Effect of acute respiratory acidosis on two populations of intercalated cells in rat cortical collecting duct. Am J Physiol 1987; 253:F1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/48\">",
"      Garg LC, Narang N. Effects of aldosterone on NEM-sensitive ATPase in rabbit nephron segments. Kidney Int 1988; 34:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/49\">",
"      Bastani B, Purcell H, Hemken P, et al. Expression and distribution of renal vacuolar proton-translocating adenosine triphosphatase in response to chronic acid and alkali loads in the rat. J Clin Invest 1991; 88:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/50\">",
"      Schuster, VL. Cortical collecting duct bicarbonate secretion. Kidney Int 1991; 40 (suppl 33):S-47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/51\">",
"      Star RA, Burg MB, Knepper MA. Bicarbonate secretion and chloride absorption by rabbit cortical collecting ducts. Role of chloride/bicarbonate exchange. J Clin Invest 1985; 76:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/52\">",
"      Karet FE, Finberg KE, Nelson RD, et al. Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 1999; 21:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/53\">",
"      Stanton BA, Biemesderfer D, Wade JB, Giebisch G. Structural and functional study of the rat distal nephron: effects of potassium adaptation and depletion. Kidney Int 1981; 19:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/54\">",
"      Garg LC. Respective roles of H-ATPase and H-K-ATPase in ion transport in the kidney. J Am Soc Nephrol 1991; 2:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/55\">",
"      Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol 1998; 9:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/56\">",
"      Armitage FE, Wingo CS. Luminal acidification in K-replete OMCDi: contributions of H-K-ATPase and bafilomycin-A1-sensitive H-ATPase. Am J Physiol 1994; 267:F450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/57\">",
"      Zhou X, Xia SL, Wingo CS. Chloride transport by the rabbit cortical collecting duct: dependence on H,K-ATPase. J Am Soc Nephrol 1998; 9:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/58\">",
"      Fejes-T&oacute;th G, N&aacute;ray-Fejes-T&oacute;th A. Isolated principal and intercalated cells: hormone responsiveness and Na+-K+-ATPase activity. Am J Physiol 1989; 256:F742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/59\">",
"      Lencer WI, Brown D, Ausiello DA, Verkman AS. Endocytosis of water channels in rat kidney: cell specificity and correlation with in vivo antidiuresis. Am J Physiol 1990; 259:C920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/60\">",
"      Koeppen BM. Electrophysiological identification of principal and intercalated cells in the rabbit outer medullary collecting duct. Pflugers Arch 1987; 409:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/61\">",
"      Brown D, Hirsch S, Gluck S. Localization of a proton-pumping ATPase in rat kidney. J Clin Invest 1988; 82:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/62\">",
"      Stone DK, Seldin DW, Kokko JP, Jacobson HR. Mineralocorticoid modulation of rabbit medullary collecting duct acidification. A sodium-independent effect. J Clin Invest 1983; 72:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/63\">",
"      DuBose TD Jr, Good DW, Hamm LL, Wall SM. Ammonium transport in the kidney: new physiological concepts and their clinical implications. J Am Soc Nephrol 1991; 1:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/64\">",
"      Flessner MF, Wall SM, Knepper MA. Permeabilities of rat collecting duct segments to NH3 and NH4+. Am J Physiol 1991; 260:F264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/65\">",
"      Jamison RL. Potassium recycling. Kidney Int 1987; 31:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/66\">",
"      Kokko JP. The role of the collecting duct in urinary concentration. Kidney Int 1987; 31:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/67\">",
"      Clapp WL, Madsen KM, Verlander JW, Tisher CC. Morphologic heterogeneity along the rat inner medullary collecting duct. Lab Invest 1989; 60:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/68\">",
"      Rocha AS, Kudo LH. Water, urea, sodium, chloride, and potassium transport in the in vitro isolated perfused papillary collecting duct. Kidney Int 1982; 22:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/69\">",
"      Diezi J, Michoud P, Aceves J, Giebisch G. Micropuncture study of electrolyte transport across papillary collecting duct of the rat. Am J Physiol 1973; 224:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/70\">",
"      Wall SM, Sands JM, Flessner MF, et al. Net acid transport by isolated perfused inner medullary collecting ducts. Am J Physiol 1990; 258:F75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/71\">",
"      Zeidel ML. Hormonal regulation of inner medullary collecting duct sodium transport. Am J Physiol 1993; 265:F159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/72\">",
"      Light DB, McCann FV, Keller TM, Stanton BA. Amiloride-sensitive cation channel in apical membrane of inner medullary collecting duct. Am J Physiol 1988; 255:F278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/73\">",
"      Benos DJ, Awayda MS, Berdiev BK, et al. Diversity and regulation of amiloride-sensitive Na+ channels. Kidney Int 1996; 49:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/74\">",
"      Volk KA, Sigmund RD, Snyder PM, et al. rENaC is the predominant Na+ channel in the apical membrane of the rat renal inner medullary collecting duct. J Clin Invest 1995; 96:2748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/75\">",
"      Zeidel ML, Kikeri D, Silva P, et al. Atrial natriuretic peptides inhibit conductive sodium uptake by rabbit inner medullary collecting duct cells. J Clin Invest 1988; 82:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/76\">",
"      Ujiie K, Nonoguchi H, Tomita K, Marumo F. Effects of ANF on cGMP synthesis in inner medullary collecting duct subsegments of rats. Am J Physiol 1990; 259:F535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/77\">",
"      Ciampolillo F, McCoy DE, Green RB, et al. Cell-specific expression of amiloride-sensitive, Na(+)-conducting ion channels in the kidney. Am J Physiol 1996; 271:C1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/78\">",
"      Knepper MA, Star RA. The vasopressin-regulated urea transporter in renal inner medullary collecting duct. Am J Physiol 1990; 259:F393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/79\">",
"      Sands JM, Timmer RT, Gunn RB. Urea transporters in kidney and erythrocytes. Am J Physiol 1997; 273:F321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/80\">",
"      Sands JM, Nonoguchi H, Knepper MA. Vasopressin effects on urea and H2O transport in inner medullary collecting duct subsegments. Am J Physiol 1987; 253:F823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/81\">",
"      Ishibashi K, Sasaki S, Yoshiyama N, et al. Generation of pH gradient across the rabbit collecting duct segments perfused in vitro. Kidney Int 1987; 31:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/82\">",
"      Murillo-Carretero MI, Ilund&aacute;in AA, Echevarria M. Regulation of aquaporin mRNA expression in rat kidney by water intake. J Am Soc Nephrol 1999; 10:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/83\">",
"      Garcia-Perez A, Burg MB. Importance of organic osmolytes for osmoregulation by renal medullary cells. Hypertension 1990; 16:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/84\">",
"      Bonventre JV, Roman RJ, Lechene C. Effect of urea concentration of pelvic fluid on renal concentrating ability. Am J Physiol 1980; 239:F609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/85\">",
"      Bargman J, Leonard SL, McNeely E, et al. Examination of transepithelial exchange of water and solute in the rat renal pelvis. J Clin Invest 1984; 74:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/86\">",
"      LEVINSKY NG, BERLINER RW. Changes in composition of the urine in ureter and bladder at low urine flow. Am J Physiol 1959; 196:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33352/abstract/87\">",
"      Walser BL, Yagil Y, Jamison RL. Urea flux in the ureter. Am J Physiol 1988; 255:F244.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7287 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33352=[""].join("\n");
var outline_f32_36_33352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CORTICAL COLLECTING TUBULE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Principal cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Sodium and potassium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Water",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intercalated Cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hydrogen and bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Potassium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Water",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEDULLARY COLLECTING TUBULE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Outer Medulla",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hydrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Potassium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Water",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Inner Medulla",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sodium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Water",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Potassium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hydrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Cell volume regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RENAL PELVIS, URETERS, AND BLADDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7287\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7287|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/31/12797\" title=\"figure 1\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/43/39613\" title=\"figure 2\">",
"      Distal acid secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/5/33885\" title=\"figure 3\">",
"      Countercurrent mechanism CCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/31/17917\" title=\"figure 4\">",
"      Distal HCO3 secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/11/37054\" title=\"figure 5\">",
"      Distal nephron segments",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=related_link\">",
"      Chapter 11A: Renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=related_link\">",
"      Chapter 11B: Regulation of renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=related_link\">",
"      Chapter 12B: Renal potassium excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=related_link\">",
"      Chapter 4B: Countercurrent mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13203?source=related_link\">",
"      Chapter 4C: Maintenance of cell volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19988?source=related_link\">",
"      Chapter 6A: Mechanisms of hormone action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42422?source=related_link\">",
"      Chapter 6D: Natriuretic peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_36_33353="Intraductal ultrasound of the pancreaticobiliary ductal system";
var content_f32_36_33353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intraductal ultrasound of the pancreaticobiliary ductal system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33353/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33353/contributors\">",
"     Michael J Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33353/contributors\">",
"     Enrique Vazquez-Sequeiros, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33353/contributors\">",
"     Maurits J Wiersema, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33353/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33353/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33353/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/36/33353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of endoscopic ultrasound (EUS) in the early 1980s overcame some of the limitations of transabdominal ultrasound for imaging the gastrointestinal tract wall and retroperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/1\">",
"     1",
"    </a>",
"    ]. One of the advantages of EUS is the ability to apply the ultrasound transducer directly against the luminal surface, which minimizes intervening adipose tissue and air between the transducer and the target tissue, thereby enhancing image quality. The proximity of the transducer to the target tissue also permits the use of higher frequency ultrasound, which further contributes to the enhanced image resolution. As a result, EUS is used routinely in the evaluation of numerous gastrointestinal disorders, including the diagnosis and staging of gastrointestinal tumors. (See appropriate topic reviews.)",
"   </p>",
"   <p>",
"    The technical evolution of EUS has lead to the development of small caliber intraductal ultrasound (IDUS) miniprobes (about 2 mm), which can be passed through standard endoscopes directly into the bile or pancreatic duct (",
"    <a class=\"graphic graphic_picture graphicRef69099 \" href=\"UTD.htm?35/47/36607\">",
"     picture 1",
"    </a>",
"    ). The small caliber, flexibility, and excellent image quality produced by these catheters makes them ideal for evaluating a variety of biliary and pancreatic disorders (",
"    <a class=\"graphic graphic_table graphicRef74332 \" href=\"UTD.htm?8/34/8747\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the role of IDUS in the evaluation of several pancreatic and hepatobiliary disorders. The role of standard EUS instruments in the evaluation of these conditions is presented separately. (See appropriate topic reviews.) The role of miniprobes for evaluation of other parts of the gastrointestinal tract is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35509?source=see_link\">",
"     \"High frequency catheter endoscopic ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IDUS is capable of producing better image resolution than standard endoscopic ultrasound (EUS; 0.07 to 0.18 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Acoustic coupling is optimized by the tubular anatomy of the pancreatic and bile ducts, which are fluid filled and only slightly larger in caliber than the probe itself. In addition, the probes operate at higher frequencies (12 to 30 MHz) than standard EUS, which leads to higher image resolution.",
"   </p>",
"   <p>",
"    Three systems are available to perform IDUS (",
"    <a class=\"graphic graphic_table graphicRef70245 \" href=\"UTD.htm?23/20/23883\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Electronic cylindrical phased array",
"     </li>",
"     <li>",
"      Combined probe (allows both radial and linear scanning)",
"     </li>",
"     <li>",
"      Mechanical radial sector scan system",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Electronic systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electronic systems use thin catheters (diameter 1.1 mm, 3.5 French), have no rotating parts, and are extremely flexible. These probes contain a ring of 64 transducer elements that produce a 360&ordm; image. The transducer ring detects the signals from the tissue and transmits them via microwires to the image processor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanical probes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Components of mechanical probes include a single transducer, a wire to rotate the transducer, a cable that excites the transducer and transfers signals to the image processor, and a flexible protective housing. The rotating transducer is mounted on the tip of the wire and produces a 360&ordm; image.",
"   </p>",
"   <p>",
"    Design variations exist for these catheter systems, some of which permit the use of a guidewire (",
"    <a class=\"graphic graphic_picture graphicRef79640 \" href=\"UTD.htm?39/47/40701\">",
"     picture 2",
"    </a>",
"    ). Single use probes are available in which a constant connection exists between the cable and the housing; the transducer rotates in a water-filled chamber whereas the shaft of the housing is free of fluid. Another multi-purpose catheter is available that requires insertion of the cable and transducer into a water-filled housing that may contain a distally attached balloon over the region of the transducer. This protective housing and balloon attachment helps minimize near field artifacts and reduces resistance during transducer rotation. Their design allows multiple uses and reduces the cost of this technology. Newer mechanical probes that permit mechanical rotating sector scanning and linear scanning have also been developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BILIARY TRACT INTRADUCTAL ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;IDUS can assist in the evaluation of patients with a variety of biliary tract disorders (",
"    <a class=\"graphic graphic_table graphicRef74332 \" href=\"UTD.htm?8/34/8747\">",
"     table 1",
"    </a>",
"    ). The most common indications for IDUS of the biliary tract include the evaluation of choledocholithiasis and obstructive jaundice. IDUS is useful for determining the cause of biliary obstruction and can also assist in local tumor staging.",
"   </p>",
"   <p>",
"    In contrast to endoscopic ultrasound (EUS), IDUS is often better able to evaluate the proximal biliary system and surrounding structures, such as the right hepatic artery, portal vein, and the hepatoduodenal ligament (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61520 \" href=\"UTD.htm?26/3/26674\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74347 \" href=\"UTD.htm?9/59/10160\">",
"     image 2",
"    </a>",
"    ). Examination of more distant tissues is hindered by its limited depth of penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. IDUS may also have limited value in evaluating lymph nodes, and unlike EUS, IDUS cannot be used to perform fine needle aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IDUS catheter can be inserted into the bile duct through an endoscopic or percutaneous approach [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Endoscopic sphincterotomy was required in approximately 10 to 15 percent of patients undergoing IDUS during endoscopic retrograde cholangiopancreatography (ERCP) in initial reports [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. New small caliber IDUS catheters permit cannulation without the need for sphincterotomy in almost all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ]. Severely stenotic strictures may require dilation with a catheter or balloon. The IDUS procedure time, including catheter insertion and imaging time, adds approximately 5 to 10 minutes to the duration of standard ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. Complications attributed directly to IDUS are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/11,12,15\">",
"     11,12,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal bile duct appears as either two or three layers, which is similar to that seen during standard EUS [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/7,16-18\">",
"     7,16-18",
"    </a>",
"    ]. The normal bile duct wall is 0.31 to 0.79 mm thick, with smooth inner and outer surfaces and homogeneous internal echoes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/19\">",
"     19",
"    </a>",
"    ]. When visualized as a two-layer structure, an internal hypoechoic layer is seen which represents the mucosa, muscularis propria (fibromuscular layer), and fibrous layer of the subserosa [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. An outer hyperechoic layer represents the adipose layer of the subserosa, the serosa, and the interface echo between the serosa and surrounding organs. A third inner hyperechoic layer, representing an interface, will occasionally be identified. It may not be possible to differentiate the fibromuscular layer from the perimuscular connective tissue in some patients in whom they appear as a single hypoechoic layer. This limits the ability to differentiate between T1 and T2 bile duct cancers, although this distinction is usually not clinically relevant when considering treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Choledocholithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of imaging modalities are available to evaluate patients with suspected choledocholithiasis, including transabdominal ultrasonography, computed tomography (CT), magnetic resonance cholangiopancreatography, ERCP, and EUS. (See appropriate topic reviews.) Initial studies have suggested a role for IDUS in patients with suspected choledocholithiasis who have normal cholangiography [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report included 62 patients who were suspected to have bile duct stones who underwent cholangiography and IDUS [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/23\">",
"       23",
"      </a>",
"      ]. The presence of bile duct stones or sludge was confirmed after sphincterotomy. Overall, the combination of cholangiography plus IDUS was significantly more accurate than cholangiography alone for diagnosing bile duct stones (97 versus 87 percent).",
"     </li>",
"     <li>",
"      Another report included 31 patients with choledocholithiasis who underwent transabdominal ultrasonography, ERCP, and IDUS [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/24\">",
"       24",
"      </a>",
"      ]. All patients underwent endoscopic sphincterotomy and stone removal to confirm the presence of bile duct stones. Wire-guided insertion of the IDUS catheter was possible in all patients. The sensitivity of IDUS was superior to ERCP and transabdominal ultrasonography (97 versus 81 and 45 percent, respectively). In the one patient in whom IDUS was falsely negative, the stone had migrated proximally into the left intrahepatic bile duct while only the right hepatic duct had been examined. A protocol requiring more complete bilateral examination may have permitted stone visualization. The sensitivity of IDUS over the other techniques was even higher for detecting small stones (&lt;5 mm) and for determining the number of stones. IDUS reliably distinguished stones from sludge and air bubbles and there were no complications.",
"     </li>",
"     <li>",
"      A third report focused on 65 patients with suspected choledocholithiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/25\">",
"       25",
"      </a>",
"      ]. IDUS successfully identified all stones in 59 patients in whom choledocholithiasis was confirmed. Two false positive diagnoses were made in the remaining six patients, giving an overall sensitivity, specificity, and accuracy of 100, 67, and 97 percent, respectively.",
"     </li>",
"     <li>",
"      In a fourth report, IDUS was performed in 35 patients with suspected choledocholithiasis with equivocal findings on cholangiography [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/26\">",
"       26",
"      </a>",
"      ]. Of 21 patients with apparent normal cholangiography, eight (38 percent) had stones or sludge detected by IDUS. All of these patients subsequently underwent sphincterotomy, which confirmed the presence of sludge or stones in seven. In contrast, IDUS permitted avoidance of sphincterotomy in five patients in whom a suspected stone on cholangiography was shown to be an air bubble by IDUS. Overall IDUS led to a change in clinical management in 13 patients (37 percent). However, the high rate of residual stones and sludge observed in this study compared with previous reports raise questions regarding the quality of the cholangiography [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/27\">",
"       27",
"      </a>",
"      ]. Furthermore, the clinical significance of the residual sludge and stones is unclear since some of these may have been small enough to pass spontaneously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;IDUS can demonstrate common duct stones in patients suspected of having choledocholithiasis in whom stones are not visualized by other imaging modalities. However, at this point, the cost and absence of more data supporting its utility will likely limit its use in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bile duct strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;IDUS can help distinguish benign from malignant strictures based upon bile duct anatomy and unique sonographic imaging characteristics (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80227 \" href=\"UTD.htm?43/21/44370\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79075 \" href=\"UTD.htm?24/59/25523\">",
"     image 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/5,15,28-33\">",
"     5,15,28-33",
"    </a>",
"    ]. Causes of bile duct strictures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trauma (eg, cholecystectomy) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"       \"Complications of laparoscopic cholecystectomy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anastomotic (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link&amp;anchor=H57890048#H57890048\">",
"       \"Long-term management of adult liver transplant recipients\", section on 'Biliary complications'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary sclerosing cholangitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Autoimmune pancreatitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link&amp;anchor=H5#H5\">",
"       \"Autoimmune pancreatitis\", section on 'Biliary tract manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic pancreatitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=see_link&amp;anchor=H4#H4\">",
"       \"Complications of chronic pancreatitis\", section on 'Bile duct or duodenal obstruction'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cholangiocarcinoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      AIDS cholangiopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=see_link\">",
"       \"AIDS cholangiopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infectious or ischemic cholangiopathy, including chronic bacterial cholangitis, recurrent pyogenic cholangitis, and biliary parasitosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14472?source=see_link\">",
"       \"Recurrent pyogenic cholangitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42087?source=see_link\">",
"       \"Endoscopic diagnosis and management of biliary parasitosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pancreatic cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lymphadenopathy (benign and malignant)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Findings suggestive of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;IDUS criteria that suggest the presence of malignancy include [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/8,9,15,30,34\">",
"     8,9,15,30,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A hypoechoic mass, especially if infiltrating surrounding tissues",
"     </li>",
"     <li>",
"      Heterogeneity of the internal echo",
"     </li>",
"     <li>",
"      Notching or irregularity of the outer border",
"     </li>",
"     <li>",
"      A papillary surface",
"     </li>",
"     <li>",
"      Disruption of the normal bile duct structure",
"     </li>",
"     <li>",
"      Suspicious lymph nodes (hypoechoic, round and smooth bordered)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Efficacy for diagnosing malignant strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following reports illustrate the range of findings in the largest published series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report included 56 consecutive patients with obstructive jaundice due to bile duct strictures in which a histologic diagnosis was available [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/15\">",
"       15",
"      </a>",
"      ]. IDUS was significantly more accurate than EUS for determining the nature of bile duct strictures (89 versus 76 percent) (",
"      <a class=\"graphic graphic_table graphicRef56303 \" href=\"UTD.htm?29/50/30507\">",
"       table 3",
"      </a>",
"      ). IDUS was also better able to determine the potential resectability of bile duct tumors and T stage (",
"      <a class=\"graphic graphic_table graphicRef72258 \" href=\"UTD.htm?16/58/17323\">",
"       table 4",
"      </a>",
"      ). The advantage of IDUS was greatest for tumors located at the hilum or mid bile duct.",
"     </li>",
"     <li>",
"      Similar conclusions were reached in another study in which IDUS was compared to ERCP and tissue sampling in 30 consecutive patients with indeterminate bile duct strictures [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/13\">",
"       13",
"      </a>",
"      ]. A malignant cause was demonstrated by histology in 18 patients. The final diagnosis was more accurately made with IDUS compared with ERCP with tissue sampling (90 versus 67 percent) (",
"      <a class=\"graphic graphic_table graphicRef52769 \" href=\"UTD.htm?33/10/33963\">",
"       table 5",
"      </a>",
"      ). IDUS was superior to ERCP in regard to the sensitivity, specificity, and accuracy in the 21 patients who underwent both studies (",
"      <a class=\"graphic graphic_table graphicRef78229 \" href=\"UTD.htm?15/29/15835\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A third series included 62 patients with suspected malignant strictures but with negative tissue sampling by ERCP [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/31\">",
"       31",
"      </a>",
"      ]. The procedure could not be completed in two patients because the stricture could not be traversed with the ultrasound probe. The gold standard final diagnosis was based upon histopathologic findings",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      follow-up of at least 12 months. The sensitivity, specificity, positive and negative predictive values of ERCP tissue sampling combined with IDUS were 90, 93, 93, and 90 percent, respectively.",
"     </li>",
"     <li>",
"      In contrast to the above reports, IDUS did not perform as well in another study, especially when compared to cholangioscopic directed percutaneous biopsy (",
"      <a class=\"graphic graphic_table graphicRef75831 \" href=\"UTD.htm?11/6/11372\">",
"       table 7",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/30\">",
"       30",
"      </a>",
"      ]. The sensitivity, specificity, and accuracy of IDUS for diagnosing cholangiocarcinoma were only 89, 50, and 76 percent, respectively. This compared to a sensitivity, specificity, and accuracy of 93, 100, and 95 percent for percutaneous cholangioscopy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18166?source=see_link\">",
"       \"Percutaneous transhepatic cholangioscopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A prospective study of cholangiography, routine cytology (RC), intraductal biopsy, digital image analysis (DIA), fluorescence in situ hybridization (FISH), and IDUS was performed in 86 patients with indeterminate bile duct strictures of whom 34 had primary sclerosing cholangitis [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/34\">",
"       34",
"      </a>",
"      ]. Overall, 47 patients were found to have malignant strictures. In 80 patients, CA 19-9 results were available as well and a value &ge;100 was used as a cutoff for malignancy. IDUS formal criteria as well as the operator's general impression were used to distinguish benign from malignant strictures. Overall accuracy for each of these tests was:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      ERCP &ndash; 78 percent",
"     </li>",
"     <li>",
"      CA 19-9 &ndash; 64 percent",
"     </li>",
"     <li>",
"      RC &ndash; 50 percent",
"     </li>",
"     <li>",
"      Histology &ndash; 66 percent",
"     </li>",
"     <li>",
"      DIA &ndash; 64 percent",
"     </li>",
"     <li>",
"      FISH &ndash; 70 percent",
"     </li>",
"     <li>",
"      IDUS (formal criteria) &ndash; 78 percent",
"     </li>",
"     <li>",
"      IDUS (endoscopist's general impression) &ndash; 90 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with negative cytology and histology who were later proven to have malignancy (n = 21), DIA, FISH, composite",
"    <span class=\"nowrap\">",
"     DIA/FISH,",
"    </span>",
"    and IDUS lead to a diagnosis of malignancy in 14, 62, 67, and 86 percent, respectively. The authors suggest that IDUS may be most helpful for targeting patients for closer follow-up testing who have concerning features on IDUS, but negative cytology, histology and",
"    <span class=\"nowrap\">",
"     DIA/FISH.",
"    </span>",
"   </p>",
"   <p>",
"    IDUS may be helpful for directing management even in patients in whom it does not provide a definitive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/30,35,36\">",
"     30,35,36",
"    </a>",
"    ]. For example, one group suggested that surgical exploration be performed in patients in whom IDUS identifies disruption of the bile duct wall by a protruding tumor, regardless of the results of tissue sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/36\">",
"     36",
"    </a>",
"    ]. Whereas directed biopsies were recommended when IDUS demonstrates a localized tumor or polypoid lesion in the presence of a normal appearing wall (except for masses greater than 8 mm in diameter, which are likely to be malignant).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Primary sclerosing cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of IDUS in patients with primary sclerosing cholangitis (PSC) is still being determined. IDUS may identify irregular foci within strictures, permitting focused endoscopic transpapillary biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/37\">",
"     37",
"    </a>",
"    ]. The accuracy of IDUS in diagnosing malignancy in PSC when formal criteria are used is lower than that seen when using an endoscopist's general impression to make the diagnosis (62 versus 82 percent). In addition, the overall accuracy is lower in patients with PSC compared with patients without PSC (62 versus 88 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In experienced hands, IDUS does appear to be useful in PSC. It offers the advantage of allowing for imaging of multiple strictures to identify findings that may suggest malignancy. In one study, it had an accuracy of 82 percent for diagnosing malignancy. Whether these results can be duplicated at other centers and lead to earlier diagnoses of cholangiocarcinoma remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cholangiocarcinoma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;IDUS can improve the accuracy of local tumor staging of bile duct carcinomas (",
"    <a class=\"graphic graphic_table graphicRef51131 \" href=\"UTD.htm?4/11/4285\">",
"     table 8",
"    </a>",
"    ). IDUS detects early lesions, determines the longitudinal tumor extent, and identifies tumor extension into adjacent organs and major blood vessels with a diagnostic accuracy of nearly 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/6,8,18,38\">",
"     6,8,18,38",
"    </a>",
"    ]. In particular, IDUS can accurately identify tumor invasion into the pancreatic parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/7,8,18\">",
"     7,8,18",
"    </a>",
"    ], portal vein [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/6,7,18,39\">",
"     6,7,18,39",
"    </a>",
"    ], and right hepatic artery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/5,7,18,38\">",
"     5,7,18,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When compared with operative findings, local tumor staging was accurately established in 77 percent of patients with IDUS, but only 54 percent of patients with EUS in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/12\">",
"     12",
"    </a>",
"    ]. The benefit of IDUS over EUS may be even greater for proximal bile duct tumors involving the mid bile duct to the bifurcation. However, the limited depth of penetration of IDUS limits its value for assessing tumor extension outside of the hepatoduodenal ligament and prohibits its use for M-staging [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/6,40\">",
"     6,40",
"    </a>",
"    ]. The utility of IDUS for N-staging is uncertain and likely to be limited by the inability to perform fine needle aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Tumor extension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because bile duct carcinomas spread longitudinally, accurate determination of the extent of spread and the necessary margin of resection is important for planning operative interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. Cholangiography is frequently inaccurate in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study comparing IDUS to cholangiography, IDUS was significantly more accurate than cholangiography in determining the longitudinal spread of the cancer toward the liver (84 versus 47 percent) and toward the duodenum (96 versus 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/11\">",
"     11",
"    </a>",
"    ]. Similar findings were described in another report in which IDUS accurately determined the proximal extent of tumor invasion in 92 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bile duct wall thickening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile duct wall thickening may result from tumor spread or peritumoral inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/7-9,35,36,47\">",
"     7-9,35,36,47",
"    </a>",
"    ]. Distinguishing tumor spread from inflammation cannot be reliably done with noninvasive bile duct imaging techniques, including IDUS [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/7,8,38,48\">",
"     7,8,38,48",
"    </a>",
"    ]. However, a number of investigators have described ultrasound criteria that may assist in making this distinction.",
"   </p>",
"   <p>",
"    A commonly used feature is based upon the observation that inflammation typically causes symmetrical wall thickening, in contrast to cancer infiltration, which typically causes asymmetrical wall thickening [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. However, this criterion has not been a reliable distinguishing feature in all reports [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bile duct stents may also lead to bile duct wall thickening [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/11,49\">",
"     11,49",
"    </a>",
"    ]. Such stents are frequently required in patients who have biliary obstruction. Biliary decompression following stent placement may lead to thickening of the duct wall and overestimation of longitudinal tumor extension [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. As a result, some authorities suggest that IDUS be performed prior to, or within a few days of, biliary decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PANCREATIC INTRADUCTAL ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with signs and symptoms suggestive of a pancreatic neoplasm typically undergo transabdominal ultrasonography or CT imaging, which often reveal the presence of a pancreatic mass or fullness. However, uncertainty may remain as to whether the lesion is an inflammatory mass or neoplasm, and whether the lesion is cystic or solid. Furthermore, up to 40 percent of small carcinomas may not be evident with these imaging modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evaluation using endoscopic procedures such as endoscopic retrograde cholangiopancreatography (ERCP)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endoscopic ultrasound (EUS) may be required in these settings. These procedures offer a means to obtain tissue, assist in staging, and provide options for palliative therapy. Increasing experience suggests that IDUS may also be helpful for selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/52-57\">",
"     52-57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with bile duct insertion, the IDUS probe can be placed within the pancreatic duct in almost all patients, usually without the need for prior sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/54,58-60\">",
"     54,58-60",
"    </a>",
"    ]. However, it may be difficult to pass the probe into the proximal pancreatic duct since the pancreatic duct is typically tortuous.",
"   </p>",
"   <p>",
"    In one series of 153 patients, the IDUS probe could be passed into the pancreatic head, body, and tail in 94, 89, and 55 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/12\">",
"     12",
"    </a>",
"    ]. In another study, papillary cannulation was possible in 17 of 20 patients (85 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/54\">",
"     54",
"    </a>",
"    ]. In the three patients where cannulation failed, it was due to the inability to pass the endoscope to the papilla. When cannulation was achieved, the probe could be passed to the head, body and tail in 100, 71, and 35 percent of patients, respectively.",
"   </p>",
"   <p>",
"    The endosonographic appearance of the main pancreatic duct wall with IDUS varies from a single hyperechoic layer to three layers. When three layers are present, the inner and outer layers are hyperechoic, with an intervening hypoechoic layer [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/17,54,61\">",
"     17,54,61",
"    </a>",
"    ]. Visualization of three layers is more likely with use of a 30 MHz (versus a 20 MHz) probe.",
"   </p>",
"   <p>",
"    Pancreatic IDUS does not appear to add significantly to the risk of standard ERCP with pancreatography. In two studies involving 443 patients, only 4 developed mild pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/12,52\">",
"     12,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"     \"Post-ERCP pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pancreatic duct strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;IDUS may be useful for determining whether a pancreatic stricture is benign or malignant. In one series, the type of stricture was correctly identified in 23 of 25 patients (92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/37\">",
"     37",
"    </a>",
"    ]. Two patients had focal pancreatitis that was incorrectly diagnosed as pancreatic cancer. Another study from the same authors compared the results of IDUS to EUS, CT, and endoscopic retrograde pancreatography (ERP) for determining the cause of localized strictures of the main pancreatic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/53\">",
"     53",
"    </a>",
"    ]. Of the 26 patients enrolled, 14 were ultimately determined to have had pancreatic carcinoma, while 12 had benign strictures from chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/53\">",
"     53",
"    </a>",
"    ]. IDUS was more sensitive than EUS, CT, and ERP (100 versus 93, 64, and 86 percent, respectively) and more specific (92, 58, 67, and 67 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pancreatic adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of IDUS in the evaluation of patients with suspected adenocarcinoma was described in a study involving 239 patients with pancreatic disorders, including 48 with adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/52\">",
"     52",
"    </a>",
"    ]. IDUS was more sensitive than EUS, CT, and ERP (100 versus 90, 67, and 90 percent, respectively) and more specific (92 versus 60, 64, and 64, percent, respectively) (",
"    <a class=\"graphic graphic_table graphicRef59414 \" href=\"UTD.htm?12/47/13051\">",
"     table 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Mucin producing tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four types of cystic neoplasms of the pancreas have been described (",
"    <a class=\"graphic graphic_table graphicRef69594 \" href=\"UTD.htm?5/20/5452\">",
"     table 10",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mucinous",
"      <span class=\"nowrap\">",
"       cystadenoma/cystadenocarcinoma",
"      </span>",
"     </li>",
"     <li>",
"      Intraductal papillary mucinous tumor",
"     </li>",
"     <li>",
"      Serous cystadenoma",
"     </li>",
"     <li>",
"      Solid pseudopapillary neoplasm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serous cystadenomas are benign, with rare exception, and can generally be managed with observation alone. The other lesions are premalignant or malignant and are generally indications for surgical resection. Correct diagnosis is important since these tumors have a better prognosis than ductal adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=see_link\">",
"     \"Classification of pancreatic cysts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=see_link\">",
"     \"Pancreatic cystic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conventional imaging studies, such as transabdominal US, CT, and MRI, often inadequately characterize and differentiate among the cystic neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. This is especially true for lesions less than 2 to 3 cm in diameter, which are often difficult to identify by conventional imaging. The role of EUS and IDUS in the evaluation of these tumors is still being determined. Initial experience suggests that EUS can be helpful and that IDUS may be more accurate than EUS [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/52,60,64,65\">",
"     52,60,64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study involving seven patients with mucin-producing tumors involving the main pancreatic duct (",
"    <a class=\"graphic graphic_picture graphicRef60088 \" href=\"UTD.htm?1/36/1615\">",
"     picture 3",
"    </a>",
"    ), IDUS identified abnormal areas that corresponded to adenomatous tissue or intraductal carcinoma, but could not distinguish between the two [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/52\">",
"     52",
"    </a>",
"    ]. A mural nodule was identified in 11 of 21 patients with ductal mucin-producing tumors; three patients had carcinoma, seven had adenoma, and one had hyperplasia. Five of these nodules were not visualized by EUS. In the 10 patients in whom IDUS did not reveal a nodular defect, one was found to have an adenoma and the other nine had hyperplasia. Thus, the finding of a mural nodule at IDUS correlated with an increased likelihood of malignant involvement.",
"   </p>",
"   <p>",
"    IDUS was also useful in evaluating the feasibility of partial pancreatic resection for mucin-producing tumors of the ductal branches and for pancreatic islet-cell tumors. Three of 21 patients with adequate distance between the duct and the lesion were able to undergo partial, rather than complete, pancreatic resection.",
"   </p>",
"   <p>",
"    Another study compared the detection rates of IDUS, transabdominal US, CT, EUS, and pancreatoscopy (",
"    <a class=\"graphic graphic_picture graphicRef71357 \" href=\"UTD.htm?32/45/33502\">",
"     picture 4",
"    </a>",
"    ) in 31 patients with mucin-producing tumors who underwent surgical and pathological confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/59\">",
"     59",
"    </a>",
"    ]. These included six patients in whom the papillary tumors originated within the main duct and 25 patients in whom the papillary tumors originated within dilated branch ducts. Papillary projections (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66688 \" href=\"UTD.htm?29/44/30401\">",
"     image 5",
"    </a>",
"    ) were limited to the side branches in 10 of the 25 patients considered to have side branch disease while they also involved the main duct in the other 15 patients.",
"   </p>",
"   <p>",
"    Surgical specimens revealed that eight patients had mucinous cystadenocarcinoma, 19 had mucinous cystadenoma, and four had hyperplasia. All patients with adenocarcinoma had papillary projections in the pancreatic ducts of 3 mm or greater in height. The detection rate of such lesions was higher for IDUS (100 percent) compared with transabdominal ultrasonography (29 percent), CT (21 percent), EUS (86 percent), and pancreatoscopy (83 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;These studies demonstrate that IDUS can detect small lesions and determine the extent of intraductal spread and parenchymal invasion. This information can help determine the necessary extent of resection for mucin-producing tumors involving the main pancreatic duct. IDUS can also help assess the indications and extent of necessary surgery for patients with side-branch disease by identifying papillary tumor projections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pancreatic endocrine tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic endocrine (islet-cell) tumors are rare tumors of neuroendocrine origin which usually arise in proximity to the pancreas. The majority of these tumors secrete biologically active substances resulting in specific clinical syndromes. The tumors have similar histologic appearances, but can be distinguished by the use of immunostaining for the hormone being secreted. (See appropriate topic reviews.)",
"   </p>",
"   <p>",
"    Several imaging modalities are available to assist in localizing the tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"    </a>",
"    .) Although experience with IDUS is limited, initial data suggest that IDUS may improve the evaluation of these patients and lead to the identification of tumors arising within the pancreas that have gone unrecognized by other techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/52,56\">",
"     52,56",
"    </a>",
"    ]. In one study, IDUS was able to identify the presence of an islet cell tumor in seven of seven patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/52\">",
"     52",
"    </a>",
"    ]. In one of these patients with multi-focal disease, IDUS accurately determined the number of tumors, while EUS failed to detect all lesions. In the patients with islet cell tumors, IDUS also accurately determined the distance from the tumors to the main pancreatic duct, thus aiding preoperative planning of wedge resection, which was possible in two patients.",
"   </p>",
"   <p>",
"    Most pancreatic endocrine tumors appear sonographically as echo-poor, homogenous, well-delineated lesions. A minority of these tumors appears as echo-rich, inhomogeneous lesions with an irregular outer margin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PAPILLA OF VATER INTRADUCTAL ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;IDUS accurately visualizes the anatomy of the papilla and is the only procedure that reliably differentiates the sphincter of Oddi musculature from the remainder of the papilla [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. As a result, IDUS can be useful for diagnosing and assessing the size and extent of papillary tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability of IDUS to diagnose tumor extension was evaluated in a prospective study involving 32 patients with cancer of the papilla of Vater who underwent surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/68\">",
"     68",
"    </a>",
"    ]. IDUS was performed percutaneously in 24 patients and endoscopically in the other eight. IDUS was able to determine the tumor extent with an accuracy of 88 percent. As expected, because of the limited depth of penetration and inability to perform fine needle aspiration, the sensitivity for determining nodal metastases was only 67 percent, with a specificity of 91 percent. Nevertheless, this compared favorably to transabdominal ultrasonography and CT, which detected only 9 and 6 percent of the tumors, respectively.",
"   </p>",
"   <p>",
"    In another prospective study involving 27 consecutive patients, IDUS (endoscopically inserted in all patients) was compared to EUS and CT with regard to tumor visualization, diagnosis, and staging [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33353/abstract/67\">",
"     67",
"    </a>",
"    ]. The final diagnosis at surgery was a benign tumor in 12 patients and papillary carcinoma in 15. IDUS was superior to EUS and CT for tumor visualization (100 versus 59 and 30 percent, respectively). IDUS was more sensitive and specific than EUS (100 versus 63, and 75 versus 50 percent, respectively). This study suggests that IDUS may be the most accurate imaging modality for the diagnosis and local staging of tumors of the papilla of Vater.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraductal ultrasound (IDUS) is a newer form of ultrasound technology and offers promise in the evaluation of patients with pancreatobiliary disorders. The use of high frequencies allows production of high-resolution images and detailed examination of ductal and periductal tissues. However, the limited depth of penetration prevents examination of more distant sites.",
"     </li>",
"     <li>",
"      IDUS can determine the etiology of bile duct strictures and significantly increases the diagnostic accuracy over other imaging studies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tissue sampling. As a result, it is becoming an essential part of the work-up of patients with indeterminate strictures in centers where the technology is available. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Bile duct strictures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with known malignant bile duct or ampullary strictures, IDUS compares favorably to other imaging modalities with regard to tumor visualization, diagnosis, staging, and predicting resectability. The information obtained from IDUS examinations also helps select appropriate candidates for surgery and often helps the surgeon to select the most appropriate technique. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cholangiocarcinoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Papilla of Vater intraductal ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with pancreatic duct strictures, IDUS can be used to distinguish between benign and malignant pancreatic duct stenosis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pancreatic duct strictures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mucinous duct ectasia (intraductal papillary mucinous tumor), IDUS is able to distinguish main duct disease versus side duct disease, and determines the extent of tumor spread and parenchymal invasion. This information can be used to determine the indications and extent of necessary surgery. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Mucin producing tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pancreatic neuroendocrine tumors, IDUS can identify otherwise undetected or multifocal tumors. This may lead to improved surgical planning and limit the extent of pancreatic resection. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Pancreatic endocrine tumors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/1\">",
"      DiMagno EP, Buxton JL, Regan PT, et al. Ultrasonic endoscope. Lancet 1980; 1:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/2\">",
"      Crowley RJ, von Behren PL, Couvillon LA Jr, et al. Optimized ultrasound imaging catheters for use in the vascular system. Int J Card Imaging 1989; 4:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/3\">",
"      Martin RW, Silverstein FE, Kimmey MB. A 20-MHz ultrasound system for imaging the intestinal wall. Ultrasound Med Biol 1989; 15:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/4\">",
"      Silverstein FE, Martin RW, Kimmey MB, et al. Experimental evaluation of an endoscopic ultrasound probe: in vitro and in vivo canine studies. Gastroenterology 1989; 96:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/5\">",
"      Tamada K, Ido K, Ueno N, et al. Assessment of hepatic artery invasion by bile duct cancer using intraductal ultrasonography. Endoscopy 1995; 27:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/6\">",
"      Tamada K, Ido K, Ueno N, et al. Assessment of portal vein invasion by bile duct cancer using intraductal ultrasonography. Endoscopy 1995; 27:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/7\">",
"      Tamada K, Ido K, Ueno N, et al. Preoperative staging of extrahepatic bile duct cancer with intraductal ultrasonography. Am J Gastroenterol 1995; 90:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/8\">",
"      Tamada K, Ueno N, Ichiyama M, et al. Assessment of pancreatic parenchymal invasion by bile duct cancer using intraductal ultrasonography. Endoscopy 1996; 28:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/9\">",
"      Kuroiwa M, Goto H, Hirooka Y, et al. Intraductal ultrasonography for the diagnosis of proximal invasion in extrahepatic bile duct cancer. J Gastroenterol Hepatol 1998; 13:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/10\">",
"      Noda T, Ido K, Ueno N. Transpapillary intraductal ultrasonography (IDUS) of the bile duct without sphincterotomy. Ultrasound Int 1995; 1:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/11\">",
"      Tamada K, Nagai H, Yasuda Y, et al. Transpapillary intraductal US prior to biliary drainage in the assessment of longitudinal spread of extrahepatic bile duct carcinoma. Gastrointest Endosc 2001; 53:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/12\">",
"      Menzel J, Domschke W. Intraductal ultrasonography (IDUS) of the pancreato-biliary duct system. Personal experience and review of literature. Eur J Ultrasound 1999; 10:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/13\">",
"      Vazquez-Sequeiros E, Baron TH, Clain JE, et al. Evaluation of indeterminate bile duct strictures by intraductal US. Gastrointest Endosc 2002; 56:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/14\">",
"      Ascher SM, Evans SR, Goldberg JA, et al. Intraoperative bile duct sonography during laparoscopic cholecystectomy: experience with a 12.5-MHz catheter-based US probe. Radiology 1992; 185:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/15\">",
"      Menzel J, Poremba C, Dietl KH, Domschke W. Preoperative diagnosis of bile duct strictures--comparison of intraductal ultrasonography with conventional endosonography. Scand J Gastroenterol 2000; 35:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/16\">",
"      Fujita N, Noda Y, Kobayashi G, et al. Staging of bile duct carcinoma by EUS and IDUS. Endoscopy 1998; 30 Suppl 1:A132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/17\">",
"      Furukawa T, Naitoh Y, Tsukamoto Y, et al. New technique using intraductal ultrasonography for the diagnosis of diseases of the pancreatobiliary system. J Ultrasound Med 1992; 11:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/18\">",
"      Kuroiwa M, Tsukamoto Y, Naitoh Y, et al. New technique using intraductal ultrasonography for the diagnosis of bile duct cancer. J Ultrasound Med 1994; 13:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/19\">",
"      Kikuchi Y, Tsuyuguchi T, Saisho H. Evaluation of normal bile duct and cholangitis by intraductal ultrasonography. Abdom Imaging 2008; 33:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/20\">",
"      Fujita N, Noda Y, Kobayashi G. Analysis of the layer structure of the gallbladder wall delineated by endoscopic ultrasound using the pinning method. Dig Endosc 1995; 7:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/21\">",
"      Noda Y, Fujita N, Kobayashi G, et al. [Comparison of echograms by a microscanner and histological findings of the common bile duct, in vitro study]. Nihon Shokakibyo Gakkai Zasshi 1997; 94:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/22\">",
"      Tamada K, Kanai N, Ueno N, et al. Limitations of intraductal ultrasonography in differentiating between bile duct cancer in stage T1 and stage T2: in-vitro and in-vivo studies. Endoscopy 1997; 29:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/23\">",
"      Das A, Isenberg G, Wong RC, et al. Wire-guided intraductal US: an adjunct to ERCP in the management of bile duct stones. Gastrointest Endosc 2001; 54:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/24\">",
"      Ueno N, Nishizono T, Tamada K, et al. Diagnosing extrahepatic bile duct stones using intraductal ultrasonography: a case series. Endoscopy 1997; 29:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/25\">",
"      Tseng LJ, Jao YT, Mo LR, Lin RC. Over-the-wire US catheter probe as an adjunct to ERCP in the detection of choledocholithiasis. Gastrointest Endosc 2001; 54:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/26\">",
"      Catanzaro A, Pfau P, Isenberg GA, et al. Clinical utility of intraductal US for evaluation of choledocholithiasis. Gastrointest Endosc 2003; 57:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/27\">",
"      Haber GB. Is seeing believing? Gastrointest Endosc 2003; 57:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/28\">",
"      Tio TL, Cheng J, Wijers OB, et al. Endosonographic TNM staging of extrahepatic bile duct cancer: comparison with pathological staging. Gastroenterology 1991; 100:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/29\">",
"      R&ouml;sch T, Lorenz R, Braig C, Classen M. Endoscopic ultrasonography in diagnosis and staging of pancreatic and biliary tumors. Endoscopy 1992; 24 Suppl 1:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/30\">",
"      Tamada K, Ueno N, Tomiyama T, et al. Characterization of biliary strictures using intraductal ultrasonography: comparison with percutaneous cholangioscopic biopsy. Gastrointest Endosc 1998; 47:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/31\">",
"      Farrell RJ, Agarwal B, Brandwein SL, et al. Intraductal US is a useful adjunct to ERCP for distinguishing malignant from benign biliary strictures. Gastrointest Endosc 2002; 56:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/32\">",
"      Domagk D, Wessling J, Reimer P, et al. Endoscopic retrograde cholangiopancreatography, intraductal ultrasonography, and magnetic resonance cholangiopancreatography in bile duct strictures: a prospective comparison of imaging diagnostics with histopathological correlation. Am J Gastroenterol 2004; 99:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/33\">",
"      Tischendorf JJ, Meier PN, Schneider A, et al. Transpapillary intraductal ultrasound in the evaluation of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2007; 42:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/34\">",
"      Levy MJ, Baron TH, Clayton AC, et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol 2008; 103:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/35\">",
"      Gress F, Chen YK, Sherman S, et al. Experience with a catheter-based ultrasound probe in the bile duct and pancreas. Endoscopy 1995; 27:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/36\">",
"      Tamada K, Tomiyama T, Ichiyama M, et al. Influence of biliary drainage catheter on bile duct wall thickness as measured by intraductal ultrasonography. Gastrointest Endosc 1998; 47:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/37\">",
"      Brambs HJ. [Intraductal ultrasound of the bile ducts]. Radiologe 1993; 33:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/38\">",
"      Tamada K, Ido K, Ueno N, et al. Assessment of the course and variations of the hepatic artery in bile duct cancer by intraductal ultrasonography. Gastrointest Endosc 1996; 44:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/39\">",
"      Yasuda K, Mukai H, Nakajima M, Kawai K. Clinical application of ultrasonic probes in the biliary and pancreatic duct. Endoscopy 1992; 24 Suppl 1:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/40\">",
"      Tamada K, Kanai N, Tomiyama T, et al. Prediction of the histologic type of bile duct cancer by using intraductal ultrasonography. Abdom Imaging 1999; 24:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/41\">",
"      Hayashi S, Miyazaki M, Kondo Y, Nakajima N. Invasive growth patterns of hepatic hilar ductal carcinoma. A histologic analysis of 18 surgical cases. Cancer 1994; 73:2922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/42\">",
"      Nimura Y, Kamiya J. Cholangioscopy. Endoscopy 1998; 30:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/43\">",
"      Sato M, Inoue H, Ogawa S, et al. Limitations of percutaneous transhepatic cholangioscopy for the diagnosis of the intramural extension of bile duct carcinoma. Endoscopy 1998; 30:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/44\">",
"      Tamada K, Kurihara K, Tomiyama T, et al. How many biopsies should be performed during percutaneous transhepatic cholangioscopy to diagnose biliary tract cancer? Gastrointest Endosc 1999; 50:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/45\">",
"      Tamada K, Yasuda Y, Nagai H, et al. Limitation of cholangiography in assessing longitudinal spread of extrahepatic bile duct carcinoma to the hepatic side. J Gastroenterol Hepatol 1999; 14:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/46\">",
"      Yamaguchi K, Chijiiwa K, Saiki S, et al. Carcinoma of the extrahepatic bile duct: mode of spread and its prognostic implications. Hepatogastroenterology 1997; 44:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/47\">",
"      Tamada K, Tomiyama T, Oohashi A, et al. Bile duct wall thickness measured by intraductal US in patients who have not undergone previous biliary drainage. Gastrointest Endosc 1999; 49:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/48\">",
"      Guibaud L, Bret PM, Reinhold C, et al. Bile duct obstruction and choledocholithiasis: diagnosis with MR cholangiography. Radiology 1995; 197:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/49\">",
"      Karsten TM, Coene PP, van Gulik TM, et al. Morphologic changes of extrahepatic bile ducts during obstruction and subsequent decompression by endoprosthesis. Surgery 1992; 111:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/50\">",
"      Palazzo L, Roseau G, Gayet B, et al. Endoscopic ultrasonography in the diagnosis and staging of pancreatic adenocarcinoma. Results of a prospective study with comparison to ultrasonography and CT scan. Endoscopy 1993; 25:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/51\">",
"      Takayama T, Suma H, Wanibuchi Y, et al. Doppler miniprobe to measure arterial graft flow in coronary artery bypass grafting. Ann Thorac Surg 1991; 52:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/52\">",
"      Furukawa T, Oohashi K, Yamao K, et al. Intraductal ultrasonography of the pancreas: development and clinical potential. Endoscopy 1997; 29:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/53\">",
"      Furukawa T, Tsukamoto Y, Naitoh Y, et al. Differential diagnosis between benign and malignant localized stenosis of the main pancreatic duct by intraductal ultrasound of the pancreas. Am J Gastroenterol 1994; 89:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/54\">",
"      Furukawa T, Tsukamoto Y, Naitoh Y, et al. Evaluation of intraductal ultrasonography in the diagnosis of pancreatic cancer. Endoscopy 1993; 25:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/55\">",
"      Inui K, Nakazawa S, Yoshino J, et al. Endoscopy and intraductal ultrasonography. Semin Surg Oncol 1998; 15:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/56\">",
"      Menzel J, Domschke W. Intraductal ultrasonography may localize islet cell tumours negative on endoscopic ultrasound. Scand J Gastroenterol 1998; 33:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/57\">",
"      Menzel J, Foerster EC, Domschke W. Intraductal ultrasound (IDUS) of the pancreas - Technique and diagnostic promise. Gut 1992; 33:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/58\">",
"      Bergman JJ, Rauws EA, Fockens P, et al. Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bileduct stones. Lancet 1997; 349:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/59\">",
"      Mukai H, Yasuda K, Nakajima M. Differential diagnosis of mucin-producing tumors of the pancreas by intraductal ultrasonography and peroral pancreatoscopy. Endoscopy 1998; 30 Suppl 1:A99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/60\">",
"      Taki T, Goto H, Naitoh Y, et al. Diagnosis of mucin-producing tumor of the pancreas with an intraductal ultrasonographic system. J Ultrasound Med 1997; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/61\">",
"      Furukawa T, Tsukamoto Y, Naitoh Y. New endoscopic approach to diagnosing pancreatic diseases using an intraductal ultrasound system. Dig Endosc 1993; 4:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/62\">",
"      Procacci C, Biasiutti C, Carbognin G, et al. Characterization of cystic tumors of the pancreas: CT accuracy. J Comput Assist Tomogr 1999; 23:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/63\">",
"      Le Borgne J, de Calan L, Partensky C. Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association. Ann Surg 1999; 230:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/64\">",
"      Inui K, Nakazawa S, Yoshino J, et al. Mucin-producing tumor of the pancreas--intraluminal ultrasonography. Hepatogastroenterology 1998; 45:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/65\">",
"      Hara T, Yamaguchi T, Ishihara T, et al. Diagnosis and patient management of intraductal papillary-mucinous tumor of the pancreas by using peroral pancreatoscopy and intraductal ultrasonography. Gastroenterology 2002; 122:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/66\">",
"      Itoh A, Tsukamoto Y, Naitoh Y, et al. Intraductal ultrasonography for the examination of duodenal papillary region. J Ultrasound Med 1994; 13:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/67\">",
"      Chak A, Isenberg G, Kobayashi K, et al. Prospective evaluation of an over-the-wire catheter US probe. Gastrointest Endosc 2000; 51:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/68\">",
"      Itoh A, Goto H, Naitoh Y, et al. Intraductal ultrasonography in diagnosing tumor extension of cancer of the papilla of Vater. Gastrointest Endosc 1997; 45:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33353/abstract/69\">",
"      Menzel J, Hoepffner N, Sulkowski U, et al. Polypoid tumors of the major duodenal papilla: preoperative staging with intraductal US, EUS, and CT--a prospective, histopathologically controlled study. Gastrointest Endosc 1999; 49:349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2664 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-115.25.216.6-89DD65BA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33353=[""].join("\n");
var outline_f32_36_33353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Electronic systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanical probes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BILIARY TRACT INTRADUCTAL ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Conclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bile duct strictures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Findings suggestive of malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Efficacy for diagnosing malignant strictures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Staging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Tumor extension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bile duct wall thickening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PANCREATIC INTRADUCTAL ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pancreatic duct strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pancreatic adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Mucin producing tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Conclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pancreatic endocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PAPILLA OF VATER INTRADUCTAL ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2664\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2664|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/3/26674\" title=\"diagnostic image 1\">",
"      IDUS showing CBD PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/59/10160\" title=\"diagnostic image 2\">",
"      IDUS showing CHD PV HA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/21/44370\" title=\"diagnostic image 3\">",
"      IDUS distal CBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/59/25523\" title=\"diagnostic image 4\">",
"      IDUS polypoid mass CBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/44/30401\" title=\"diagnostic image 5\">",
"      IDUS papillary projections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2664|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/47/36607\" title=\"picture 1\">",
"      IDUS catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/47/40701\" title=\"picture 2\">",
"      Wire-guided IDUS passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/36/1615\" title=\"picture 3\">",
"      IDUS pancreatic duct mucin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/45/33502\" title=\"picture 4\">",
"      Pancreatic tumor pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2664|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/34/8747\" title=\"table 1\">",
"      Indications for IDUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/20/23883\" title=\"table 2\">",
"      Available IDUS systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/50/30507\" title=\"table 3\">",
"      IDUS accuracy versus EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/58/17323\" title=\"table 4\">",
"      IDUS vs EUS for resectability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/10/33963\" title=\"table 5\">",
"      IDUS versus ERCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/29/15835\" title=\"table 6\">",
"      IDUS accuracy versus ERCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/6/11372\" title=\"table 7\">",
"      Accuracy IDUS cytology biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/11/4285\" title=\"table 8\">",
"      TNM perihilar cholangio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/47/13051\" title=\"table 9\">",
"      IDUS vs ERCP EUS ERP panc ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/20/5452\" title=\"table 10\">",
"      WHO classif panc cyst neopl",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=related_link\">",
"      AIDS cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=related_link\">",
"      Autoimmune pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=related_link\">",
"      Classification of pancreatic cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=related_link\">",
"      Complications of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=related_link\">",
"      Complications of laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42087?source=related_link\">",
"      Endoscopic diagnosis and management of biliary parasitosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35509?source=related_link\">",
"      High frequency catheter endoscopic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=related_link\">",
"      Long-term management of adult liver transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3368?source=related_link\">",
"      Pancreatic cystic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18166?source=related_link\">",
"      Percutaneous transhepatic cholangioscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14472?source=related_link\">",
"      Recurrent pyogenic cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_36_33354="Alternative and experimental agents for the treatment of asthma";
var content_f32_36_33354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Alternative and experimental agents for the treatment of asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33354/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33354/contributors\">",
"     Richard J Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33354/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33354/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33354/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/36/33354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/36/33354/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/36/33354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard treatment of patients with asthma is based upon trigger avoidance combined with bronchodilator and antiinflammatory therapy. Beta agonists, glucocorticoids, leukotriene modifiers, and, to a lesser extent, methylxanthines, cromoglycates, and anticholinergics all have a role in the conventional treatment of asthma. However, some patients are difficult to treat solely with conventional therapy. For these patients, consideration may be given to the administration of nonstandard therapeutic regimens in order to ameliorate the acute or chronic manifestations of the disease.",
"   </p>",
"   <p>",
"    Alternative and experimental therapies for the treatment of acute and chronic asthma will be reviewed here. The standard treatment regimens for asthma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonstandard therapies for the patient with an acute asthma exacerbation include the administration of helium-oxygen gas mixtures, intravenous leukotriene modifiers, empiric antibiotics, anesthesia, and nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    . The specific recommendation of these therapies is difficult, however, since adequate controlled studies evaluating the effectiveness of these modalities in specific asthmatic populations have not yet been performed. Two of these therapies are being used with greater frequency than the others, and are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Empiric antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical practice guidelines recommend against empiric antibiotic therapy for the treatment of an asthma exacerbation because most respiratory infections that trigger an exacerbation of asthma are viral rather than bacterial [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/1\">",
"     1",
"    </a>",
"    ]. In a meta-analysis of two randomized, controlled trials (97 patients, 115 exacerbations), empiric antibiotics did not confer any benefit compared to placebo when administered to patients with asthma exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of anesthetic agents for patients with status asthmaticus has been described since the 1930s. Experience is greatest with halothane for this indication, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/47/34548?source=see_link\">",
"     enflurane",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    have shown effectiveness in case reports or animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Idiosyncratic reactions to these anesthetics have been described, and a given patient may respond better to one than to another. The mechanism by which bronchodilation is produced remains unclear; a direct relaxant effect on airway smooth muscle, and attenuation of cholinergic tone, have both been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of inhalational anesthetic is titrated to the clinical response (eg, improvement in airway resistance) and avoidance of intolerable side effects. Hypotension is often the limiting factor in the administration of these agents, and myocardial depression and increased ventricular irritability have been observed with halothane, particularly when used in the presence of acidosis, beta-agonists, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The use of inhalational anesthetics for treatment of status asthmaticus is limited by its expense, the need for a full-time anesthesiologist at the bedside, adaptation of equipment for long-term provision of anesthetics, and the abrupt return of bronchoconstriction upon discontinuation. There is also the issue of scavenging anesthetic gases released into the immediate environment in order to avoid second-hand inhalation of aerosolized anesthetic gases by health care personnel or other patients.",
"   </p>",
"   <p>",
"    There have been several case reports in which children and adults with status asthmatics have been successfully treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. Although experience with this therapy is limited, an intravenous bolus of 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is usually infused over 2 to 4 minutes, followed by a continuous infusion of 0.5 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In one report, improvement followed increasing the infusion rate to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/12\">",
"     12",
"    </a>",
"    ]. Beneficial results are seen within 30 minutes to several hours. Depending on the setting, ketamine infusions in this dose range may fall under the category of conscious sedation or of anesthesia and require appropriate monitoring. In general, though, ketamine can be administered in the intensive care unit, rather than the operating room, making it preferable to general anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H10#H10\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Ketamine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nebulized furosemide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    has been studied both as prophylactic treatment for patients with exercise-induced bronchoconstriction, and as therapy for acute asthma. Small early studies reported that nebulized furosemide in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    was safe, well tolerated, and resulted in significantly improved peak expiratory flow rates compared with albuterol alone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, subsequent larger trials have not noted a significant clinical benefit when nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    was used in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    or compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Thus, the therapeutic value of this intervention, if any, appears to be small.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHRONIC ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various therapeutic agents have been used in an attempt to ameliorate the many adverse effects of chronic oral glucocorticoid therapy in the patient whose asthma is difficult to treat. Attempted alternative therapies in this setting include nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , gold,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , intravenous immunoglobulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , troleandomycin, and anti-tumor necrosis factor alpha (TNFa) agents [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/18\">",
"     18",
"    </a>",
"    ]. Also, multiple non-pharmacologic agents have been used in chronic asthma, despite limited evidence of efficacy.",
"   </p>",
"   <p>",
"    Despite this large number of possible therapeutic agents, the ability to recommend specific alternative therapies is hampered by the lack of well-controlled trials, the small numbers of patients evaluated in existing studies, and the substantial costs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    side effects associated with some of these therapies. As a result, it is difficult to determine with certainty if one alternative therapy is superior to another, or to presently available therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77146118\">",
"    <span class=\"h2\">",
"     Tiotropium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"     Tiotropium",
"    </a>",
"    , an inhaled anticholinergic bronchodilator, is approved for once daily treatment of chronic obstructive pulmonary disease, but not asthma. In Europe, tiotropium is administered via a Respimat inhaler (2 inhalations of 2.5 mcg), which is roughly comparable to the dry-powder Handihaler device (18 mcg) used in the United States. A small number of studies have evaluated tiotropium as a potential therapy for asthma. Trials of tiotropium as add-on therapy for severe asthma and the role of tiotropium in COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link&amp;anchor=H16608339#H16608339\">",
"     \"Treatment of severe asthma in adolescents and adults\", section on 'Tiotropium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33305?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of anticholinergic therapy in COPD\", section on 'Tiotropium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      on asthma control was examined in the Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC) trial [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/19\">",
"       19",
"      </a>",
"      ]. The TALC trial randomly assigned 210 patients with moderate persistent asthma, whose disease was not well-controlled by inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      , 80 mcg twice daily, to three treatment arms: addition of tiotropium to beclomethasone, doubling the dose of beclomethasone, or addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      to beclomethasone. Based on morning peak expiratory flow (mean difference of 25.8 liters per minute), evening peak expiratory flow, and symptom scores, the addition of tiotropium to beclomethasone resulted in improved asthma control relative to doubling the dose of beclomethasone and was not inferior to addition of salmeterol. Further trials are needed to evaluate safety and efficacy with long-term treatment.",
"     </li>",
"     <li>",
"      The efficacy and safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      were compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      and placebo in patients with moderate-to-severe asthma who have the beta2-adrenergic receptor",
"      <span class=\"nowrap\">",
"       B16-Arg/Arg",
"      </span>",
"      genotype. Tiotropium was not inferior to salmeterol in the primary outcome of changes in morning peak expiratory flow (PEF); both active treatments were better than placebo. This trial is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link&amp;anchor=H16608339#H16608339\">",
"       \"Treatment of severe asthma in adolescents and adults\", section on 'Tiotropium'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nebulized lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of studies have shown nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    to be beneficial in asthma management, although the drug is associated with seizures and fatalities in overdose and is not currently being developed commercially for use in asthma.",
"   </p>",
"   <p>",
"    A randomized trial evaluated the efficacy of nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (4 percent solution, 100 mg four times daily) compared to placebo in 50 patients with mild-to-moderate asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/20\">",
"     20",
"    </a>",
"    ]. All subjects were receiving inhaled glucocorticoid therapy at baseline, and additionally received nebulized lidocaine or placebo. Treatment took place over two months, during which subjects were instructed to reduce their inhaled glucocorticoid medication by one-half at weekly intervals, and discontinue it at week four. Patients receiving lidocaine showed improvements in symptom scores, nighttime awakenings, bronchodilator use, forced expiratory volume in one second (FEV1), and eosinophil counts. Patients inhaling placebo showed decrements in these measurements of asthma severity.",
"   </p>",
"   <p>",
"    An earlier uncontrolled trial showed benefit in patients with severe, glucocorticoid-dependent asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/21\">",
"     21",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    has also been shown to inhibit exercise-induced bronchospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/22\">",
"     22",
"    </a>",
"    ]. Antiinflammatory effects of lidocaine have been postulated [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/23\">",
"     23",
"    </a>",
"    ], although the role of this mechanism in asthma patients has not been demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nebulized heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    decreases inflammation, smooth muscle proliferation, eosinophil recruitment, and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The effect of nebulized heparin on airway inflammation and hyperresponsiveness has been evaluated in patients with asthma and allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. One placebo controlled study in patients with atopic asthma examined the effect upon the late asthmatic response (LAR) and the baseline forced expiratory volume in one second (FEV1) of multiple doses of nebulized heparin (1,000",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per dose) given at 90 and 30 minutes pre-allergen and at 2, 4, and 6 hours post-allergen [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/27\">",
"     27",
"    </a>",
"    ]. In this study, nebulized heparin was found to significantly reduce the LAR (p = 0.005). In addition, although no statistically significant difference was found between the acute effects of heparin and placebo upon baseline FEV1, a beneficial trend with heparin was observed (p = 0.08). Whether heparin is clinically beneficial in the management of chronic asthma is the subject of ongoing investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immune modulatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous agents with antiinflammatory properties have been studied in an effort to eliminate or decrease the inflammation that underlies chronic asthma. These agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , gold,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , intravenous immunoglobulin (IVIG),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , macrolide antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) (5 to 50 mg per week) is an established and approved form of therapy for certain inflammatory diseases, including psoriasis and both psoriatic and rheumatoid arthritis. MTX, however, is associated with a frequent incidence of side effects, seen in up to one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several mechanisms have been proposed to explain the effect of MTX in asthmatic patients, including an increased sensitivity of lymphocytes to the inhibitory effects of glucocorticoid, as well as a reduction in serum immunoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. As observed with a number of other alternative therapies, studies evaluating the effectiveness of MTX in patients with asthma have reported varying efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/33-39\">",
"     33-39",
"    </a>",
"    ]. Thus, it is difficult to determine the true effectiveness of this agent.",
"   </p>",
"   <p>",
"    A meta-analysis selecting 12 randomized, double-blind, placebo controlled trials in which low dose MTX was given to glucocorticoid-dependent asthmatics has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/40\">",
"     40",
"    </a>",
"    ]. The use of MTX was associated with a 6 percent improvement in FEV1 and a 3.3",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    reduction in oral glucocorticoid use. A second systematic review also noted a 3 to 4 mg reduction in daily glucocorticoid dose; however, no significant improvement in spirometry was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastrointestinal complaints and transient elevations in liver enzymes were more common in patients randomized to MTX, and 3 patients with MTX developed potentially life-threatening complications, including pneumonitis in 2 patients, and severe liver dysfunction in 1 patient.",
"   </p>",
"   <p>",
"    Although the overall risk of significant side effects with MTX appears to be small, its use has also been reported to result in an increased risk of Pneumocystis pneumonia, which can cause death [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/36,41,42\">",
"     36,41,42",
"    </a>",
"    ]. Therefore, MTX may offer no significant overall clinical benefit over aggressive conventional therapy combined with close follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gold",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise mechanism of action by which gold exerts an antiinflammatory effect is unknown, but it has been reported to inhibit neutrophil and lymphocyte activity, antibody secretion, and IgE-induced release of histamine. Japanese investigators have the largest clinical experience with gold therapy in patients with asthma, using open trial design [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. The following is a synthesis of the results of these trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 20 to almost 50 percent of patients, the response to treatment may be delayed; for example, up to five months of therapy may elapse prior to any observed therapeutic effect.",
"     </li>",
"     <li>",
"      In oral glucocorticoid-dependent asthmatics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"       auranofin",
"      </a>",
"      (oral gold) appears to be more effective in patients receiving between 10 and 19 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      per day [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adverse reactions, which are less frequent with oral than parenteral forms, limit the usefulness of gold in asthma. Side effects include mucocutaneous reactions, exfoliative dermatitis, renal toxicity, hematologic abnormalities (including aplastic anemia), and interstitial pneumonitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=see_link\">",
"       \"Major side effects of gold\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34918?source=see_link\">",
"       \"Gold-induced pulmonary disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis from the Cochrane database evaluated 311 stable patients with glucocorticoid-dependent asthma who were studied before and after treatment with gold; there was a small but significant decrease in their required glucocorticoid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/48\">",
"     48",
"    </a>",
"    ]. There were insufficient data to study effects on lung function or other clinical outcomes. Gold was associated with an increased risk of proteinuria and dermatologic reactions, although this trend was not significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    may have a glucocorticoid-sparing effect in approximately 50 percent of patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/49-53\">",
"     49-53",
"    </a>",
"    ]. Cyclosporine probably works by altering lymphokine (IL-2, IL-4, IL-5) production by T-lymphocytes, and IL-1 production by monocytes and macrophages. Cyclosporine may also induce apoptosis of CD4+ T-lymphocytes, which are crucial to the late asthmatic response [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three placebo controlled trials, using parallel or crossover design, have been systematically reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/55\">",
"     55",
"    </a>",
"    ]. Overall,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    treatment resulted in a 0.5 to 1 mg reduction in the required daily glucocorticoid dose, with a modest improvement in spirometry noted in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For this indication, typical doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    range from 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, with serum concentrations between 120 and 150",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    These doses and levels are lower than those normally seen among patients taking cyclosporine following organ transplantation.",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are minimized with low dose therapy. However, they still can occur, and include hypertension, renal and liver impairment, hypertrichosis, paresthesias, tremor, and headache. As a result, the",
"    <span class=\"nowrap\">",
"     benefit/risk",
"    </span>",
"    ratio with the use of cyclosporine does not appear large enough to replace the use of oral steroids. Aerosolized cyclosporine, designed to limit systemic absorption and side effects, is under active investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    is an antiinflammatory agent primarily used for the control of gouty arthritis and familial Mediterranean fever. Although low dose oral colchicine (0.6 mg bid) is inexpensive and has few significant side effects, studies examining the effectiveness of colchicine in asthmatics have also revealed mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective multicenter study evaluated the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    to be substituted for inhaled glucocorticoids in moderate asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients were stabilized on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide (400 mcg twice daily) and then enrolled in a two-week run-in period, during which all 71 patients took both colchicine (0.6 mg twice daily) and triamcinolone. The patients were then randomized to colchicine or placebo with discontinuation of the inhaled glucocorticoid. After glucocorticoid withdrawal, 60 percent of colchicine-treated and 56 percent of placebo-treated subjects were considered treatment failures. There were no significant differences between the placebo and colchicine groups with regard to \"survival\" curves, FEV1, peak flow, symptoms, rescue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    use, or quality of life scores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hydroxychloroquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimalarial agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    is effective in a number of connective tissue diseases, including rheumatoid arthritis and lupus erythematosus. The only serious adverse effect appears to be the development of a dose-dependent retinopathy, which can culminate in blindness. As observed with other agents, trials report conflicting results concerning the efficacy of this agent among patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Administered doses ranged from 300 to 400 mg per day. The dose is adjusted for body weight to keep it below 6.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous or subcutaneous immunoglobulin (IG, also known as IVIG when given intravenously) is used as replacement therapy in certain immune deficiency disorders and as an immunomodulator in various immune-mediated disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to its general antiinflammatory actions, IG has been investigated as a possible therapeutic agent in patients with severe asthma. The limited number of studies using high-dose (eg, 1 to 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per month) IVIG for asthma have yielded conflicting results; however, the largest trials did not support a beneficial effect, as illustrated by the following examples [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/62-68\">",
"     62-68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter trial, patients with severe asthma were randomly assigned to one of three groups, 2 g",
"      <span class=\"nowrap\">",
"       IVIG/kg",
"      </span>",
"      per month (16 patients); 1 g",
"      <span class=\"nowrap\">",
"       IVIG/kg",
"      </span>",
"      per month (9 patients); or 2 g IV albumin",
"      <span class=\"nowrap\">",
"       (placebo)/kg",
"      </span>",
"      per month (15 patients) for seven months [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/68\">",
"       68",
"      </a>",
"      ]. The primary outcome was mean daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      -equivalent dose requirements and there was no significant difference in this parameter among the groups. In addition, no differences were noted in the number of emergency department visits, hospitalizations, or missed days of work or school. Three patients in the high dose IVIG group developed symptoms consistent with aseptic meningitis.",
"     </li>",
"     <li>",
"      A prospective, double-blind, placebo controlled trial was performed in children with severe bronchial asthma, and incorporated a two month stabilization period, three month treatment period of IVIG (1",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      or placebo, and one additional month of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/65\">",
"       65",
"      </a>",
"      ]. The IVIG or placebo was given as two initial doses one day apart then two additional doses at four-week intervals. There were no statistical differences between groups in symptom scores, bronchial hyperreactivity, or peak flow variability. Although the incidence of upper respiratory tract infections was also similar between groups, the IVIG group appeared to have less protracted infections.",
"     </li>",
"     <li>",
"      Another double-blind, placebo controlled trial of IVIG (loading dose 2",
"      <span class=\"nowrap\">",
"       g/kg,",
"      </span>",
"      then 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 3 weeks) in 28 patients showed mixed results [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/66\">",
"       66",
"      </a>",
"      ]. Significant reduction in oral GC dose was observed with both IVIG and placebo, which reinforces the necessity of placebo controlled studies. Only patients requiring &gt;2000 mg of oral glucocorticoid (GC) in the year prior to the study had a significant reduction of oral GC dose with IVIG therapy.",
"     </li>",
"     <li>",
"      One open label, uncontrolled study of high dose IVIG over 6 months investigated potential mechanisms of action [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/67\">",
"       67",
"      </a>",
"      ]. IVIG acted synergistically with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in suppressing lymphocyte activation and significantly improved GC binding affinity, although no difference in efficacy was observed among GC sensitive and GC insensitive asthmatics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=see_link\">",
"       \"Glucocorticoid-resistant asthma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    has both well-known antimicrobial activity (eg, in leprosy) and antiinflammatory effects, and it has therefore been evaluated as a possible therapeutic agent for chronic asthma. One open trial of 10 patients with asthma, for example, found that twice a day treatment with 100 mg of dapsone had significant GC-sparing effects [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/69\">",
"     69",
"    </a>",
"    ]. In this study, the average cumulative monthly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose decreased from 428 to 82 mg; despite this decrease in GC use, pulmonary function and asthmatic symptoms remained unchanged. Nine of the ten patients, however, developed significant anemia, with an average fall in hemoglobin of 3.6",
"    <span class=\"nowrap\">",
"     gm/dL.",
"    </span>",
"    A subsequent systematic review concluded that, given the absence of a randomized controlled trial, there was no reliable evidence to support the use of dapsone in the management of chronic severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Macrolide antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrolide antibiotics have both antimicrobial and antiinflammatory actions that may be useful in asthma treatment. Some patients with severe asthma have persistent infection with Chlamydophila pneumoniae or Mycoplasma pneumoniae that may contribute to neutrophilic inflammation in the airways and poor asthma control [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. One possible role for macrolide antibiotic therapy is to eradicate these infections. Another hypothesis is that macrolides may be useful as glucocorticoid-sparing agents due to their antiinflammatory effects.",
"   </p>",
"   <p>",
"    A randomized trial that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    500 mg twice daily for eight weeks with placebo in 45 patients with refractory asthma found improvements in airway neutrophil numbers and quality of life, but not asthma control scores, lung function, or airway hyperresponsiveness to hypertonic saline [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/73\">",
"     73",
"    </a>",
"    ]. In a separate randomized trial, clarithromycin or placebo was added to inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    in patients with mild-to-moderate asthma that was suboptimally controlled on fluticasone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/74\">",
"     74",
"    </a>",
"    ]. Treatment assignments were stratified based on positive or negative evidence of M. pneumoniae or C. pneumoniae infection on polymerase chain reaction (PCR) of endobronchial biopsies. An improvement in airway hyperresponsiveness was noted, but asthma control, lung function, and airway inflammation did not change. No significant difference was noted between the groups with or without evidence of lower airway infection.",
"   </p>",
"   <p>",
"    Troleandomycin is a macrolide antibiotic that was used in the past as a glucocorticoid-sparing agent in chronic, severe asthma. Its mechanism of action is primarily related to reduced hepatic glucocorticoid metabolism rather than specific antiinflammatory or antibacterial properties. However, a meta-analysis of 112 patients in three studies failed to show a significant reduction in the required dose of oral glucocorticoids in patients treated with troleandomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/75\">",
"     75",
"    </a>",
"    ]. There was no improvement in lung function when pooled data from two of these studies were analyzed.",
"   </p>",
"   <p>",
"    A broader systematic review of macrolide therapy for chronic asthma, including studies of roxithromycin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    as well as troleandomycin, found insufficient data on which to base a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Anti-TNFa agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials of anti-TNF-alpha agents have been performed in patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. Anti-tumor necrosis factor-alpha (TNF-a) agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    . Infliximab and golimumab are monoclonal antibodies that bind and neutralize tumor necrosis factor alpha (TNFa). Etanercept is a soluble TNFa receptor fusion protein that binds TNFa and has a longer half life than the native soluble receptor.",
"   </p>",
"   <p>",
"    Overall, these studies do NOT support a beneficial effect for anti-TNFa agents in the treatment of asthma. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large trial randomly assigned 309 patients with severe asthma to treatment with the fully humanized monoclonal antibody to TNF-alpha,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      , or placebo for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/77\">",
"       77",
"      </a>",
"      ]. The trial did not achieve the primary endpoints of reduction in exacerbations and improvement in FEV1; substantial side effects were noted.",
"     </li>",
"     <li>",
"      In a randomized, open-label study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      was administered for 12 weeks to 10 patients with refractory asthma, 10 patients with mild-to-moderate asthma, and 10 patients without asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/78\">",
"       78",
"      </a>",
"      ]. None of the subjects could reduce or discontinue other therapies, although most patients experienced statistically significant improvements in symptom scores and quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Anti-IL-2R antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of Th2 cells by allergen leads to production of interleukin 2 (IL-2) and its receptor IL-2R. Binding of IL-2 to Th2 cells expressing IL-2R leads to proliferation of that clone of specifically sensitized Th2 cells. The humanized monoclonal antibody to the CD25 subunit of IL-2R, daclizumab, inhibits various T cell functions, including T cell proliferation and cytokine production. The potential role of daclizumab in the treatment of moderate to severe asthma was examined in a study of 115 patients randomized to intravenous daclizumab or placebo (3:1) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/80\">",
"     80",
"    </a>",
"    ]. Daclizumab treatment was associated with small improvements in pulmonary function and asthma control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Anti-IL-5 antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-interleukin 5 (IL-5) antibodies have been studied in asthma because of the potent effect of IL-5 on eosinophil recruitment to the airways. It is hypothesized that anti-eosinophil therapy with an anti-IL-5 monoclonal antibody (eg, mepolizumab, reslizumab) may be beneficial in a small subgroup of patients with uncontrolled asthma and persistent airways eosinophilia despite glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/81\">",
"     81",
"    </a>",
"    ]. Evidence for this comes from the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the multicenter Dose Ranging Efficacy And safety with Mepolizumab in severe asthma (DREAM) trial, 621 patients with severe recurrent asthma exacerbations and evidence of eosinophilic inflammation (eg, sputum eosinophils, peripheral blood eosinophilia, elevated exhaled nitric oxide) were randomly assigned to intravenous mepolizumab (75 mg, 250 mg, 750 mg), 13 infusions at 4 week intervals [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/82\">",
"       82",
"      </a>",
"      ]. The rate of clinically significant exacerbations was decreased in all mepolizumab groups compared with placebo with the greatest reduction in the 750 mg group (52 percent reduction, 95% CI 36-64%). However, symptoms and pulmonary function were not consistently improved. The possibility of a glucocorticoid sparing effect was not addressed.",
"     </li>",
"     <li>",
"      In one study, 61 patients with refractory eosinophilic asthma were randomly assigned to mepolizumab infusions or placebo for 50 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/83\">",
"       83",
"      </a>",
"      ]. Mepolizumab therapy was associated with a decreased risk of exacerbation (RR 0.57; 95% CI, 0.32 to 0.92) and an improvement in quality of life.",
"     </li>",
"     <li>",
"      In another study, 20 patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      -dependent, eosinophilic asthma were randomly assigned to mepolizumab infusions or placebo for 5 months [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/84\">",
"       84",
"      </a>",
"      ]. A reduction in the number of exacerbations was noted in the mepolizumab group (p=0.008).",
"     </li>",
"     <li>",
"      In a randomized trial, 106 patients with poorly-controlled eosinophilic asthma received intravenous infusions of reslizumab or placebo for 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/85\">",
"       85",
"      </a>",
"      ]. The reslizumab group had a greater reduction in sputum eosinophils and improved airflow obstruction, but only a trend toward improved asthma control as measured by the Asthma Control Questionnaire (ACQ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, previous studies of anti-IL-5 antibodies, performed in patients with milder asthma that was not necessarily eosinophilic have not shown benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/86-88\">",
"     86-88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32959293\">",
"    <span class=\"h3\">",
"     Anti-IL-13 antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-13 (IL-13) promotes IgE production by B cells, generation of eosinophil chemoattractants, and contractility of airway smooth muscle cells, among other effects, and is therefore of interest as a potential target for asthma therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis of asthma\", section on 'Th2 lymphocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a preliminary study, the effect of IL-13 antibodies on late phase asthmatic responses to inhaled allergen was assessed in subjects with mild atopic asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/89\">",
"     89",
"    </a>",
"    ]. Subjects were randomly assigned to receive one of two anti-IL-13 antibodies (one that blocks the IL-13 epitope, which binds to the IL-4 receptors, and another that blocks the epitope recognized by only IL-13 receptors) or placebo, administered subcutaneously in two doses a week apart. The antibody that blocked the IL-4 epitope substantially reduced the fall in forced expiratory volume in one second (FEV1) following allergen inhalation, when assessed at 14, but not 35, days following injection. The other antibody did not attenuate the asthmatic response to allergen inhalation on either day.",
"   </p>",
"   <p>",
"    The humanized IgG4 monoclonal anti-IL-13 antibody lebrikizumab was compared with placebo in 219 subjects with asthma that was inadequately controlled at baseline by medium-to-high dose of inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/90\">",
"     90",
"    </a>",
"    ]. At 12 weeks, subjects who received lebrikizumab had a significant increase in FEV1 (mean 5.5 percent); however, the improvement in FEV1 was no longer significant at 24 weeks. A subgroup analysis found that subjects with high initial peripheral blood periostin levels (an indirect measure of baseline IL-13 activity) had a greater response to lebrikizumab than the low-periostin group. No differences in asthma exacerbations, symptom scores, or beta agonist rescue use were noted over the 24 weeks of the trial.",
"   </p>",
"   <p>",
"    The effect of tralokinumab, a different human IgG4 monoclonal antibody to IL-13, was assessed in 194 adults with moderate-to-severe uncontrolled asthma in a dose ranging trial [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/91\">",
"     91",
"    </a>",
"    ]. Patients were randomly assigned to receive tralokinumab or placebo subcutaneously every two weeks for 13 weeks. The primary end-point of the change from baseline in mean Asthma Control Questionnaire score was not different between the groups. The improvement in FEV",
"    <sub>",
"     1",
"    </sub>",
"    in the tralokinumab group compared with placebo did not reach statistical significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with asthma are sensitized to fungi such as Alternaria, Aspergillus, Cladosporium, Penicillium, Candida, and Trichophyton [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. It is hypothesized that external exposure to these airborne fungi may lead to low level airway colonization, sufficient to cause an ongoing allergic reaction. A randomized trial examined whether treating patients with severe asthma with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    for 32 weeks would lead to improved asthma control [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/92\">",
"     92",
"    </a>",
"    ]. The Asthma Quality of Life Questionnaire (AQLQ) score, morning peak flow, and total serum IgE were all statistically improved in the itraconazole group, although these improvements were not sustained after discontinuation of itraconazole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link&amp;anchor=H17#H17\">",
"     \"Allergic bronchopulmonary aspergillosis\", section on 'Antifungal agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Herbal medicines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chinese herbs have been used for centuries in Asia to treat asthma. A discussion regarding the use of Chinese herbal medicine to treat asthma is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31496?source=see_link&amp;anchor=H3#H3\">",
"     \"Chinese herbal medicine for the treatment of allergic diseases\", section on 'Therapy for asthma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nonpharmacologic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several nonpharmacologic approaches to asthma management have been proposed, including acupuncture, massage, breathing exercises, herbal medications, and dietary alterations. A 10-step process on how to handle requests for alternative and complementary therapy may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence in support of these nonpharmacologic therapies is limited by the small number and size of well-designed trials, and the lack of clinically significant differences between intervention and placebo groups in most reports. A meta-analysis of 15 trials, many of which are discussed in detail below, found insufficient evidence to recommend any of these interventions as a useful addition to standard asthma management [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/95\">",
"     95",
"    </a>",
"    ]. A subsequent systemic review reached the same conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been multiple reports of acupuncture as a therapy for asthma. Most studies were uncontrolled, but with positive outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. In contrast, a prospective sham-controlled crossover study of acupuncture therapy in 20 patients with moderate persistent asthma found that acupuncture was not associated with any improvement in pulmonary function, airway hyperreactivity, or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/99\">",
"     99",
"    </a>",
"    ]. Another controlled study again demonstrated no benefit in asthma control with acupuncture [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/100\">",
"     100",
"    </a>",
"    ]. Sixty-six subjects with mild to moderate asthma were randomly assigned to real or sham acupuncture, or no acupuncture at all. Various asthma outcomes were similar in all groups.",
"   </p>",
"   <p>",
"    A meta-analysis of 11 randomized, placebo controlled trials conducted between 1970 and 2000 found acupuncture was not associated with significant clinical improvements in asthmatic control; however, the range of trial designs, missing information, and small sample sizes underscored the need for larger, better-designed trials to definitively address the question [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Chiropractic manipulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the few controlled trials using chiropractic techniques was reported in 80 children who received either active spinal manipulation or a simulated technique [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/102\">",
"     102",
"    </a>",
"    ]. All children were receiving standard medical treatment and had mild to moderate asthma. Outcomes were analyzed at 2 and 4 months of therapy, and there were no significant differences noted between groups in morning peak flow rates, symptoms of asthma, use of beta-agonists, quality of life measurements, spirometric measurements, or airway responsiveness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41222?source=see_link\">",
"     \"Spinal manipulation in the treatment of musculoskeletal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Massage therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study that evaluated the effect of parents giving massage therapy to their children for 20 minutes each night before bed yielded interesting results [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/103\">",
"     103",
"    </a>",
"    ]. Children 4 to 8 years of age had better results than those between 9 to 14 years. The younger group showed an immediate decrease in behavioral anxiety and cortisol levels after massage; their attitude toward asthma and their pulmonary function tests also improved over the month of the study. The older group reported lower anxiety and better attitude toward their asthma, but the forced expiratory flow at 25 to 75 percent of forced vital capacity (FEF 25-75) was the only spirometric parameter that improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Breathing exercises",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breathing techniques designed to prolong exhalation and decrease minute ventilation have been studied as nonpharmacologic therapies for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/104-108\">",
"     104-108",
"    </a>",
"    ]. Pranayama, or yoga breathing exercises, emphasize deep respiration with slow exhalation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/104-106,109-111\">",
"     104-106,109-111",
"    </a>",
"    ]. Similarly, Buteyko breathing exercises were developed based on the theory that a reduction in minute ventilation might improve asthmatic control [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/105,107,112\">",
"     105,107,112",
"    </a>",
"    ]. Most studies of these approaches show no significant benefit, but have been limited by small sample size or retrospective analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/113\">",
"     113",
"    </a>",
"    ]. However, data from systematic reviews and randomized controlled trials provide evidence of benefit, although confirmation is needed with additional trials that better specify baseline breathing patterns and are free of methodologic concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/114-118\">",
"     114-118",
"    </a>",
"    ]. In the largest trial (single blind), 183 patients with asthma were randomly assigned to physiotherapist-supervised breathing training or asthma nurse-delivered asthma education. Improvements in asthma quality of life, anxiety, and depression occurred in the breathing training group, as well as a trend toward an improvement in asthma control based on the Asthma Control Questionnaire (ACQ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/115\">",
"     115",
"    </a>",
"    ]. No changes were noted in measures of airway physiology or inflammation.",
"   </p>",
"   <p>",
"    A separate randomized controlled trial compared use of an expiratory flow-limiting device (designed to simulate Pranayama breathing) with training in Buteyko breathing in 90 asthmatic adults [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/105\">",
"     105",
"    </a>",
"    ]. A control group used a sham device identical to the flow-limiting device, and patients were followed for six months. Neither intervention resulted in decreased bronchial hyperresponsiveness, assessed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge, or improvements in lung function, based on FEV1. However, patients who used Buteyko breathing reported fewer symptoms and a decrease in the use of inhaled bronchodilators.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Biofeedback and functional relaxation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians, psychologists, social workers, and other mainstream health professionals use biofeedback and relaxation techniques to treat a range of disorders. Most systematic reviews assessing studies of biofeedback and asthma severity have not detected a significant effect [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]. However, a subsequently published controlled trial of 94 asthmatic patients found that those trained in heart rate variability biofeedback, with or without breathing modifications, experienced decreased medication usage, fewer symptoms and improved pulmonary function when compared to a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/122\">",
"     122",
"    </a>",
"    ]. If confirmed in larger trials, this approach may be particularly useful in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35529?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of complementary and alternative medicine in pediatrics\", section on 'Guided imagery and biofeedback'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of functional relaxation and guided imagery techniques on lung function was assessed in a randomized trial with 64 patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/123\">",
"     123",
"    </a>",
"    ]. After four weeks, those in the functional relaxation groups experienced increases in forced expiratory volume in one second (FEV1) compared with placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Dietary alterations",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is very difficult to study the impact of dietary changes upon the course of asthma and most studies show no effect [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/124,125\">",
"     124,125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antioxidants &ndash; Patients with severe asthma appear to have decreased plasma levels of both dietary and nondietary antioxidants, providing the rationale of antioxidant supplementation in these individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/126\">",
"       126",
"      </a>",
"      ]. One study using ozone-induced challenge in asthma suggested a small, but significant effect of 400 international units of vitamin",
"      <span class=\"nowrap\">",
"       E/500",
"      </span>",
"      mg vitamin C on sulfur dioxide inhalation challenge following ozone exposure; however, other studies of vitamin E supplementation alone have failed to show a therapeutic effect [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/127,128\">",
"       127,128",
"      </a>",
"      ]. The clinical relevance of these findings needs to be clarified in larger studies [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/129\">",
"       129",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"       \"Vitamin supplementation in disease prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Omega-3 fatty acids &ndash; Diets rich in antiinflammatory omega-3 fatty acids have been proposed to be beneficial in the treatment of asthma. A systemic review of the literature was unable to find any evidence of benefit, although this was largely attributable to inconsistency in study design and measures of respiratory outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/130\">",
"       130",
"      </a>",
"      ]. Subsequent to this analysis, one study demonstrated positive effects of omega-3 fatty acids (fish oil supplements) in patients with exercise-induced bronchoconstriction (EIB). This double blind, crossover study randomly assigned 16 subjects to treatment with 3 weeks of supplements (containing 3.2 g of eicosapentaenoic acid and 2 g of docosahexaenoic acid) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/131\">",
"       131",
"      </a>",
"      ]. The group on fish oil supplements had reduced leukotriene, PGD2, IL-1 beta, and TNF alpha in induced sputa. Pulmonary function improved and bronchodilator use was reduced. This suggests that a diet enriched with omega-3 fatty acids may be helpful in asthmatics with EIB, a finding that warrants further study.",
"      <br/>",
"      <br/>",
"      A meta-analysis found no benefit to dietary supplementation with omega 3 or omega 6 fatty acids in the prevention of allergic sensitization [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low calorie diets &ndash; There are very limited numbers of well-performed studies examining low calorie diets in the treatment of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/133\">",
"       133",
"      </a>",
"      ]. One study from Finland reported that obese patients with asthma randomized to a supervised weight reduction program manifested small but significant improvements in lung function and health status [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/134\">",
"       134",
"      </a>",
"      ]. It is not known if low calorie diets would benefit non-obese people with asthma.",
"     </li>",
"     <li>",
"      Elimination diets &ndash; While a rare patient has food allergies, radical alteration of diet or the use of emetic or purgative drugs has no role in asthma treatment at this time [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/135\">",
"       135",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Magnesium supplementation &ndash; Intravenous magnesium is used as adjuvant therapy for acute asthma exacerbations. To determine whether chronic magnesium supplementation would improve asthma control, 55 adults with mild to moderate asthma were randomly assigned to oral magnesium supplementation 340 mg daily or placebo for 6.5 months [",
"      <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/136\">",
"       136",
"      </a>",
"      ]. Magnesium supplementation was associated with improved asthma control and quality of life and also decreased bronchial hyperreactivity to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      challenge, but only a marginal improvement in peak expiratory flow rate. Further evaluation of magnesium supplementation in patients with symptomatic asthma is warranted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84379794\">",
"    <span class=\"h3\">",
"     Speleotherapy and halotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Speleotherapy and halotherapy are types of &ldquo;physical therapies&rdquo; that have been pursued in countries of the former Soviet Union to avoid the costs and side effects of drug-based therapies, as well as the problems of microbial and tumor resistance. Thus, the majority of the clinical trials are reported in Russian-language journals and have focused on the treatment of asthma, chronic bronchitis, and other respiratory diseases. Physical therapies are most commonly used in spas in central and eastern Europe and around the Dead Sea in Israel.",
"   </p>",
"   <p>",
"    Speleotherapy involves spending time in underground environments (from &ldquo;speleos,&rdquo; which is Greek for cave). People spend short periods in specifically designated caves or mines, sometimes doing particular physical or breathing exercises. Some forms involve longer stays on special wards. Speleotherapy is most commonly used in northern Mediterranean and Aegean Sea cultures. Benefit is believed to result from air quality, air pressure, underground climate, or radon or radiation exposure. No evidence from randomized controlled trials has demonstrated an effect greater than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/119,137\">",
"     119,137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Halotherapy (from &ldquo;halos,&rdquo; Greek for salt) uses dry aerosol microparticles of salt or minerals to simulate the microclimate of salt mines. It has been used to treat a variety of &ldquo;chronic&rdquo; respiratory diseases including asthma and, occasionally, upper respiratory problems such as chronic sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/138-141\">",
"     138-141",
"    </a>",
"    ]. The effect of halotherapy was examined in 29 patients with moderate asthma who were randomly assigned to halotherapy or placebo inhalation five times a week for two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/142\">",
"     142",
"    </a>",
"    ]. Bronchial responsiveness to histamine challenge decreased slightly in the halotherapy group. In a separate trial, peak expiratory flow and rescue bronchodilator use did not differ between active and placebo groups [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Bronchial thermoplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial thermoplasty (BT) refers to a technique of applying controlled radiofrequency waves to the airways during bronchoscopy to theoretically reduce the increased mass of airway smooth muscle associated with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/144-148\">",
"     144-148",
"    </a>",
"    ]. The goal is to attenuate bronchoconstriction and airway hyperresponsiveness.",
"   </p>",
"   <p>",
"    Three separate bronchoscopies are performed under moderate sedation about three weeks apart. A radiofrequency controller and a specialized catheter are used to administer thermal energy (target tissue temperature 65��C) to the airway walls. All accessible airways distal to the mainstem bronchus that are 3 to 10 mm in diameter are treated once, except those in the right middle lobe, which are left untreated due to accessibility issues.",
"   </p>",
"   <p>",
"    In a trial of BT for severe asthma, 288 patients were randomly assigned to BT or a sham procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/149\">",
"     149",
"    </a>",
"    ]. Patients with a history of life-threatening asthma or three or more hospitalizations for asthma in the previous year were excluded. A statistically, but not clinically significant, improvement in the primary endpoint, Asthma Quality of Life Questionnaire (AQLQ), was noted. There were no differences in the secondary outcomes of changes in asthma control, symptom-free days, peak expiratory flow, forced expiratory volume in one second, and use of rescue medication. In a separate trial without sham control, BT reduced the frequency of mild exacerbations in patients with moderate to severe persistent asthma, although there was no effect on the rate of severe exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/147\">",
"     147",
"    </a>",
"    ]. In another randomized nonblinded trial in 34 patients with severe asthma, BT resulted in an initial worsening of asthma control and seven hospitalizations for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/150\">",
"     150",
"    </a>",
"    ]. However, after the perioperative period, the BT group experienced improvements in rescue medication use and Asthma Control Questionnaire scores that persisted over 52 weeks of the study.",
"   </p>",
"   <p>",
"    The Food and Drug Administration has approved marketing of Alair Bronchial Thermoplasty System for the treatment of adult patients (&ge;18 years old) with severe asthma not well-controlled with inhaled glucocorticoids and long-acting beta agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?32/36/33354/abstract/151\">",
"     151",
"    </a>",
"    ]. Due to the risk of the procedure and modest degree of improvement, additional data are needed regarding long-term effects and morphologic changes in the airways prior to determining when to use BT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, data from well-controlled trials are limited regarding use of alternative forms of therapy in both acute and chronic settings. As a result, it is difficult to compare these agents with currently available forms of therapy or make specific recommendations regarding their use. However, the following approach may be of value:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Therapies for acute exacerbations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the acute situation, if the patient is not responding and facing intubation with mechanical ventilation, helium-oxygen mixture can be rapidly tried and evaluated. This step should not delay intubation when it is needed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With the patient on the ventilator and high pressures being needed, again not responding to standard medications, general anesthesia can be tried with the purpose of preventing barotrauma from mechanical ventilation. Alternatively, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      may be given. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Therapies for chronic asthma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the chronic situation, the \"first alternative therapy\" should be frequent patient visits, even at weekly intervals. This will improve compliance, and evaluation of inhaler technique can be done with corrections as needed. These steps usually obviate the need for \"alternative agents.\" (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Nonpharmacologic interventions'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Evidence supporting the use of alternative and complementary medical approaches to improve asthma management is limited. Most studies suggest that such an effect, if present, is small. The risks and benefits of such an approach should be considered on a case-by-case basis. A 10 step approach may be useful in addressing requests for alternative or complementary therapy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Nonpharmacologic interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/1\">",
"      National Asthma Education and Prevention Program. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002. J Allergy Clin Immunol 2002; 110:S141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/2\">",
"      Graham V, Lasserson T, Rowe BH. Antibiotics for acute asthma. Cochrane Database Syst Rev 2001; :CD002741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/3\">",
"      Rosseel P, Lauwers LF, Baute L. Halothane treatment in life-threatening asthma. Intensive Care Med 1985; 11:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/4\">",
"      Hirshman CA, Bergman NA. Halothane and enflurane protect against bronchospasm in an asthma dog model. Anesth Analg 1978; 57:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/5\">",
"      Bierman MI, Brown M, Muren O, et al. Prolonged isoflurane anesthesia in status asthmaticus. Crit Care Med 1986; 14:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/6\">",
"      Habre W, Wildhaber JH, Sly PD. Prevention of methacholine-induced changes in respiratory mechanics in piglets: a comparison of sevoflurane and halothane. Anesthesiology 1997; 87:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/7\">",
"      SHNIDER SM, PAPPER EM. Anesthesia for the asthmatic patient. Anesthesiology 1961; 22:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/8\">",
"      Shah MV, Hirshman CA. Mode of action of halothane on histamine-induced airway constriction in dogs with reactive airways. Anesthesiology 1986; 65:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/9\">",
"      Strube PJ, Hallam PL. Ketamine by continuous infusion in status asthmaticus. Anaesthesia 1986; 41:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/10\">",
"      Rock MJ, Reyes de la Rocha S, L'Hommedieu CS, Truemper E. Use of ketamine in asthmatic children to treat respiratory failure refractory to conventional therapy. Crit Care Med 1986; 14:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/11\">",
"      Hemming A, MacKenzie I, Finfer S. Response to ketamine in status asthmaticus resistant to maximal medical treatment. Thorax 1994; 49:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/12\">",
"      Denmark TK, Crane HA, Brown L. Ketamine to avoid mechanical ventilation in severe pediatric asthma. J Emerg Med 2006; 30:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/13\">",
"      Shlamovitz GZ, Hawthorne T. Intravenous ketamine in a dissociating dose as a temporizing measure to avoid mechanical ventilation in adult patient with severe asthma exacerbation. J Emerg Med 2011; 41:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/14\">",
"      Pendino JC, Nannini LJ, Chapman KR, et al. Effect of inhaled furosemide in acute asthma. J Asthma 1998; 35:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/15\">",
"      Hinckley JB. Inhaled furosemide in the treatment of acute exacerbations of asthma. Acad Emerg Med 2000; 7:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/16\">",
"      Gonz&aacute;lez-S&aacute;nchez R, Trujillo-Hern&aacute;ndez B, Huerta M, et al. Furosemide plus albuterol compared with albuterol alone in children with acute asthma. Allergy Asthma Proc 2002; 23:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/17\">",
"      Rodr&iacute;guez V&aacute;zquez JC, Pino Alfonso PP, Gassiot Nu&ntilde;o C, P&aacute;ez Prats I. Usefulness of inhaled furosemide in a bronchial asthma attack. J Investig Allergol Clin Immunol 1998; 8:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/18\">",
"      Niven AS, Argyros G. Alternate treatments in asthma. Chest 2003; 123:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/19\">",
"      Peters, SP, Kunselman, SJ, Icitovic, N. Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma. N Engl J Med 2010; 363:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/20\">",
"      Hunt LW, Frigas E, Butterfield JH, et al. Treatment of asthma with nebulized lidocaine: a randomized, placebo-controlled study. J Allergy Clin Immunol 2004; 113:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/21\">",
"      Hunt LW, Swedlund HA, Gleich GJ. Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. Mayo Clin Proc 1996; 71:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/22\">",
"      Enright PL, McNally JF, Souhrada JF. Effect of lidocaine on the ventilatory and airway responses to exercise in asthmatics. Am Rev Respir Dis 1980; 122:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/23\">",
"      She ZW, Liming JD, Fagan JB, et al. Inhibition of hypochlorous acid by lidocaine and native components of alveolar epithelial lining fluid. Am Rev Respir Dis 1991; 144:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/24\">",
"      Koyama N, Kinsella MG, Wight TN, et al. Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells. Circ Res 1998; 83:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/25\">",
"      Li CM, Newman D, Khosla J, Sannes PL. Heparin inhibits DNA synthesis and gene expression in alveolar type II cells. Am J Respir Cell Mol Biol 2002; 27:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/26\">",
"      Lever R, Page C. Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness. Pulm Pharmacol Ther 2001; 14:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/27\">",
"      Diamant Z, Timmers MC, van der Veen H, et al. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med 1996; 153:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/28\">",
"      Vancheri C, Mastruzzo C, Armato F, et al. Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol 2001; 108:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/29\">",
"      Ceyhan B, Celikel T. Effect of inhaled heparin on methacholine-induced bronchial hyperreactivity. Chest 1995; 107:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/30\">",
"      Methotrexate in rheumatoid arthritis. Health and Public Policy Committee, American College of Physicians. Ann Intern Med 1987; 107:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/31\">",
"      Vrugt B, Wilson S, Bron A, et al. Low-dose methotrexate treatment in severe glucocorticoid-dependent asthma: effect on mucosal inflammation and in vitro sensitivity to glucocorticoids of mitogen-induced T-cell proliferation. Eur Respir J 2000; 15:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/32\">",
"      Corrigan CJ, Shiner RJ, Shakur BH, Ind PW. Methotrexate therapy of oral corticosteroid-dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy. Clin Exp Allergy 2005; 35:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/33\">",
"      Mullarkey MF, Blumenstein BA, Andrade WP, et al. Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study. N Engl J Med 1988; 318:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/34\">",
"      Dyer PD, Vaughan TR, Weber RW. Methotrexate in the treatment of steroid-dependent asthma. J Allergy Clin Immunol 1991; 88:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/35\">",
"      Shiner RJ, Nunn AJ, Chung KF, Geddes DM. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990; 336:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/36\">",
"      Erzurum SC, Leff JA, Cochran JE, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study. Ann Intern Med 1991; 114:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/37\">",
"      Trigg CJ, Davies RJ. Comparison of methotrexate 30 mg per week with placebo in chronic steroid-dependent asthma: a 12-week double-blind, cross-over study. Respir Med 1993; 87:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/38\">",
"      Mullarkey MF, Lammert JK, Blumenstein BA. Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann Intern Med 1990; 112:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/39\">",
"      Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000; :CD000391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/40\">",
"      Aaron SD, Dales RE, Pham B. Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials. Respir Med 1998; 92:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/41\">",
"      Kuitert LM, Harrison AC. Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma. Thorax 1991; 46:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/42\">",
"      Vallerand H, Cossart C, Milosevic D, et al. Fatal pneumocystis pneumonia in asthmatic patient treated with methotrexate. Lancet 1992; 339:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/43\">",
"      Miyamoto T. Treatment of bronchial asthma in Japan. Chest 1986; 90:71S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/44\">",
"      Muranaka M, Nakajima K, Suzuki S. Bronchial responsiveness to acetylcholine in patients with bronchial asthma after long-term treatment with gold salt. J Allergy Clin Immunol 1981; 67:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/45\">",
"      Okatani Y. A few clinical statistical observations on the use of Solganal-B-Oleosum n bronchial asthma. J Asthma Res 1980; 17:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/46\">",
"      Muranaka M, Miyamoto T, Shida T, et al. Gold salt in the treatment of bronchial asthma--a double-blind study. Ann Allergy 1978; 40:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/47\">",
"      Bernstein IL, Bernstein DI, Dubb JW, et al. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol 1996; 98:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/48\">",
"      Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001; :CD002985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/49\">",
"      Szczeklik A, Nizankowska E, Dworski R, et al. Cyclosporin for steroid-dependent asthma. Allergy 1991; 46:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/50\">",
"      Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992; 339:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/51\">",
"      Coren ME, Rosenthal M, Bush A. The use of cyclosporin in corticosteroid dependent asthma. Arch Dis Child 1997; 77:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/52\">",
"      Nizankowska E, Soja J, Pinis G, et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995; 8:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/53\">",
"      Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996; 153:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/54\">",
"      Ying S, Khan LN, Meng Q, et al. Cyclosporin A, apoptosis of BAL T-cells and expression of Bcl-2 in asthmatics. Eur Respir J 2003; 22:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/55\">",
"      Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001; :CD002993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/56\">",
"      Fukaya H, Iimura A, Hoshiko K, et al. A cyclosporin A/maltosyl-alpha-cyclodextrin complex for inhalation therapy of asthma. Eur Respir J 2003; 22:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/57\">",
"      Schwarz YA, Kivity S, Ilfeld DN, et al. A clinical and immunologic study of colchicine in asthma. J Allergy Clin Immunol 1990; 85:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/58\">",
"      Fish JE, Peters SP, Chambers CV, et al. An evaluation of colchicine as an alternative to inhaled corticosteriods in moderate asthma. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Am J Respir Crit Care Med 1997; 156:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/59\">",
"      Roberts JA, Gunneberg A, Elliott JA, Thomson NC. Hydroxychloroquine in steroid dependent asthma. Pulm Pharmacol 1988; 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/60\">",
"      Charous BL. Open study of hydroxychloroquine in the treatment of severe symptomatic or corticosteroid-dependent asthma. Ann Allergy 1990; 65:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/61\">",
"      Charous BL. Effectiveness of long-term treatment of severe asthma with hydroxychloroquine (HCQ). Ann N Y Acad Sci 1991; 629:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/62\">",
"      Mazer BD, Gelfand EW. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 1991; 87:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/63\">",
"      Landwehr LP, Jeppson JD, Katlan MG, et al. Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma. Chest 1998; 114:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/64\">",
"      Vrugt B, Wilson S, van Velzen E, et al. Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients. Thorax 1997; 52:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/65\">",
"      Niggemann B, Leupold W, Schuster A, et al. Prospective, double-blind, placebo-controlled, multicentre study on the effect of high-dose, intravenous immunoglobulin in children and adolescents with severe bronchial asthma. Clin Exp Allergy 1998; 28:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/66\">",
"      Salmun LM, Barlan I, Wolf HM, et al. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. J Allergy Clin Immunol 1999; 103:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/67\">",
"      Spahn JD, Leung DY, Chan MT, et al. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol 1999; 103:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/68\">",
"      Ballow M. Is steroid-dependent asthma a disease treatable with intravenous immunoglobulin? Clin Immunol 1999; 91:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/69\">",
"      Berlow BA, Liebhaber MI, Dyer Z, Spiegel TM. The effect of dapsone in steroid-dependent asthma. J Allergy Clin Immunol 1991; 87:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/70\">",
"      Dewey A, Bara A, Dean T, Walters H. Dapsone as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2002; :CD003268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/71\">",
"      Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest 2007; 132:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/72\">",
"      Martin RJ, Kraft M, Chu HW, et al. A link between chronic asthma and chronic infection. J Allergy Clin Immunol 2001; 107:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/73\">",
"      Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/74\">",
"      Sutherland ER, King TS, Icitovic N, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010; 126:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/75\">",
"      Evans DJ, Cullinan P, Geddes DM. Troleandomycin as an oral corticosteroid steroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001; :CD002987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/76\">",
"      Richeldi L, Ferrara G, Fabbri LM, Gibson PG. Macrolides for chronic asthma. Cochrane Database Syst Rev 2002; :CD002997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/77\">",
"      Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/78\">",
"      Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/79\">",
"      Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008; 63:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/80\">",
"      Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008; 178:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/81\">",
"      Wenzel SE. Eosinophils in asthma--closing the loop or opening the door? N Engl J Med 2009; 360:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/82\">",
"      Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/83\">",
"      Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/84\">",
"      Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/85\">",
"      Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/86\">",
"      Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/87\">",
"      Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/88\">",
"      Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/89\">",
"      Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011; 183:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/90\">",
"      Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/91\">",
"      Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013; 41:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/92\">",
"      Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/93\">",
"      Matsuoka H, Niimi A, Matsumoto H, et al. Specific IgE response to trichophyton and asthma severity. Chest 2009; 135:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/94\">",
"      Engler RJ, With CM, Gregory PJ, Jellin JM. Complementary and alternative medicine for the allergist-immunologist: where do I start? J Allergy Clin Immunol 2009; 123:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/95\">",
"      Markham AW, Wilkinson JM. Complementary and alternative medicines (CAM) in the management of asthma: an examination of the evidence. J Asthma 2004; 41:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/96\">",
"      Passalacqua G, Bousquet PJ, Carlsen KH, et al. ARIA update: I--Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol 2006; 117:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/97\">",
"      Jobst KA. Acupuncture in asthma and pulmonary disease: an analysis of efficacy and safety. J Altern Complement Med 1996; 2:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/98\">",
"      Linde K, Jobst K, Panton J. Acupuncture for chronic asthma. Cochrane Database Syst Rev 2000; :CD000008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/99\">",
"      Shapira MY, Berkman N, Ben-David G, et al. Short-term acupuncture therapy is of no benefit in patients with moderate persistent asthma. Chest 2002; 121:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/100\">",
"      Medici TC, Grebski E, Wu J, et al. Acupuncture and bronchial asthma: a long-term randomized study of the effects of real versus sham acupuncture compared to controls in patients with bronchial asthma. J Altern Complement Med 2002; 8:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/101\">",
"      Martin J, Donaldson AN, Villarroel R, et al. Efficacy of acupuncture in asthma: systematic review and meta-analysis of published data from 11 randomised controlled trials. Eur Respir J 2002; 20:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/102\">",
"      Balon J, Aker PD, Crowther ER, et al. A comparison of active and simulated chiropractic manipulation as adjunctive treatment for childhood asthma. N Engl J Med 1998; 339:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/103\">",
"      Field T, Henteleff T, Hernandez-Reif M, et al. Children with asthma have improved pulmonary functions after massage therapy. J Pediatr 1998; 132:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/104\">",
"      Manocha R, Marks GB, Kenchington P, et al. Sahaja yoga in the management of moderate to severe asthma: a randomised controlled trial. Thorax 2002; 57:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/105\">",
"      Cooper S, Oborne J, Newton S, et al. Effect of two breathing exercises (Buteyko and pranayama) in asthma: a randomised controlled trial. Thorax 2003; 58:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/106\">",
"      Vedanthan PK, Kesavalu LN, Murthy KC, et al. Clinical study of yoga techniques in university students with asthma: a controlled study. Allergy Asthma Proc 1998; 19:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/107\">",
"      Opat AJ, Cohen MM, Bailey MJ, Abramson MJ. A clinical trial of the Buteyko Breathing Technique in asthma as taught by a video. J Asthma 2000; 37:557.",
"     </a>",
"    </li>",
"    <li>",
"     O&rsquo;Connor E, Patnode CD, Burda BU, et al. Breathing Exercises and/or Retraining Techniques in the Treatment of Asthma: Comparative Effectiveness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Sep. (Comparative Effectiveness Reviews, No. 71.) file://www.ncbi.nlm.nih.gov/books/NBK109355/ (Accessed on November 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/109\">",
"      Singh V, Wisniewski A, Britton J, Tattersfield A. Effect of yoga breathing exercises (pranayama) on airway reactivity in subjects with asthma. Lancet 1990; 335:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/110\">",
"      Nagendra HR, Nagarathna R. An integrated approach of yoga therapy for bronchial asthma: a 3-54-month prospective study. J Asthma 1986; 23:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/111\">",
"      Nagarathna R, Nagendra HR. Yoga for bronchial asthma: a controlled study. Br Med J (Clin Res Ed) 1985; 291:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/112\">",
"      Bowler SD, Green A, Mitchell CA. Buteyko breathing techniques in asthma: a blinded randomised controlled trial. Med J Aust 1998; 169:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/113\">",
"      Holloway E, Ram FS. Breathing exercises for asthma. Cochrane Database Syst Rev 2004; :CD001277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/114\">",
"      Bruton A, Thomas M. The role of breathing training in asthma management. Curr Opin Allergy Clin Immunol 2011; 11:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/115\">",
"      Thomas M, McKinley RK, Mellor S, et al. Breathing exercises for asthma: a randomised controlled trial. Thorax 2009; 64:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/116\">",
"      Bott J, Blumenthal S, Buxton M, et al. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. Thorax 2009; 64 Suppl 1:i1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/117\">",
"      Holloway EA, West RJ. Integrated breathing and relaxation training (the Papworth method) for adults with asthma in primary care: a randomised controlled trial. Thorax 2007; 62:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/118\">",
"      Cowie RL, Conley DP, Underwood MF, Reader PG. A randomised controlled trial of the Buteyko technique as an adjunct to conventional management of asthma. Respir Med 2008; 102:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/119\">",
"      Gy&ouml;rik SA, Brutsche MH. Complementary and alternative medicine for bronchial asthma: is there new evidence? Curr Opin Pulm Med 2004; 10:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/120\">",
"      Ritz T, Dahme B, Roth WT. Behavioral interventions in asthma: biofeedback techniques. J Psychosom Res 2004; 56:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/121\">",
"      Huntley A, White AR, Ernst E. Relaxation therapies for asthma: a systematic review. Thorax 2002; 57:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/122\">",
"      Lehrer PM, Vaschillo E, Vaschillo B, et al. Biofeedback treatment for asthma. Chest 2004; 126:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/123\">",
"      Lahmann C, Nickel M, Schuster T, et al. Functional relaxation and guided imagery as complementary therapy in asthma: a randomized controlled clinical trial. Psychother Psychosom 2009; 78:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/124\">",
"      Monteleone CA, Sherman AR. Nutrition and asthma. Arch Intern Med 1997; 157:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/125\">",
"      McKeever TM, Britton J. Diet and asthma. Am J Respir Crit Care Med 2004; 170:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/126\">",
"      Misso NL, Brooks-Wildhaber J, Ray S, et al. Plasma concentrations of dietary and nondietary antioxidants are low in severe asthma. Eur Respir J 2005; 26:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/127\">",
"      Trenga CA, Koenig JQ, Williams PV. Dietary antioxidants and ozone-induced bronchial hyperresponsiveness in adults with asthma. Arch Environ Health 2001; 56:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/128\">",
"      Pearson PJ, Lewis SA, Britton J, Fogarty A. Vitamin E supplements in asthma: a parallel group randomised placebo controlled trial. Thorax 2004; 59:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/129\">",
"      Ram FS, Rowe BH, Kaur B. Vitamin C supplementation for asthma. Cochrane Database Syst Rev 2004; :CD000993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/130\">",
"      Reisman J, Schachter HM, Dales RE, et al. Treating asthma with omega-3 fatty acids: where is the evidence? A systematic review. BMC Complement Altern Med 2006; 6:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/131\">",
"      Mickleborough TD, Lindley MR, Ionescu AA, Fly AD. Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma. Chest 2006; 129:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/132\">",
"      Anandan C, Nurmatov U, Sheikh A. Omega 3 and 6 oils for primary prevention of allergic disease: systematic review and meta-analysis. Allergy 2009; 64:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/133\">",
"      Cheng J, Pan T, Ye GH, Liu Q. Calorie controlled diet for chronic asthma. Cochrane Database Syst Rev 2005; :CD004674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/134\">",
"      Stenius-Aarniala B, Poussa T, Kvarnstr&ouml;m J, et al. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ 2000; 320:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/135\">",
"      Ziment I. Alternative therapies for asthma. Curr Opin Pulm Med 1997; 3:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/136\">",
"      Kazaks AG, Uriu-Adams JY, Albertson TE, et al. Effect of oral magnesium supplementation on measures of airway resistance and subjective assessment of asthma control and quality of life in men and women with mild to moderate asthma: a randomized placebo controlled trial. J Asthma 2010; 47:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/137\">",
"      Beamon S, Falkenbach A, Fainburg G, Linde K. Speleotherapy for asthma. Cochrane Database Syst Rev 2001; :CD001741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/138\">",
"      Sokolova MIu, Ivanova NA, Shabalov NP. [Optimal therapy of children with bronchial asthma at Pyatigorsk spa]. Vopr Kurortol Fizioter Lech Fiz Kult 2007; :8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/139\">",
"      Chervinskaia AV. [The scientific validation and outlook for the practical use of halo-aerosol therapy]. Vopr Kurortol Fizioter Lech Fiz Kult 2000; :21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/140\">",
"      Maev EZ, Vinogradov NV. [Halotherapy in the combined treatment of chronic bronchitis patients]. Voen Med Zh 1999; 320:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/141\">",
"      Chervinskaya AV, Zilber NA. Halotherapy for treatment of respiratory diseases. J Aerosol Med 1995; 8:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/142\">",
"      Hedman J, Hugg T, Sandell J, Haahtela T. The effect of salt chamber treatment on bronchial hyperresponsiveness in asthmatics. Allergy 2006; 61:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/143\">",
"      Sandell J, Hedman J, Saarinen K, Haahtela T. Salt chamber treatment is ineffective in treating eosinophilic inflammation in asthma. Allergy 2013; 68:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/144\">",
"      Solway J, Irvin CG. Airway smooth muscle as a target for asthma therapy. N Engl J Med 2007; 356:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/145\">",
"      Cox PG, Miller J, Mitzner W, Leff AR. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J 2004; 24:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/146\">",
"      Cox G, Miller JD, McWilliams A, et al. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med 2006; 173:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/147\">",
"      Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007; 356:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/148\">",
"      Wahidi MM, Kraft M. Bronchial thermoplasty for severe asthma. Am J Respir Crit Care Med 2012; 185:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/149\">",
"      Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/150\">",
"      Pavord ID, Cox G, Thomson NC, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007; 176:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/36/33354/abstract/151\">",
"      Bronchial thermoplasty for asthma. Med Lett Drugs Ther 2010; 52:65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 526 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33354=[""].join("\n");
var outline_f32_36_33354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Empiric antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nebulized furosemide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHRONIC ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77146118\">",
"      Tiotropium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nebulized lidocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nebulized heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immune modulatory therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gold",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Colchicine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hydroxychloroquine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Dapsone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Macrolide antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Anti-TNFa agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Anti-IL-2R antibody",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Anti-IL-5 antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32959293\">",
"      - Anti-IL-13 antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Herbal medicines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nonpharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Chiropractic manipulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Massage therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Breathing exercises",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Biofeedback and functional relaxation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Dietary alterations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H84379794\">",
"      - Speleotherapy and halotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Bronchial thermoplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Therapies for acute exacerbations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Therapies for chronic asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31496?source=related_link\">",
"      Chinese herbal medicine for the treatment of allergic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=related_link\">",
"      Glucocorticoid-resistant asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34918?source=related_link\">",
"      Gold-induced pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=related_link\">",
"      Major side effects of gold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35529?source=related_link\">",
"      Overview of complementary and alternative medicine in pediatrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33305?source=related_link\">",
"      Role of anticholinergic therapy in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41222?source=related_link\">",
"      Spinal manipulation in the treatment of musculoskeletal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_36_33355="Improving our approach to pts";
var content_f32_36_33355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Techniques for improving our approach to patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Make some quiet time to reflect on satisfying and unsatisfying visits. What did you do, and what did the patient do that made the difference? What life experiences influenced your behavior in that circumstance?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Observe your interactions with patients directly. Obtain permission from your patients to audiotape or videotape visits for the purpose of self-improvement. Assure your patients about the fate of the recordings (eg, destruction after you have studied them). We all have \"blind spots\" about our behaviors that the recorders can reveal to us.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Talk with trusted colleagues about challenging interactions with patients, seeking their insights and their strategies for dealing with similar situations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seek feedback about your interactions with patients from colleagues who have opportunities to observe at least parts of your clinician-patient visits. Support staff may have very useful feedback about what patients say to them about you.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When you sense an absence of rapport with a patient and cannot comprehend the source of the disconnection, put the difficulty in the relationship nonjudgementally \"on the table\" for discussion with the patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Read the world's great literature with an ear to hearing people's stories. Many physician-authors have contributed their special insights into how we can hear our patients' life stories amid their \"biomedical stories.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Write about your insights into the human condition -- in a private journal, or for publication.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33355=[""].join("\n");
var outline_f32_36_33355=null;
var title_f32_36_33356="Risk factors BP VSP rx";
var content_f32_36_33356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for adverse consequences of high blood pressure (BP)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Systolic BP &ge;160 mmHg or diastolic BP &ge;100 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Established CV disease including any history of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ischemic stroke, cerebral hemorrhage, or transient ischemic attack",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myocardial infarction, angina, coronary revascularization, or heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peripheral artery disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Retinal hemorrhages or exudates and papilledema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Established or subclinical renal disease including:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microalbuminuria or proteinuria (&gt;30 mg/24 h)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum creatinine in men &gt;1.5 mg/dL, women &gt;1.4 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calculated or estimated glomerular filtration rate &lt;60 mL/min/1.73 m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Subclinical organ damage previously documented by:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ECG or echocardiogram revealing left ventricular hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carotid ultrasound study revealing wall thickening or plaque",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Three or more of the following CV risk factors:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age (men &gt;55 y, women &gt;65 y)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cigarette smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Dyslipidemia as measured by:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Total cholesterol &gt;190 mg/dL or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Low-density lipoprotein cholesterol &gt;130 mg/dL or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        High-density lipoprotein cholesterol (men &lt;40 mg/dL; women &lt;46 mg/dL) or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Triglyceride &gt;150 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fasting plasma glucose &gt;100 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Family history of premature CV disease (first-degree male relative age &lt;55 y or first-degree female relative &lt;65 y)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abdominal obesity male waist circumference &gt;40 in; female &gt;35 in (in persons of East Asian ancestry: male waist circumference &gt;35 in and for women &gt;31 in)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CV: cardiovascular.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102:596. Copyright &copy; 2010 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33356=[""].join("\n");
var outline_f32_36_33356=null;
var title_f32_36_33357="Tamoxifen in osteoporosis";
var content_f32_36_33357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Tamoxifen increases bone density in postmenopausal women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 217px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Change in bone mineral density in the lumbar spine and hip in postmenopausal women treated with tamoxifen or placebo. Tamoxifen was associated with an increase in bone density at both sites.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.&nbsp;J Clin Oncol 1996; 14:78.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33357=[""].join("\n");
var outline_f32_36_33357=null;
var title_f32_36_33358="Evaluation of gonadotropin-dependent precocious puberty";
var content_f32_36_33358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52565%7EPEDS%2F59268%7EPEDS%2F72054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52565%7EPEDS%2F59268%7EPEDS%2F72054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of gonadotropin-dependent (\"central\") precocious puberty",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gonadotropin levels",
"       </td>",
"       <td class=\"subtitle1\">",
"        LH response after GnRH stimulation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sex steroid hormone levels",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Additional evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Idiopathic",
"        </p>",
"        <p>",
"         <em>",
"          (80 percent of girls with GDPP)",
"         </em>",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         or CNS tumor",
"        </p>",
"       </td>",
"       <td>",
"        Pubertal levels, with prominent LH pulses during sleep: LH &gt;0.6 IU/L",
"       </td>",
"       <td>",
"        Pubertal response: LH level post GnRH &gt;7 IU/L",
"       </td>",
"       <td>",
"        Pubertal values of estradiol (&gt;9 pg/mL), testosterone (20-1200 ng/dL), and DHEAS",
"       </td>",
"       <td>",
"        <p>",
"         Pubertal development accelerated, but proceeds in normal timing and sequence",
"        </p>",
"        <p>",
"         Enlargement of ovary/uterus (by ultrasound) or testes (by exam)",
"        </p>",
"        <p>",
"         Bone age &gt;height age &gt;chronological age",
"        </p>",
"        <p>",
"         Responsive to GnRH agonist therapy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Contrast-enhanced MRI of brain to rule out CNS abnormality",
"        </p>",
"        <p>",
"         In boys, measure hCG to exclude an hCG-secreting tumor",
"        </p>",
"        <p>",
"         Skin examination and skeletal survey to rule out McCune-Albright syndrome",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LH: luteinizing hormone; GnRH: gonadotropin-releasing hormone; CNS: central nervous system; DHEAS: dehydroepiandrosterone sulfate; MRI: magnetic resonance imaging; hCG: human chorionic gonadotropin.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of gonadotropin-independent (\"peripheral\") precocious puberty",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gonadotropin levels",
"       </td>",
"       <td class=\"subtitle1\">",
"        LH response after GnRH stimulation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sex steroid hormone levels",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Additional evaluation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Congenital adrenal hyperplasia",
"        </p>",
"        (untreated)",
"       </td>",
"       <td>",
"        Prepubertal",
"       </td>",
"       <td>",
"        Absent LH response",
"       </td>",
"       <td>",
"        Sex hormone levels vary depending on the adrenal enzyme block",
"       </td>",
"       <td>",
"        Boys have prepubertal testes with enlarged phallus and pubic hair development. Girls with \"nonclassic\" CAH may present with early pubic and/or axillary hair, and other signs of androgen excess.",
"       </td>",
"       <td>",
"        After therapy with glucocorticoids, GDPP may develop and require GnRH agonist therapy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Leydig cell tumor",
"        </p>",
"        (boys)",
"       </td>",
"       <td>",
"        Suppressed",
"       </td>",
"       <td>",
"        Absent LH response",
"       </td>",
"       <td>",
"        Very high levels of testosterone",
"       </td>",
"       <td>",
"        Irregular and asymmetrical enlargement of testes",
"       </td>",
"       <td>",
"        Tumor may not be palpable; testicular ultrasound aids in diagnosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Ovarian cyst",
"       </td>",
"       <td>",
"        Suppressed",
"       </td>",
"       <td>",
"        Absent LH response",
"       </td>",
"       <td>",
"        Normal or elevated estradiol; occasionally elevated androgens",
"       </td>",
"       <td>",
"        Pubertal development accelerated; occasionally presents with ovarian torsion and abdominal pain",
"       </td>",
"       <td>",
"        Abdominal ultrasound and/or MRI",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         hCG-secreting germ cell tumors",
"        </p>",
"        (boys)",
"       </td>",
"       <td>",
"        High hCG or positive pregnancy test",
"       </td>",
"       <td>",
"        Absent LH response",
"       </td>",
"       <td>",
"        Pubertal values of testosterone",
"       </td>",
"       <td>",
"        <p>",
"         Testes symmetric and &gt;2.5 cm diameter (&gt;4 mL volume), but smaller than expected for the degree of pubertal development",
"        </p>",
"        Precocious puberty is seen only in boys as hCG only activates LH receptors (estrogen biosynthesis in the ovaries requires both FSH and LH receptor activation)",
"       </td>",
"       <td>",
"        <p>",
"         These tumors may occur in gonads, brain, liver, retroperitoneum, or mediastinum",
"        </p>",
"        When in anterior mediastinum, a karyotype must be performed because of a strong association of this finding with Klinefelter syndrome",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Familial male-limited (gonadotropin-independent) precocious puberty",
"        </p>",
"        (boys)",
"       </td>",
"       <td>",
"        Suppressed",
"       </td>",
"       <td>",
"        Absent LH response",
"       </td>",
"       <td>",
"        Pubertal values of testosterone",
"       </td>",
"       <td>",
"        <p>",
"         Testes symmetric and &gt;2.5 cm diameter (&gt;4 mL volume), but smaller than expected for degree of pubertal development; spermatogenesis may occur",
"        </p>",
"        <p>",
"         Familial: Male-limited autosomal dominant trait",
"        </p>",
"        Precocious puberty is seen only in boys as there is only activation of the LH receptors, and ovarian estrogen biosynthesis requires both FSH and LH receptor activation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         McCune-Albright syndrome",
"        </p>",
"        (girls&gt;&gt;boys)",
"       </td>",
"       <td>",
"        Suppressed",
"       </td>",
"       <td>",
"        Absent LH response",
"       </td>",
"       <td>",
"        Pubertal values of estradiol in girls and testosterone in boys",
"       </td>",
"       <td>",
"        <p>",
"         Ovaries: Enlarged for age and usually containing multiple large cysts",
"        </p>",
"        <p>",
"         Testes: Symmetric and &gt;2.5 cm diameter (&gt;4 mL volume), but smaller than expected for pubertal development",
"        </p>",
"        <p>",
"         Skin: Multiple irregular-edged caf&eacute;-au-lait spots",
"        </p>",
"        Bone: Polyostotic fibrous dysplasia",
"       </td>",
"       <td>",
"        <p>",
"         Ultrasound: Ovaries enlarged, with follicular cysts",
"        </p>",
"        May have other hyperactive endocrine disorders: ie, thyrotoxicosis and/or gigantism",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Virilizing adrenal tumor",
"       </td>",
"       <td>",
"        Suppressed",
"       </td>",
"       <td>",
"        Absent LH response",
"       </td>",
"       <td>",
"        High DHEA or DHEAS*; high androstenedione and testosterone",
"       </td>",
"       <td>",
"        Testes prepubertal",
"       </td>",
"       <td>",
"        CT, MRI, or ultrasound of adrenal glands to locate tumor; if still undetectable selective venous sampling of androgen",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Adrenal cancer",
"       </td>",
"       <td>",
"        Suppressed",
"       </td>",
"       <td>",
"        Absent LH response",
"       </td>",
"       <td>",
"        High DHEA or DHEAS*; high 17-ketosteroids in urine",
"       </td>",
"       <td>",
"        May present with signs of glucocorticoid excess, and may be associated with hereditary cancer syndromes",
"       </td>",
"       <td>",
"        CT, MRI, or ultrasound of adrenal glands to locate tumor; if still undetectable, selective venous sampling of androgen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exogenous sex steroids (eg, testosterone creams and estradiol spray or creams)",
"       </td>",
"       <td>",
"        Suppressed",
"       </td>",
"       <td>",
"        Absent LH response",
"       </td>",
"       <td>",
"        Elevated testosterone in boys and estradiol in girls",
"       </td>",
"       <td>",
"        Estrogen preparations cause feminization, while topical androgens cause virilization in both sexes",
"       </td>",
"       <td>",
"        Clinical history explores use of exogenous sex steroids by caretakers and folk remedies. Monitor sex steroid hormone levels and clinical status after removal of inciting agent.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GDPP: gonadotropin-dependent precocious puberty; LH: luteinizing hormone; GnRH: gonadotropin-releasing hormone; CAH: congenital adrenal hyperplasia; hCG: human chorionic gonadotropin; FSH: follicle-stimulating hormone; DHEAS: dehydroepiandrosterone sulfate; CT: computed tomography; MRI: magnetic resonance imaging; 17-OHP: 17-hydroxyprogesterone.",
"     <br/>",
"     * If adrenal tumor tissue loses sulfokinase activity, DHEAS may not be elevated.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of incomplete precocious puberty",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gonadotropin levels",
"       </td>",
"       <td class=\"subtitle1\">",
"        LH response after GnRH stimulation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sex steroid hormone levels",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Additional evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature adrenarche",
"       </td>",
"       <td>",
"        Prepubertal LH levels",
"       </td>",
"       <td>",
"        No LH response",
"       </td>",
"       <td>",
"        <p>",
"         DHEAS values elevated for age (at Tanner 2 levels, ie, &gt;50 micrograms/dL)",
"        </p>",
"        <p>",
"         17-OHP and testosterone normal",
"        </p>",
"        <p>",
"         Early pubertal response to ACTH",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         No other signs of pubertal development; normal growth rate",
"        </p>",
"        <p>",
"         Gonads prepubertal",
"        </p>",
"        <p>",
"         Onset usually after six years of age",
"        </p>",
"        <p>",
"         Associated more frequently with brain injury, obesity, or children born SGA",
"        </p>",
"       </td>",
"       <td>",
"        Monitor for possible early progression to full puberty",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Premature thelarche",
"       </td>",
"       <td>",
"        Prepubertal LH levels",
"       </td>",
"       <td>",
"        No LH response, normal FSH response",
"       </td>",
"       <td>",
"        Prepubertal",
"       </td>",
"       <td>",
"        No other signs of pubertal development; normal growth rate",
"       </td>",
"       <td>",
"        Monitor for possible early progression to full puberty",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LH: luteinizing hormone; GnRH: gonadotropin-releasing hormone; DHEAS: dehydroepiandrosterone sulfate; 17-OHP: 17-hydroxyprogesterone; ACTH: adrenocorticotropic hormone; SGA: small for gestational age; FSH: follicle-stimulating hormone.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33358=[""].join("\n");
var outline_f32_36_33358=null;
var title_f32_36_33359="Chronic thromboemboli Angio";
var content_f32_36_33359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic thromboemboli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right-sided pulmonary angiogram demonstrating multiple findings consistent with chronic thromboembolic disease including \"pouch defect,\" webs, post-stenotic dilation, and abrupt cut-offs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter F Fedullo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_36_33359=[""].join("\n");
var outline_f32_36_33359=null;
